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NOTAS PRÉVIAS 
 
 
Para a elaboração da presente tese de doutoramento foram usados como capítulos vários artigos 
científicos publicados, ou em preparação para posterior publicação, em revistas científicas 
internacionais indexadas. Uma vez que estes trabalhos foram realizados em colaboração com 
outros investigadores, e de acordo com o disposto no nº 1 do Artigo 40º do Regulamento de 
Estudos Pós-Graduados da Universidade de Lisboa, publicado no Diário da República – no 153, 
II Série de 5 de Julho de 2003, esclareço que participei integralmente na concepção e execução 
do trabalho experimental, na interpretação dos resultados e na redacção dos manuscritos, 
exceptuando o capítulo 5. Relativamente ao capítulo 5 apenas participei nos procedimentos 
experimentais relativos às figuras 3, 4, 5 e 6. 
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Resumo 
 
O sistema cardiovascular constitui o primeiro sistema de órgãos que se forma durante o 
desenvolvimento embrionário dos vertebrados, tendo como principais funções oxigenação e 
nutrição de todos os tecidos assim como a remoção de produtos secundários do metabolismo e 
regulação térmica via vasoconstrição e dilatação. Os principais componentes do sistema 
cardiovascular são o coração, o sangue e os vasos sanguíneos. Por sua vez os vasos sanguíneos 
têm como unidade funcional e estrutural a célula endotelial (CE) ao nível da qual são feitas as 
trocas celulares, metabólicas e gasosas entre as células de todos os tecidos e o sangue.  
A formação de vasos sanguíneos ocorre durante o desenvolvimento embrionário sendo um 
processo extremamente complexo que envolve essencialmente dois mecanismos celulares 
distintos mas interligados: vasculogénese e angiogénese. A vasculogénese é o processo através 
do qual células precursoras endoteliais, denominadas angioblastos, migram, agregam-se e 
coalescem formando uma rede primitiva de tubos endoteliais. O subsequente crescimento, 
expansão e estabilização dessa rede vascular primitiva ocorre através da proliferação, migração e 
consequente ramificação de CE activadas, num processo denominado angiogénese. 
Num organismo adulto as CE, assim como os vasos sanguíneos que elas constituem encontram-
se num estado não proliferativo, denominado quiescência. No entanto, na presença de estímulos 
específicos nomeadamente em situações fisiológicas (cicatrização de feridas, revascularização de 
tecidos isquemicos, ovulação, menstruação ou gravidez) ou patológicas (cancro, psoriase, artrite, 
retinopatias, aterosclerose ou em feridas com cicatrização atrasada) as CE podem tornar-se 
activas e por angiogénese geram novos vasos sanguíneos. No entanto dados recolhidos na ultima 
década sugerem que à semelhança do que acontece durante o desenvolvimento embrionário, 
também no adulto novos vasos sanguíneos se podem formar por vasculogénese. Efectivamente 
foram identificados em indivíduos adultos células denominadas progenitores endoteliais (PE), 
que partilham semelhanças com angioblastos embrionários, e que em situações fisiológicas e 
patológicas são recrutados e diferenciam-se em CE, que por sua vez incorporam os novos vasos 
formados, num processo denominado vasculogénese pós-natal. PE são definidos como células 
com origem na medula óssea e que são caracterizados pela expressão de marcadores moleculares 
específicos de células estaminais como o CD133, CD34 ou o Sca-1 (em ratinho) assim como 
marcadores endoteliais como o VEGFR-2 (receptor 2 do factor de crescimento vascular). Em 
resposta a estímulos específicos provenientes de tecidos em remodelação vascular os PE são 
mobilizados da medula óssea para a circulação, onde são transportados até atingirem os locais de 
remodelação vascular onde abandonam a circulação por extravasão, invadem os tecidos 
adjacentes e eventualmente diferenciam-se em CE incorporando os novos vasos formados.  
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O processo de diferenciação endotelial dos PE pode ser dividido em 3 fases essenciais: adesão, 
mediada por integrinas, dos PE aos componentes da matriz extracelular, sobrevivência e 
proliferação dos PE aderentes em resposta a factores de crescimento e a sinais da matriz 
extracelular e finalmente aquisição de marcadores e propriedades endoteliais. Apesar de já ser 
conhecida e descrita a contribuição dos PE em diversas condições fisiológicas e patológicas os 
mecanismos que regulam a sua diferenciação em CE ainda são desconhecidos.  
 
Assim sendo os objectivos desta tese de doutoramento são a compreensão dos mecanismos 
moleculares envolvidos na diferenciação endotelial, em contexto de cicatrização de feridas e de 
progressão tumoral, com especial foco em vias que são essenciais para a vasculogénese 
embrionária: via de interacção entre integrinas e proteínas da matriz extracelular e via de 
sinalização Notch-Delta. Além da compreensão dos mecanismos moleculares que regulam a 
diferenciação endotelial em PE também foi feita investigação relativa ao papel da via de 
sinalização Notch-Delta na comunicação entre outras populações celulares derivadas da medula 
óssea (além dos PE) e células tumorais, durante a progressão tumoral. 
 
No capítulo 3 desta tese de doutoramento abordámos o papel da matriz extracelular provisória 
composta essencialmente por fibrina e pelos seus fragmentos de degradação, que se forma 
durante a cicatrização de feridas, na função dos PE. Em particular caracterizámos in vitro o papel 
do fragmento de degradação da fibrina E (FnE), que tem potentes propriedades pró-angiogénicas, 
na diferenciação e nas propriedades vasculogénicas dos PE. De acordo com os nossos resultados 
FnE potencia a adesão dos PE, via integrina α5β1, assim como a sua diferenciação endotelial 
comparativamente a outros componentes da matriz extracelular. Surpreendentemente 
observámos que PE cultivados em FnE produzem níveis mais elevados de factores paracrinos, 
nomeadamente de factores pró-angiogénicos e de inúmeras citoquinas. Utilização de meios 
condicionados de PE cultivados em diferentes componentes da matriz revelou que os meios 
condicionados dos PE na presença de FnE têm propriedades pró angiogénicas assim como 
propriedades quimiatractoras de monócitos sanguíneos extremamente elevados 
comparativamente às restantes condições. Para validarmos o papel pró-vasculogénico do FnE em 
PE in vivo, utilizámos uma matriz sintética enriquecida com FnE (denominada Smart Matrix – 
SM) em modelos murinos de cicatrização de feridas. De acordo com os nossos resultados a 
adição de SM conjuntamente com PE potenciou significativamente o fecho das feridas, estando 
associado a uma maior vascularização da ferida comparativamente com as restantes condições. 
Em conclusão os resultados apresentados no capítulo 3 sugerem que FnE tem grandes 
propriedades vasculogénicas, pelo que a sua administração sob a forma de uma matriz sintética 
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conjuntamente com PE representa uma possível abordagem terapêutica para potenciar a 
cicatrização de feridas quer resultantes de trauma, queimadura ou ulceração crónica resultante de 
diabetes, pressão ou estase venosa. 
 
No capítulo 4 investigámos o papel da via de sinalização Notch-Delta na diferenciação 
endotelial e nas propriedades vasculogénicas dos PE, num contexto de cicatrização de feridas. 
De acordo com os nossos resultados os PE expressam ligandos e receptores da via Notch-Delta e 
durante a diferenciação endotelial destas células observámos um aumento na activação da via 
Notch-Delta. Curiosamente a inibição farmacológica da via Notch-Delta levou a uma redução 
drástica na adesão dos PE a diversos componentes das matriz extracelular assim como a uma 
redução significativa do número de CE obtidas no final do ensaio de diferenciação endotelial in 
vitro. Mecanisticamente observámos que inibição da via Notch-Delta nos PE conduzia a uma 
redução da expressão da integrina α3β1, razão pela qual observámos redução na adesão e 
consequentemente na diferenciação dos PE. Adicionalmente verificámos que inibição 
farmacológica da via Notch-Delta nos PE reduzia a capacidade destas células induzirem 
angiogénese e migração endotelial em ensaios in vitro, sugerindo que a via Notch-Delta é 
essencial não so para a adesão e diferenciação endotelial dos PE mas também para as suas 
propriedades pró-angiogenicas. Após constatarmos o papel essencial da via Notch-Delta nos PE, 
testámos o efeito da inibição desta via em PE em modelos murinos de cicatrização de feridas. 
Em confirmação dos resultados in vitro observámos que ratinhos injectados com PE normais têm 
um aumento da taxa de cicatrização associado a um aumento do numero de vasos sanguíneos 
presentes na ferida. Por outro lado o efeito dos PE na cicatrização e vascularização perde-se 
quando a via Notch-Delta é inibida, curiosamente PE com a via Notch-Delta inibida estão 
presentes na ferida em frequências menores que os PE normais. Estes dados demonstram que a 
activação da via Notch-Delta em PE potencia as suas propriedades vasculogénicas e pró-
angogénicas, sendo essencial para a sua capacidade de acelerar a cicatrização de feridas em 
modelos murinos. 
 
No capitulo 5 abordámos o papel de um dos ligandos da via Notch-Delta expresso em PE, o 
Dll4 (Delta-like ligand 4) na angiogénese tumoral. De acordo com os nossos resultados a 
expressão de Dll4 em PE é regulada directamente por 2 factores mobilizadores de PE: VEGF 
(factor de crescimento vascular) e SDF-1 (factor derivado do estroma de medula óssea).  Para 
testar o efeito de Dll4 na activação da via Notch-Delta em CE, co-cultivámo PE com diferentes 
níveis de expressão de Dll4 conjuntamente com CE e posteriormente analisámos os genes 
expressos diferencialmente nas CE consoante os níveis de Dll4 dos PE. De acordo com a nossa 
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análise a activação da via Notch-Delta nas CE via Dll4 expresso pelos PE conduziu ao aumento 
da expressão de componentes da matriz extracelular (nomeadamente fibronectina) e de 
componentes das adesões endoteliais (ICAM2 e VE-Caderina). In vivo observámos que em 
ratinhos transplantados com PE heterozigóticos para Dll4 (Dll4+/-) o crescimento tumoral era 
reduzido relativamente a ratinhos transplantados com PE normais, no entanto analise do tecido 
tumoral revelou que os tumores dos ratinhos transplantados com PE Dll4+/- tinham maior 
densidade vascular, mas menor proliferação, maior frequência de células apoptóticas e áreas de 
hipoxia mais extensas relativamente aos tumores crescidos em ratinhos transplantados com PE 
normais. Esta observação sugeriu que os vasos tumorais desenvolvidos em ratinhos 
transplantados com PE Dll4+/- eram mais instáveis embora existissem em maior numero. De 
facto análise histológica revelou que estes vasos apresentam menor expressão de fibronectina e 
menor cobertura com pericitos (células vasculares musculares), confirmando que a activação da 
via Notch-Delta em CE via Dll4 expresso por PE é essencial para a estabilização da vasculatura 
tumoral nascente e consequentemente para o crescimento tumoral. Finalmente para validar o 
efeito de Dll4 expresso nos PE na estabilização da vasculatura tumoral transplantámos ratinhos 
com PE com sobre-expressão de Dll4 e analisámos a vasculatura tumoral. De facto observámos 
que embora o crescimento tumoral não tenha sido alterado, assim como o numero total de vasos 
formados, a quantidade de fibronectina assim como o calibre dos vasos tumorais era superior nos 
ratinhos transplantados com PE com sobre-expressão de Dll4 do que nos ratinhos transplantados 
com PE normais, confirmando que a activação da via Notch-Delta em CE via Dll4 expresso em 
PE conduz à estabilização vascular. Concluindo, os dados apresentados no capitulo 5 descrevem 
o papel essencial de Dll4 expresso por PE na activação da via Notch-Delta em CE, conduzindo 
ao aumento de proteínas da matriz extracelular assim como de componentes das junções 
celulares entre células endoteliais essenciais para a estabilização e funcionalidade da vasculatura 
tumoral.  
 
Finalmente no capítulo 6 investigámos a contribuição de outras populações celulares derivadas 
da medula óssea para a progressão tumoral. Para este efeito utilizámos ratinhos nos quais 
transplantámos medula óssea proveniente de ratinhos actina-GFP, pelo que obtivemos ratinhos 
nos quais todas as células na medula expressavam GFP. Posteriormente inoculámos estes 
ratinhos com tumores derivados de linhas celulares isoladas de carcinoma de cólon (HCT15) e 
procedemos à analise histológica dos tumores, após estes crescerem durante 1 ou 4 semanas 
(tumores precoces e tardios). Análise histológica revelou que em tumores tardios há uma 
contribuição significativa de células derivadas da medula óssea (GFP+) e que estas células 
expressam essencialmente marcadores mielóides (CD11b). Inesperadamente constatámos que 
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nas regiões tumorais onde as células derivadas da medula óssea se acumulavam, as células 
tumorais perdiam a expressão de marcadores epiteliais (nomeadamente a E-Caderina), 
adquirindo a expressão de marcadores mesenquimatosos (nomeadamente Vimentina) sugerindo 
que estas células tumorais estavam em transição epitelial-mesenquimal (TEM). Para confirmar a 
suspeita que células derivadas da medula óssea poderiam estar a induzir TEM em células 
tumorais de carcinoma do cólon, procedemos a co-culturas in vitro com células derivadas da 
medula associadas ao tumor com células do carcinoma do cólon. Surpreendentemente 
verificámos que células derivadas da medula óssea associadas ao tumor tinham a capacidade de 
induzir TEM em células tumorais e ainda que essa capacidade dependia da activação da via 
Notch-Delta nas células tumorais. Após uma caracterização detalhada da população de células 
derivadas da medula associadas ao tumor capazes de induzir TEM nas células tumorais, 
definimos esta população como sendo constituída por macrófagos associados a tumor ou MAT 
(CD11b+ F4/80+) que expressava o ligando da via Notch Jagged-2. Experiências de co-cultura 
in vitro desta população com células tumorais confirmaram que esta população consegue via 
Jagged-2 induzir a activação da via Notch-Delta promovendo TEM nas células tumorais sendo 
essencial para a progressão tumoral. Em conjunto os dados apresentados no capitulo 6 sugerem 
que durante a progressão tumoral, populações de células derivadas da medula podem de facto 
modular propriedades das células tumorais induzindo TEM e consequentemente induzindo um 
fenotipo mais invasivo e potencialmente mais metastático nos tumores primários. 
 
Em conclusão, o trabalho realizado neste projecto de doutoramento permitiu atribuir à via Notch-
Delta e também as interacções entre integrinas e proteínas da matrix extracelular um papel 
essencial na comunicação entre populações celulares derivadas da medula óssea, em particular 
PE e MAT, e componentes celulares e da matrix extracelular presentes durante a cicatrização de 
feridas ou durante a progressão tumoral, sugerindo assim o uso destas vias e destas populações 
como potenciais alvos terapêuticos. 
 
Palavras chave: 
Progenitores endoteliais; Diferenciação endotelial; Via de sinalização Notch-Delta; Integrina; 
Matriz extracelular; Cicatrização de feridas; Tumores; Macrófagos associados a tumores; 
Transição epitelial mesenquimal 
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Abstract 
Bone marrow (BM)-derived cell populations participate in numerous physiological and 
pathological conditions in adult individuals, directly interacting with tissue specific cellular and 
extracellular matrix (ECM) components. In particular BM-derived endothelial progenitors 
(EPCs) contribute to physiological and pathological new vessel formation, a process termed 
posnatal-vasculogenesis. However the molecular mechanisms regulating their contribution are 
still lacking. In the present PhD thesis we adressed the role of two major pathways that regulate 
embryonic vasculogenesis: the Notch-Delta signalling pathway and Integrin-ECM pathway on 
EPC function during wound healing and tumor progression. To address the contribution of 
Integrin-ECM interactions to EPC function we tested the effect of the pro-angiogenic fibrin 
fragment E (FnE) on EPC vasculogenic properties. Our data shows that FnE potentiates the in 
vitro vasculogenic properties of EPCs, increasing their adhesion (via integrin α5β1), 
endothelial differentiation and paracrine factor production thus leading to increased in vivo 
wound vascularization and healing. Concerning the contribution of the Notch-Delta signalling 
pathway we defined that this pathway mediates bidirectional interactions between BM-derived 
cells and tissue resident cells during wound healing and tumor progression. In detail we 
observed that activation of the Notch pathway on EPCs increases integrin α3β1 expression, 
improving EPC adhesion and endothelial differentiation as well as their pro-angiogenic and 
wound healing potential in vitro and in vivo. In a tumor setting we observed that EPC-mediated 
activation of the Notch signaling on ECs regulates vessel stability by increasing the expression 
of basement membrane components as well as endothelial cell-cell junction proteins, thus being 
essential for neo-vessel normalization during tumor growth. Further characterization of BM-
derived cells recruited to tumor tissues lead us to the identification of BM-derived tumor 
associated macrophages (TAMs) that can activate Notch signaling on colon carcinoma cells 
inducing tumor epithelial to mesenchymal transition (EMT) thus contributing to tumor 
progression and metastisation.  
Taken together our results suggests that both Integrin-ECM and Notch-Delta pathways 
modulate the properties of BM-derived populations, being essential for the vasculogenic 
properties of EPCs and for the tumor promoting functions of TAMs, thus making these 
pathways valid targets in both wound healing and tumor progression. 
 
Key words: 
Endothelial progenitor cell; Endothelial differentiation; Notch-Delta signaling pathway; 
Integrins; Extracellular matrix; Wound healing; Tumor; Tumor associated macrophages; 
Epithelial to mesnchymal transitio 
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Abreviations 
AcLDL  (Acetylated Low Density Lipoprotein) 
ADAM  (A Dsintegrin And Metalloproteinase) 
Ang-1/2  (Angiopoietins 1/2) 
ATRA  (All-Trans-Retinoic Acid) 
β-GLUC  (Beta Glucuronidase) 
bFGF  (Basic Fibroblast Growth Factor)  
BM  (Bone-Marrow)  
BM-PC (Bone Marrow-Derived Progenitor Cells) 
BM-VPC (Bone Marrow-Derived Vascular Progenitors) 
BMT  (Bone Marrow Transplant) 
CAFs  (Cancer-Associated Fibroblasts) 
CaN4 (Constitutively Active Notch 4) 
CB  (Cord Blood) 
CCR2/5  (Chemokine C-C Motif Receptor 2/5) 
cDNA  (complementary DNA) 
CIPM  (Centro Investigação em Patobiologia Molecular) 
CK19 (Cytokeratin 19) 
ColI/III/IV  (Collagen type I/III/IV) 
CSL  (CBF-1/RBP-jκ, Su(H), Lag-1) 
CXCL1/2/12  (C-X-C motif Chemokine Ligand 1/2/12) 
CXCR2/4  (C-X-C motif Chemokine Receptor Type 2/4)  
D  (Day) 
Dll1/3/4  (Delta-like 1/3/4)  
E (Embryonic day) 
E-Cadherin (Epithelial Cadherin) 
EBs  (Embryoid Bodies) 
EC  (Endothelial Cell) 
ECM  (Extracellular Matrix) 
EEC  (Embryonic ectoderm) 
eEPC  (Embryonic EPC) 
EGF  (Epidermal Growth Factor)  
EMT (Epithelila to Mesenchymal Transition) 
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eNOS  (endothelial Nitric Oxide Synthase) 
EPAC1  (Exchange Protein Directly Activated by cAMP) 
EPC  (Endothelial Progenitor Cell)  
Epo  (Erythropoietin) 
ESCs  (Embryonic Stem Cells) 
EXE  (Extraembryonic Ectoderm) 
FACS  (Fluorescence Activated Cell Sorting) 
FBS  (Fetal Bovine Serum) 
FDA  (Food and Drug Administration) 
Flk-1  (Fetal Liver Kinase 1) 
Fn  (Fibrin) 
FN  (Fibronectin) 
FnE  (Fibrin Fragment E) 
G-CSF  (Granulocyte Colony Stimulating Factor)  
Gel (Gelatin) 
GFP  (Green Fluorescent Protein) 
GM-CSF  (Granulocyte-Monocyte Colony Stimulating Factor) 
Gr-1  (Granulocyte-Differentiation Antigen-1) 
Gro-a  (Growth Regulated Oncogene-alpha) 
GSI (gamma-Secretase Inhibitor) 
HC  (Hematopoietic Cell) 
HDAC  (Histone deacetylases)  
H&E (Hematoxylin and Eosin) 
Hes  (Hairy/Enhancer of Split) 
Hey  (Hairy/Enhancer of Split related with YRPW) 
HGF  (Hepatocyte Growth Factor) 
HIF  (Hypoxia-Inducible Factor)  
HMGB-1  (High-Mobility Group Box-1) 
HPF  (High Power Field) 
HSCs  (Hematopoietic Stem Cell)  
HUVEC (Human Umbilical Vein Endothelial Cell) 
HDMEC (Human Dermal Microvascular Endothelial Cell) 
ICAM-1/2  (Inter-Cellular Adhesion Molecule 1/2) 
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ID  (Inhibitor of Differentiation) 
IFN-γ  (Interferon-gamma) 
IGC  (Instituto Gulbenkian de Ciência) 
IGF  (Insulin-Like Growth Factor) 
IL-1/3/4/6/8/10/13  (Interleukine 1/3/4/6/8/10/13) 
IMG  (intussusceptive microvascular growth) 
Jag1/2  (Jagged-1/2) 
JAM  (Junctional Adhesion Molecule) 
KDR  (Kinase insert Domain Receptor) 
KGF  (Keratinocyte Growth Factor) 
KitL  (Kit Ligand) 
KO  (knock-out) 
Lac Z  (β-Galactosidase) 
LFA-1  (Lymphocyte Function-Associated Antigen 1) 
Lin  (Lineage) 
LN  (Laminin) 
LOX  (Lysyl Oxidase) 
LPS  (Lipopolysaccharide) 
MACS  (Magnetic Cell Sorting) 
Maml  (Mastermind-like) 
MC  (mural cells)  
MCP-1  (Monocyte Chemotactic Protein 1)  
MDSCs  (Myeloid–Derived Surpressor Cells) 
MIP-1a  (Macrophage Inflammatory Protein 1 alpha)  
mKitL  (Membrane-bound Kit Ligand) 
MNCs  (Mononuclear Cells)  
mRNA  (messenger RNA) 
MSCs  (Mesenchymal Stem Cells)  
MT1-MMP  (Membrane Type 1-Matrix Metalloproteinase ) 
MVD (Microvessel Density) 
N1/2/3/4  (Notch receptor 1/2/3/4) 
N/D (Notch/Delta) 
NECD  (Notch extracellular domain) 
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NICD  (Notch intracellular domain) 
NK  (Natural Killer) 
Nrarp  (Notch regulated ankyrin repeat protein) 
Nrp-1  (Neuropillin 1) 
NSCs  (Neural Stem Cells) 
P (Post-natal day) 
PB  (Peripheral Blood) 
PBS (Phosphate Buffer Saline) 
PDGF-α/β  (Platelet Derived Growth Factor alpha/beta) 
PDGFR  (Platelet Derived Growth Factor Receptor)  
PECAM  (Platelet Endothelial Cell Adhesion Molecule)  
PGs  (Proteoglycans) 
PlGF  (Placental Growth Factor) 
PPCs  (Pericyte Progenitor Cells) 
PPS  (Posterior Primitive Streak) 
PSLG-1  (P-Selectin-Glycoprotein Ligand -1) 
RANTES  (Regulated upon Activation, Normal T-cell Expressed, and Secreted) 
RAP-1  (Ras-Related Protein 1) 
RBPj  (Recombining Binding Protein Suppressor of Hairless) 
RQ-PCR  (Real-Time Quantative PCR) 
RT-PCR  (Reverse Transcription-Polimerase Chain Reaction) 
SCA-1  (Stem Cell Antigen 1) 
SCF  (Stem Cell Factor) 
SCID  (Severe Combined Immunodeficiency) 
SD (Standart Deviation) 
SDF-1a  (Stromal Derived Factor 1 alpha) 
siRNA  (small interfering RNA) 
SM  (Smart Matrix) 
SMA  (Smooth Muscle Actin) 
t-PA  (tissue-type Plasminogen Activator) 
TAF  (Tumor Angiogenic Factor) 
TAL1 (T-cell Acute Lymphocytic Leukemia Protein 1)  
TAMs  (Tumor Associated Macrophages) 
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TEMs  (Tie-2 Expressing Macrophages) 
TGF-β1  (Transforming Growth Factor-beta1) 
Tie1/2  (tyrosine kinase with immunoglobulin-like and EGF-like domains 1/2) 
TNF-α  (Tumor Necrosis Factor alpha) 
u-PA  (urokinase-type Plasminogen Activator)  
VCAM-1  (Vascular Cell Adhesion 1) 
VE-cadherin  (Vascular Endothelial cadherin)  
VEGF  (Vascular Endothelial Growth Factor) 
VEGFR-1/2/3  (Vascular Endothelial Growth Factor Receptor-1/2/3) 
VEGI  (Vascular Endothelial Growth Inhibitor) 
VLA4  (Very Late Antigen 4) 
VN (Vitronectin) 
VPF  (Vascular Permeability Factor) 
VSMCs  (Vascular Smooth Muscle Cells) 
vWF  (Von Willebrand Factor) 
WT  (Wild-Type) 
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General Introduction 
 
Section 1 – Vascular system and neo-vascularization 
 
The cardiovascular system is the first functional organ system to develop in the vertebrate 
embryo and is required for survival of the embryo. Its main functions are to promote gas 
exchange, nutrient delivery, waste product removal and it also contributes towards the control of 
temperature and pressure/perfusion through vasoconstriction and vasodilatation. The 
cardiovascular system is composed by the heart (myogenic muscular organ responsible for 
pumping blood throughout the blood vessels by repeated, rhythmic contractions), blood (bodily 
fluid composed of different cell types and plasma, responsible for the transport and diffusion of 
oxygen, nutrients and waste products into to tissue cells) and blood vessels. Blood vessels are 
composed by a basic structural and functional unit termed endothelial cell (EC) which line the 
vessel lumens and is responsible for cellular and metabolic changes between all tissues and the 
blood1. 
 
1.1 – Formation of a vascular system during embryonic development 
Blood vessel formation during embryonic development starts during gastrulation (early phase of 
animal development during which the morphology of the embryo is reorganized to form the 
germ layers: 3 ecto-, meso- and endoderm). During gastrulation, the outer layer of the embryo 
(epiblast) invaginates into the primitive streak giving rise to the ecto-, meso- and endoderm. 
Subsequently, in the lateral and posterior mesoderm, the first cell population expressing an 
endothelial marker arises termed angioblasts2,3. Consequently angioblasts migrate into extra-
embryonic (extra-embryonic ectoderm, yolk sac and allantois) and intraembryonic sites 
(embryonic ectoderm). Around embryonic days 6.5 to 7.5 (E6.5-7.5), in the yolk-sac angioblasts 
differentiate into cell clusters denominated – blood islands. The outer cells of the blood islands 
give rise to ECs whereas the inner cells give rise to haematopoietic progenitors (primitive 
nucleated erythrocytes), that will give rise to hematopoietic cells (HCs). The angioblast derived 
ECs from neighbouring blood islands then fuse with each other and generate a primary capillary 
plexus, consisting of primitive endothelial tubes. These tubes will later form a functional 
vascular network that constitutes the vitelline circulation, which is adapted to transfer nutrients 
from the yolk sac to the embryo proper. Extraembryonic vasculogenesis also occurs in the 
allantois. Concomitantly, in the embryo, angioblasts migrate, aggregate and differentiate directly 
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into ventral/dorsal aorta and the cardinal veins. At the same time, proendocardial cells migrate 
and line up along the intestinal portal to form a single endocardial tube4. The process by which 
angioblast migrate into discrete locations, differentiate in situ and assemble into endothelial 
tubes is termed vasculogenesis and gives rise to the primary and secondary, more complex, 
vascular plexus. The subsequent growth, expansion and remodelling of this primitive plexus into 
a functional vascular network is termed angiogenesis5. During angiogenesis occurs splitting of 
vessel lumens by intussusceptive microvascular growth (IMG) and vessel branching from pre-
existing ones through sprouting, migration and proliferation of activated ECs.  At later stages 
ECs recruit mural cells (MC - pericytes and vascular smooth muscle cells - VSMCs) that 
promote vessel stabilization and regulation of vessel prefusion. In addition, the blood vasculature 
becomes further specialized into arteries, veins and capillaries (Figure 1). As the embryo further 
develops, the vascular system will form an extremely organized network that allows fully 
nutrition and oxygenation of all tissues6, 7.   
 
1.1.1 – Angioblasts, hemangioblasts and endothelial progenitor cells (EPCs) 
Angioblasts can be defined as dispersed (not associated with an organized vessel) mesodermal 
cells capable of differentiating into ECs. The differentiation of angioblasts into ECs can be 
defined molecularly and temporally. As defined molecularly a TAL1+ (T-cell acute lymphocytic 
leukemia protein 1) /VEGFR-2+ (vascular endothelial growth factor receptor-2) dispersed cell 
population of angioblasts first appears around E6.5 in extraembryonary tissues and around E7.3 
in intraembryonary tissues. Consequently the morphogenesis and maturation of blood vessels 
proceeds with the sequential expression of PECAM (platelet endothelial cell adhesion molecule) 
around E7.8, followed by CD34 (cluster of differentiation protein expressed in early HC and 
ECs), VE-cadherin, and later Tie2 (tyrosine kinase with immunoglobulin-like and EGF-like 
domains) around E8.2-8.5. Concomitantly there is a downregulation of TAL1 as angioblasts 
mature into ECs. The emergence of a TAL1+/VEGFR-2 negative hematopoietic progenitor cell 
population occurs in parallel, in the centre of blood islands8. These observations suggested that 
angioblasts can behave as an hemangioblast9: common progenitor to hematopoietic and 
endothelial lineages. Numerous studies have subsequently described the isolation of a VEGFR-
2+ progenitor cell population, capable of differentiating into either ECs or HCs depending on the 
culture media conditions. VEGFR-2+ progenitors/angioblasts have been isolated from the caudal 
mesoderm of the gastrulating avian embryo10, mouse embryo11, or murine embryonic stem cells 
(ESCs)12.  However an alternative theory has emerged suggesting that HCs originate from a 
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specific type of endothelium designated as hemogenic, and not from common precursors. Indeed, 
transient, time specific, “hemogenesis” arising at the floor of aortic endothelium is prominent in 
embryos of many vertebrate species13,14.  
The existence of angioblasts during embryonic development has prompted scientists to search 
for the presence of a progenitor population capable of differentiating into ECs also in adult 
individuals, which if found would suggest vasculogenesis might be recapitulated in adulthood. 
Indeed, an endothelial progenitor cell (EPC) population has been isolated from the bone-marrow 
(BM) and mobilized peripheral blood, (PB) of adult individuals15 and its contribution to 
physiological and pathological vessel formation has been extensively documented (Table 5). The 
process by which EPCs differentiate into ECs and form neovessels is termed postnatal 
vasculogenesis15; this mechanism will be extensively discussed in the next sections of this 
introduction. The concept of postnatal vasculogenesis is further supported by the observation that 
both EPC and angioblasts share common features, namely:  surface markers (ex. VEGFR2), both 
proliferate in an anchorage-independent manner and can be induced to migrate from discrete 
sites (BM or lateral/posterior mesoderm respectively) to sites of new vessel formation were they 
differentiate into ECs16.  
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Figure 1 – Blood vessel formation during embriogenesis. 1. Angioblasts originate in the posterior primitive streak 
(PPS) as VEGFR-2/Flk-1 + cells; 2. VEGFR-2/Flk1+ cells in the primitive streak give rise to both blood and 
endothelium (haemangioblasts) but are restricted to haematopoietic or angiogenic fate after emigrating into 
extraembryonic sites (extraembryonic ectoderm (EXE), yolk sac and allantois) and intra- embryonic sites 
(embryonic ectoderm (EEC); 3. In the yolk sac, these progenitors aggregate into endothelial-lined blood islands that 
then (4.) fuse to generate a primary/secondary capillary plexus; 5. The primary/secondary capillary plexus 
undergoes remodeling along with intraembryonic vessels to form a mature vessel network; 6. Intra-embryonic 
angioblasts migrate along distinct pathways before (7.) aggregating directly into the dorsal aorta or cardinal vein, 
without a plexus intermediate. 8. The primary vessels (capillary plexus,dorsal aorta, cardinal vein and endocardial 
tube) then remodel, together with the extra-embryonic plexus, to form a mature vasculature; 9. Mural cells 
(pericytes and smooth-muscle cells) proliferate, differentiate and are recruited in response to growth factors released 
by ECs. Figure adapted from Coultas, L. Endothelial cells and VEGF in vascular development. Nature 9, 653-660 
(2003). 
 
 
1.2 - Molecular regulation of blood vessel formation during embryonic development 
The complete molecular regulation of blood vessel formation during embryogenesis is still 
unclear. However several key molecules and pathways regulating different aspects of embryonic 
blood vessel formation have been identified and can be grouped according to the different steps 
of vessel formation: vasculogenesis (angioblast migration and differentiation into ECs) and 
angiogenesis (EC proliferation, migration, tube formation, MC recruitment, MC differentiation, 
EC maturation and EC specialization -artery vs vein)17, see table 3. In the next section a few of 
the main pathway regulating embrionary blood vessel formation will be further addressed, 
namely: Vascular Endothelial Growth Factor (VEGF) signalling pathway, Notch-Delta 
signalling pathway and also Integrin:Extracelular  matrix interactions. 
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1.2.1 – Vascular Endothelial Growth Factor (VEGF) signalling pathway 
The key regulator of vasculogenesis is the VEGF signalling pathway. The VEGF family includes 
VEGF-A18,19 and its related ligands VRF/VEGF-B20, VEGF-C21 VEGF-D22, VEGF-F23 and 
PlGF24. The VEGF receptors are tyrosine kinase receptors: VEGFR-1/Flt-125, VEGFR-
2/KDR/Flk-126,27, VEGFR-3/Flt-428 have several co-receptors including neuropilins and heparan 
sulphate proteoglycans29. VEGFR-1 and VEGFR-2 are expressed mainly by vascular ECs, 
monocytes, macrophages and hematopoietic stem cells. VEGFR-1 binds specifically PlGF and 
VEGF-A, while VEGFR-2 binds specifically VEGF-A (with ~10 fold lower affinity than 
VEGFR-1). The crucial role of VEGF-A in vascular development has been demonstrated by 
genetic studies (ie by the generation of knockout, KO, and transgenic mice). VEGF-A is 
essential for early development of the vasculature to the extent that inactivation of a single allele 
of the VEGF gene results in embryonic lethality. Heterozygous VEGF-A-deficient mouse 
embryos display abnormal vessels, and blood island formation and angiogenesis are impaired, 
resulting in embryonic death around E11-E12. Homozygous VEGF-A mice die in mid-gestation 
(E9.5) due to more severe cardiovascular defects30. Interestingly two-to threefold expression of 
VEGF-A from its endogenous locus results in embryonic abnormal heart development and 
embryonic lethality around E12.5-E1431. This data indicates that embryonic VEGF-A expression 
requires a precise dose-dependent regulation.  
VEGFR-2 is considered to be the main receptor acting as transducer of the VEGF-A mitogenic 
and chemotactic signals. VEGFR-2 targeted disruption leads to embryonic lethality between 
E8.5–E9.5 due to complete absence of ECs and HCs. This results from the incorrect migration, 
location of angioblasts into the mutant yolk sac and possibly to the embryonic sites of early 
haematopoiesis32,33. Interestingly VEGFR-1 null mutant mice die between E8-E8 because of the 
overgrowth of ECs and vascular disorganization. In these mice angioblasts are found lining but 
also in the lumen of blood islands and consequently fail to form secondary vascular plexus34,35. In 
contrast, mice expressing the VEGFR-1 that lacks the tyrosine kinase domain develop a normal 
cardiovascular system, suggesting that VEGFR-1 kinase activity might not be required for 
vascular development during embryogenesis and that VEGFR-1 may act as a decoy receptor 
preventing VEGF-A binding to VEGFR-236. In conclusion, VEGF/VEGFR-2 is one of the main 
axis regulating angioblast migration and differentiation during vasculogenesis. 
 
1.2.2 – Notch-Delta signalling pathway  
The Notch-Delta signalling pathway is an evolutionarily conserved signaling pathway that is 
required for embryonic development, the regulation of tissue homeostasis, and the maintenance 
 30 
of stem cells in adults. Notch pathway has multiple roles in cell fate specification, tissue 
patterning, and morphogenesis through effects on differentiation, proliferation, survival, and 
apoptosis37-39. In mammals, there are five canonical DSL (Delta, Serrate, LAG-2) ligands: Delta-
like 1 (Dll1), Delta-like 3 (Dll3), Delta-like 4 (Dll4), Jagged-1 (Jag1), and Jagged-2 (Jag2). 
These ligands are type 1 cell-surface proteins with multiple tandem epidermal growth factor 
(EGF) repeats in their extracellular domains40. DSL ligands bind to Notch receptors, which are 
single-pass, type I transmembrane receptors. In mammals, there are four Notch receptors, 
Notch1 to Notch4 (N1-N4). Binding of a DSL ligand to the extra cellular domain of Notch 
receptor (NECD) triggers a series of proteolytic cleavages of Notch, first by a member of the 
disintegrin and metalloproteases (ADAM) family within the juxtamembrane region, followed by 
gamma-secretase within the transmembrane domain. The final cleavage releases the Notch 
intracellular domain (NICD) from the cell membrane, which translocates to the nucleus and 
directly interacts with the transcription factor CSL (CBF1/RBPjκ/Su(H)/Lag-1)39,41. In the 
absence of NICD, CSL represses transcription through interactions with a corepressor complex 
that contains a histone deacetylase42. Binding of the NICD to CSL displaces the corepressor 
complex and replaces it with a transcriptional activation complex that includes the NICD, 
Mastermind-like (Maml), and histone acetyltransferase to turn on the expression of Notch target 
genes such as the basic helix-loop-helix proteins Hairy/Enhancer of Split (Hes), Hes-related 
proteins (Hey/HRT/HERP), and Notch regulated ankyrin repeat protein (Nrarp). Proteins 
encoded by the Hes and Hey genes are, in turn, transcriptional repressors of both their own 
expression and further downstream genes43 (Figure 2).  
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Figure 2 – Schematic representation of the Notch-Delta signalling pathway. The Notch receptor (N1-N4) is 
expressed on the cell surface as a heterodimeric receptor. The extracellular and membrane-bound intracellular 
fragments of Notch receptors (NECD and NICD) are held together trough noncovalent interactions. Upon ligand 
(Jag1-2, Dll1,3,4) binding DSL-ligand mediated endocytosis nonenzymaticaly dissociates the Notch heterodimer. 
The NECD is transendocytosed into the signal-sending cell, exposing the remaining membrane-bound receptor to 
ADAM and γ-secretase proteolysis the release the NICD. The NICD translocates into the nucleus to trigger 
transcriptional activation of Notch targets genes Hey, Hes and Nrarp. HDAc, Histone deacetylase; MAML, 
Mastermind-like; HAc, Histone acetyltransferase; NECD, Notch extracellular domain; NICD, Notch intracellular 
domain; ADAM, a disintegrin and metalloprotease; Ub, ubiquitin. Figure adapted from Phng, L.K. & Gerhardt, H. 
Angiogenesis: A Team Effort Coordinated by Notch. Developmental cell 16, 196-208 (2009) 
 
 
Of the Notch receptors, Notch1 and Notch4 are expressed by ECs; among the DSL ligands, Dll1, 
Dll4, Jag1, and Jag2 are expressed by ECs. Notch signaling components expressed in endothelial 
cells also include Rbpj, Hey1, Hey2, Maml, and Nrarp44,45. Functional studies using genetically 
modified animals have provided convincing evidence that Notch signalling plays a key role in 
embryonic blood vessel formation (table 1). 
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Table 1. Vascular phenotypes in genetically modified mice for components of the Notch-Delta pathway. 
Adapted from Al Haj Zen A, Madeddu, P.Notch signalling in ischeamia-induced angiogenesis. Biochem Soc Trans. 
7(Pt 6):1221-7 (2009). 
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1.2.2.1 – Notch-Delta signalling pathway during embryonic blood vessel formation 
The Notch-Delta signalling during embryonic vessel formation is essential for both 
vasculogenesis and angiogenesis. The role of Notch signalling in early vasculogenesis has been 
addressed by Sato, Y et al. These authors show that in chick embryos Notch signalling modulates 
the migration of a subpopulation of angioblasts from the lateral mesoderm towards the dorsal 
aorta and induces their specification to ECs that in turn incorporate the primary dorsal aorta46. 
This Notch-induced ventral migration is mediated by EphrinB2 and by an attractant action of the 
primary aorta involving a chemoattractant still not identified47. The role of the Notch-Delta 
pathway in early vasculogenesis has been further demonstrated in zebrafish where it regulates 
angioblast specification, migration, and maintenance trough snrk-1 and gridlock48-49.  
As the primary and secondary vascular plexus are established by vasculogenesis, angiogenesis 
will remodel and further increase the vascular system. At this stage Notch-Delta signalling is 
essential since it regulates numerous aspect of EC biology, namely: cell specification; 
proliferation; motility; matrix production/assembly and cell adhesion and vessel stabilization50. 
Concerning EC specification it has been shown that notch signaling directly regulates the 
expression of arterial markers (namely EphrinB2) thus conferring an arterial phenotype to ECs 
when active51. Another EC phenotype regulated by Notch-Delta pathway together with the 
VEGF pathway is the tip/stalk cell phenotype, which are EC transient states that determine if a 
cell sprouts into a new branch (tip cell - widespread filopodia formation, 
Dll4+PDGFR+Unc5b+VEGFR-2+VEGFR-3+) or not (stalk cell)52.  Dll4 mediated Notch-1 
activation in ECs determines a stalk phenotype while its inhibition results in a tip cell 
phenotype53. Notch signaling activation also regulates EC proliferation, decreasing it via a 
decrease in the activation of the MAPK and PI3K/Akt signaling pathways involving MAML-
mediated transcription of target genes. In fact, Notch signalling regulates MAPK and PI3K/Akt 
indirectly through differential regulation of VEGFR-1 and VEGFR-2 thereby reducing VEGFR-
2-mediated MAPK and PI3K/Akt signalling54. Also Notch activation decreases the expression of 
p21CIP1 leading to cell cycle arrest55. Another phenotype that results from notch activation in ECs 
is a decrease in vessel filopodia formation and migratory ability, which possibly results from a 
decrease in VEGFR-2, 3 and Nrp-1 expression and consequent reduced migration of ECs 
towards VEGF-A50. Notch pathway also regulates EC adhesion and ECM production. Namely, 
N1 activation induces integrin β1 activation and consequent adhesion by inducing R-Ras 
activation. Concerning ECM production embryos overexpressing Dll4 show increased FN, LN 
and ColIV transcription in ECs56. Finally the role of Notch in vessel stabilization is also 
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documented, namely Notch activation induces EC senescence and therefore less responsiveness 
to pro angiogenic stimuli. Namely as mention above by reducing tip cell phenotype, EC 
proliferation, migration/filopodia formation, integrin adhesion and increasing ECM production 
the Notch pathway activation leads to more stable and less activated vessels contributing to the 
maturations of newly formed vasculature50.  
 
Besides these fundamental signalling pathways in determining angioblast identity, differentiation, 
migration and finally vessel formation during embryogenesis, many other pathways have been 
implicated in this intricate and complex process (Table 3). In the context of this PhD Thesis, it is 
of particular importance to describe and discuss the function of structural/morphogenic signals 
during vessel formation namely interaction between integrins and extracellular matrix (ECM) 
components. The influence of these signals in embryonic vessel formation will be discussed in 
the next sections.  
 
1.2.3 – Integrin:extracellular matrix (ECM) signalling pathways 
Integrins are a family of noncovalently associated heterodimeric transmembrane glycoproteins 
adhesion proteins which mediate cell-ECM and cell-cell interactions. Integrins are responsible 
for cellular/tissue arquitecture and also function as signal transducers regulating survival, 
proliferation, differentiation and migratory signalling pathways.  Each integrin is composed of 
two sub-units: one α (around 800 amino acids) and one β–subunit (approximately 1000 amino 
acids). In higher vertebrates 18 α-	   and 8 β-subunits combine to form more than 24 different	  
integrin heterodimers. Heterodimer composition confers ligand	   specificity, with most integrins 
recognizing several	   ECM proteins that in turn bind to more than one integrin57. ECs express a 
subset of mammalian integrins including: the fibronectin (FN) receptors, α4β1, α5β1; the 
collagen receptors, α1β1, α2β1; the laminin receptors, α3β1, α6β1, and α6β4; the vitronectin 
receptors αvβ3 and αvβ5 (that also bind FN) and the osteopontin and tenascin receptor, α9β158. 
The effect of genetic ablation of different integrin subunits on embryonic blood vessel formation 
is summarized in Table 2. 
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Table 2. Vascular phenotypes of the different integrin subunit KO mice. Adapted from Silva R, D'Amico G, 
Hodivala-Dilke KM, Reynolds LE. Integrins: the keys to unlocking angiogenesis. Arterioscler Thromb Vasc Biol. 
28(10):1703-13 (2008). 
 
 
1.2.3.1 – Integrin:ECM signalling pathways during embryonic blood vessel formation 
The role of the different integrin subunits in initial steps of vasculogensis is still under debate. 
However integrin subunit β1 has an essential role in vasculogenesis, since its inhibition with 
neutralizing antibodies during quail embryos vasculogenesis impairs cord-like assemblies of 
angioblasts and consequently aortic vessel formation59. In a similar study Drake et al revealed 
that integrin αVβ3 also regulates angioblast cellular protrusions thus impairing vessel formation 
and maturation60. More recently, using β1 integrin-deficient mouse ESCs (embryonary stem 
cells) it was shown that vessel formation was abnormal due to reduced endothelial cell 
maturation, migration and elongation and increase apoptosis61. In another study using ESCs, α5-
integrin–null and FN-null EBs (embryoid bodies) show abnormal vascular formation compared 
with wild-type, β3-integrin–null, or αv-integrin–null EBs62. These data indicates that α5β1 
integrin/FN interactions are necessary for basic cellular processes involved in normal vessel 
development and that the endothelial functions of α5 integrin can be separated from those of αv 
integrin and β3 integrin63. 
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The role of different integrin subunits in embryonic angiogenesis is somewhat clarified. The 
integrins expressed by ECs that seem to be essential for embryonic blood vessel formation, 
assessed during the analysis of their KO mice vascular phenotypes, are the FN binding integrins 
α5β1 and α4β1 and the vitronectin binding αV-integrins. Genetic ablation of α5 integrin results 
in a lethal phenotype at E10-11 of gestation where the yolk sac and embryonic vascular network 
fail to form properly. However deletion of α5 integrin on ECs (Tie-2 expressing cells) has no 
effect on vascular formation, due to compensation by subunit αV64. Interestingly α5β1 integrin is 
poorly expressed on normal quiescent endothelial cells, but its expression is markedly 
upregulated during angiogenesis where it activates intracellular signalling pathways when bound 
to FN that protect ECs from apoptosis, enhance their migration, and regulate their 
proliferation65,66. Global deletion of the α4 integrin subunit results in an embryonic lethal 
phenotype caused by failure of the allantois to fuse with the chorion during placentation and 
defects in the developing epicardium and coronary vessels. However deletion of α4 integrin on 
ECs generates viable mice with no vascular defects, suggesting that vascular defects in the 
knockout mice might be due to defects in MC migration and vessel stabilization67. β1 integrin-
null embryos die at E5.5 and do not develop far enough to begin to produce vasculature. 
Moreover, mice with deletion of integrin β1 specifically on ECs (Tie-2 expressing cells) develop 
until E9.5-E10.5, allowing the formation of a simple vasculature. Analysis of the vasculature 
revealed defects in angiogenic sprouting and vascular branching morphogenesis, implying that 
β1 integrin is essential for angiogenesis68-70. These authors propose that integrin β1 is not 
essential for vasculogenesis, however they have only tested the lack of integrin β1 on Tie-2+ 
expressing ECs and not on early angioblasts (TAL1+ VEGFR-2+ CD31 negative CD34 negative 
Tie-2 negative17). αV-null mice develop normally until embryonic day 9.5. However, only 20% 
survive until birth and 100% die within the first day of birth. These mice develop intracerebral 
hemorrhage attributable to defective interactions between blood vessels and brain parenchymal 
cells. However mice with vascular deletion of αV integrins show no vascular defects due to 
compensation by α5 subunit64. 
 
1.2.3.2 – ECM components during embryonic vessel formation 
ECM is a non-cellular component present within all tissues and organs, and provides not only 
essential physical scaffolding for the cellular constituents but also initiates crucial biochemical 
and biomechanical cues that are required for tissue morphogenesis, differentiation and 
homeostasis71. The ECM is composed of two main classes of macromolecules: proteoglycans 
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(PGs) and fibrous proteins72,73. The main fibrous ECM proteins are collagens (Col), elastins, 
fibronectins (FNs) and laminins (LNs). PGs fill the majority of the extracellular interstitial space 
within the tissue in the form of a hydrated gel74. The ECM provides critical support for vascular 
ECs and consequently for vessels assembly and function. Primarily through adhesive interactions 
with integrins on the ECs surface, ECM provides a scaffold essential for maintaining the 
organization of vascular ECs into blood vessels. In addition, EC adhesion to ECM provides 
signals required for EC proliferation, migration, morphogenesis, survival, and ultimately blood 
vessel stabilization. Concerning blood vessel formations there are two types of ECM structures: 
the interstitial ECM that is outside blood vessels and is composed mainly by collagens (types I 
and III) and provisional plasma-derived FN/fibrin matrices and there is also the basement 
membrane (BM) ECM composed mainly by LN, collagen type IV (col IV), perlecans and 
nidogens-1 and 2.  Intersticial ECM is associated with EC activation, proliferation, migration and 
tube formation while the basement membrane ECM is associated with proliferation cessation, 
differentiation and vessel stabilization74. Interestingly knockout mice for components of both 
types of ECMs show vascular defects, mainly the basement membrane components. Namely, FN 
knockout mice are embryonic lethal on E8.5, showing failures in development of both embryonic 
and extraembryonic vasculatures75. Mice lacking ColIV (isoforms α1 and α2) are embryonic 
lethal on E10.5-E11.5, showing hemorrhage in heart, arteries and yolk sack76. LN α4 chain 
knockout mice die after birth, with diffuse hemorrhagic phenotype from smaller vessels (display 
a discontinuous BM in capillaries)77. LN α5 chain knockout mice die on E13.5-16.5 with 
abnormalities in placental blood vessels78. Perlecan knockout mice are lethal on E13.5-E16.5, 
with few vascular defects except for some aneurisms in lung, skin and brain79. Mice lacking 
nidogens 1 and 2 are viable with no obviously vascular defects80,81. Considering this it is 
apparent that the ECM component that shows a stronger effect on vessel formation is FN, 
resembling FN binding integrins α5β1 and α4β1 knockout phenotypes, suggesting an essential 
role of this molecular interaction on embryonic vascologenesis and angiogenesis. Interestingly 
coronary vasculogenesis, which first occurs in gestation day 13 hearts (in rats) was preceded by 
the deposition of FN indicating that FN may provide a primary scaffolding for the migration of 
angioblasts82. It has also been shown previously that abundant levels of FN are present in blood 
islands and the capillary plexus whereas LNs, Cols, and other extracellular matrix molecules are 
produced by ECs later in vasculogenesis83. Adding to this, the phenotypes on LN and Col IV 
knockout mice suggest that these ECM proteins are essential for blood vessel maturation and 
stabilization, during angiogenesis and not vasculogenesis. 
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1.2.4 – Major signalling pathways regulating embryonic blood vessel formation 
Besides the above-mentioned fundamental pathways regulating vessel formation during 
embryogenesis, many other pathways have been implicated in this intricate and complex process. 
Depicted on table 3 are some of these pathways, their function and the vascular phenotypes 
observed in the KO mice. 
 
Table 3 Molecular mechanisms involved in embryonic blood vessel formation. Adapted from Ribatti, D., Nico, 
B. & Crivellato, E. Morphological and molecular aspects of physiological vascular morphogenesis. Angiogenesis 12, 
101-111 (2009). 
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1.3 – Postnatal blood vessel formation 
1.3.1 – Angiogenesis: physiological and pathological  
In healthy adult individuals most blood vessels do not proliferate. EC are among the longest- 
lived cells in the body, and only 1 in every 10000 EC of a blood vessel is in cell division at any 
given time84,85. However in response to specific stimuli ECs can be activated, proliferate, migrate, 
differentiate and mature into new stable blood vessels. This process of capillary formation from 
pre-existing ones is termed angiogenesis and is necessary for various physiological processes 
such as organ growth, wound healing, revascularization of ischemic tissue, ovulation, 
menstruation, implantation and pregnancy. Physiologic angiogenesis is a tightly regulated 
process, i.e. turned on for brief periods and then completely inhibited (Figure 3). Abnormalities 
in the molecular processes regulating angiogenesis can lead to innumerous pathologies as a result 
of excessive/abnormal angiogenesis (ex. cancer, psoriasis, arthritis or blindness) or insufficient 
angiogenesis/vessel regression (ex. delayed wound healing, tissue ischemia or 
atherosclerosis)1,86. A fine regulation of angiogenesis is possible due to the existence of multiple 
molecular pathways that regulate positively (pro-angiogenic) and negatively (anti-angiogenic) 
angiogenesis (termed “angiogenesis balance”). Hypoxia is a key regulator of angiogenesis, since 
cells can sense low levels of O2 wich in turn will activate the transcription of several hypoxia-
inducible factors (HIFs) and other molecules that promote the initiation of angiogenesis and the 
vascularization of avascular zones. Thus the first steps of angiogenesis involve induction of 
hypoxia and consequent activation of the hypoxia-inducible factor – HIF-1α that induces the 
transcription of several genes including Vegf-A and Vegfr-287. VEGF-A will generate a gradient 
that, concomitantly with the Notch-Delta signaling, determines the formation of endothelial “tip” 
and “stalk cells”88. The differentiated tip cell up regulates the expression of a membrane type 1-
matrix metalloproteinase (MT1-MMP) that degrades the vessel basement membrane and invades 
the surrounding matrix89. Concomitantly VEGF-A along with other EC mitogenic factors 
produced by hypoxic cells or released from the ECM by proteolytic cleavage (including basic 
fibroblast growth factor – bFGF; platelet derived growth factor – PDGF and epidermal growth 
factor – EGF) induces EC proliferation, resulting in the formation of a new vessel sprout. As 
ECs respond to VEGF-A there is up-regulation of Notch-Delta ligands in “tip cells” (namely 
Dll4) that binds to its receptors N1 and N4 in adjacent “stalk” ECs blocking their proliferation, 
thus limiting the extent of the new sprout50. As the new sprout is established and perfused, VEGF 
levels decline and the vessel maturation initiates with a rise in PDGF-BB, angiopoietins (Ang), 
and transforming growth factor-β1 (TGFβ1) expression responsible for the recruitment and 
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stabilization of pericytes and vascular smooth muscle cells (VSMC) around the newly formed 
vessel. Pericytes and VSMC provide stabilization and maturation signals, namely the production 
of tissue inhibitor of metalloproteinases 2 (TIMP2) that switches off the EC proteolytic 
phenotype. Consequently vessel lumen is tightly sealed by adjoining ECs held together by tight 
junctions and adherens junctions and a BM is then produced by ECs (induced by TGFβ1 
signaling) and surrounding cells, providing structural support and maintaining ECs quiescent. In 
fact, besides the proliferative and differentiation stages of ECs, one of the crucial steps in 
angiogenesis is the recruitment of pericytes to the newly formed endothelial tubes90. Pericytes 
and VSMCs express Ang-1 that binds TIE2 receptors expressed by ECs. This tight interaction 
mediates blood vessel stabilization, but can be antagonized by Ang-2 expression. During the 
transition from the quiescent to the activated phenotype, release of Ang-2 from ECs antagonizes 
Ang-1 function and increases BM degradation and EC migration91. Once tube formation is 
complete, blood flow to the newly vascularized area increases local oxygen levels resulting in a 
decrease in VEGF-A levels and an end to angiogenesis92,93. 
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Figure 3 – Molecular mechanisms involved in postnatal angiogenesis. 1. Increased tissue hypoxia causes 
increased production of VEGF, creating a gradient from the hypoxic area to the nearest blood vessel. In the absence 
of antiangiogenic signals such as MC (white cells) coverage, ECs (green cells) become sensitive to VEGF, 
increasing VEGFR-2, Dll4 and MMP expression thus becoming sprouting “tip-cells”. Sprouting requires the 
flipping of apical–basal polarity, the induction of motile and invasive activity, the modulation of cell–cell contacts 
and local basement membrane (blue) degradation; 2. In response to the VEGF gradient “tip-cells” extend filopodia 
into the intersticial ECM (blue grid) and become higly invasive. Progressive invasion of “tip-cell” EC into the ECM 
promotes its degradation and consequent growth factor (GF) release; 3. Sprout extrension occurs as endothelial 
“stalk-cells” proliferate in response to VEGF and other GF released upon ECM breakdown. Adhesive or repulsive 
interactions that occur when tip cells encounter each other regulate the fusion of adjacent sprouts and vessels. 
Lumen formation in “stalk” ECs involves the fusion of vacuoles but other mechanisms may also contribute. 4. 
Fusion processes at the EC–EC interfaces establish a continuous lumen. Blood flow improves oxygen delivery and 
thereby reduces VEGF and other hypoxia regulated factors production.  Perfusion is also likely to promote 
maturation processes such as the stabilization of cell junctions, basement membrane deposition and tight MC 
attachment via production of PDGF, Ang1 and TGF-β. Figure adapted Adams, R.H. & Alitalo, K. Molecular 
regulation of angiogenesis and lymphangiogenesis. Nat Rev Mol Cell Biol 8, 464-478 (2007) 
 
 
1.4 – Postnatal Vasculogenesis 
Historically, vasculogenesis has been defined as an embryonic process by which new vessel are 
generated by migration and differentiation of VEGR2-2+ mesodermal precursors, termed 
angioblasts/hemangioblasts, into ECs that coalesce to form a primary vascular plexus. 
Nevertheless the existence of an equivalent process during adulthood – postnatal vasculogenesis 
- has been intriguing vascular/hematological research since the early 20th century, when the first 
studies describing blood vessel formation from peripheral blood (PB) and bone-marrow (BM) 
mononuclear cells (MNCs) were published94-97. These studies suggested the existence of a 
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population of cells in the PB and/or BM capable of generating ECs when cultured under specific 
conditions98. However only in 1997 Asahara et al isolated and characterized for the first time a 
CD34+ or VEGFR-2+ cell populations, derived from peripheral blood (PB) capable of 
differentiating into ECs in vitro when coated on FN and exposed to angiogenic growth factor 
stimuli (namely VEGF). According to Asahara et al, in vivo animal model of ischemia show that 
these CD34+/VEGFR-2+ cells incorporated newly formed vessels and acquired the expression 
of EC antigens. These cells where thus termed EPCs15. In 1998 Shi et al proposed that EPCs 
could derive from the BM and significantly contribute to the endothelization of Dacron graft 
placed on the descending thoracic aorta in dogs99. Later Peichev et al limited the molecular 
definition of human EPCs to CD133+ (prominin, early stem cell marker with no attributed 
function) CD34+ VEGFR-2+ cells present in adult mobilized peripheral blood, chord blood and 
also fetal livers100. This seminal paper proposed that CD133, together with other endothelial 
markers including VEGFR2, CD34, among others, could be used to distinguish EPC from 
mature EC and also from other tissue stem cells. Subsequently, numerous papers have been 
published where an EPC population has been identified using CD34 or CD133 or VEGFR-2 or 
any combination thereof101. In an attempt to identify a single EPC marker Gehling et al. showed 
that CD133+ cells from granulocyte colony-stimulating factor–mobilized peripheral blood have 
the capacity to differentiate into ECs in vitro and in vivo102. Besides the effort to molecularly 
define EPCs, other cell types have also been show to behave as EPCs and/or to differentiate into 
ECs. In fact, ECs can be ex vivo differentiated from multiple cell populations residing at 
different organs and tissues. In the BM ECs can be differentiated from HSCs (CD34+ CD133+), 
myeloid cells (CD14+/CD34-)103,104 and mesenchymal stem cells (MSCs CD105+ CD73+ 
CD166+ CD90+ and CD44+ and negative for typical HC and EC markers)105. In non-BM tissues 
ECs can be differentiated from tissue resident stem cells including stromal vascular fraction 
(CD34+/CD31- cells) of adipose tissue130, from heart stem cells (c-Kit+ cells)106 and from neural 
stem cells (NSCs)107. More recently EPC have been found localized in the adventitial layer of the 
endothelium were they might be important for EC replacement in large vessels108. Other sources 
of EPCs are the chord-blood CD133+ CD34+ cells109 and fetal liver VEGFR-2+ CD133+ 
CD34+110. Considering the above there is no simple and clear molecular definition of EPCs 
possibly because the different cell phenotypes may reflect different maturation stages or different 
subpopulations of EPCs.  
For the sake of clarity, in the context of this Thesis, EPCs will be defined based on 3 basic 
properties: EPCs are nonadherent cells that gain adhesive and other endothelial properties during 
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EC differentiation; are capable of clonal expansion and most importantly have stemness 
characteristics (such as proliferation and resistance to stress) and markers (CD133, CD34, c-Kit, 
Sca-1 only in mice)111. Despite the controversy regarding their identity it is now accepted that 
EPCs are BM, PB, CB or fetal liver derived-cells defined as: lineage negative (Lin-), CD133+ 
CD34+ c-KIT+ (Sca-1+ in mice) CD146+ VEGFR2+ CXCR4+ vWF+ PECAM+ Tie-2+, 
AcLDL+, lectin binding cells that upon endothelial differentiation loose expression of stem 
antigens: CD133 in humans and Sca-1 in mice112. 
The contribution of EPCs in vascular remodelling in physiological and pathological conditions 
has been further demonstrated in animal models of BM transplants with genetically engineered 
cells (see table 5). The existence of EPCs and their ability to participate in vessel formation by 
differentiation into ECs confirmed the existence of vasculogenesis in adulthood – termed 
postnatal vasculogenesis – constituting a major paradigm shift in the field of vascular biology. 
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Section 2 – Molecular Mechanisms Regulating Postnatal Vasculogenesis 
 
2.1 – Endothelial Progenitor Cells (EPCs) 
Since Asahara and colleagues first described EPCs there have been numerous studies concerning 
the biology and the function of this cell population. Interestingly in the last decade, it has been 
established that in order to exert their role on the vasculature EPCs have to accomplish 4 distinct 
but interrelated steps 1) Respond to chemoattracting signals and mobilize to the PB; 2) Home at 
sites of vascular remodeling, repair and angiogenesis; 3) Invade and migrate at the same sites; 4) 
Differentiate into mature ECs and/or regulate pre-existing ECs via paracrine or justacrine 
signals113 (Figure 4). 
 
 
 
Figure 4 – Molecular mechaninsms by which EPC contributes to postnatal vasculogenesis. Recruitment and 
incorporation of EPCs into angiogenic sites requires a coordinated multistep process including mobilization, 
chemoattraction, adhesion, endothelial transmigration, migration, tissue invasion, in situ differentiation and 
paracrine/justacrine factor production. Factors that are proposed to regulate the distinct steps are indicated. Figure 
adapted from Fusieng, N. & Marmé, D. Tumor Angiogenesis: Basic Mechanisms and Cancer therapy. Springer 
Chapter 17 (2008). 
 
 
 
2.2 – Molecular regulation of EPC localization and mobilization  
The BM niche is the main anatomical site where EPCs are believed to reside in steady-state 
conditions. The BM is a very complex tissue, composed of different cell types (EPCs, MSCs, 
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progenitor/mature HCs and stromal cells – fibroblasts, macrophages, adipocytes, osteoblasts, 
osteoclasts, ECs and MCs) and its main function is the production and release into the PB of 
HCs – termed hematopoiesis114. Altogether the vascular compartment (ECs and MCs) of the BM 
constitutes the “vascular niche” while the bone compartment (osteoclasts and osteoblasts) 
constitutes the osteoblastic (or endosteal) niche115,116. The adult BM is known to contain a 
population of hematopoietic stem cells (HSCs) that can be divided into a more mature fraction 
(lineage positive, Lin+, which represents cells that have undergone hematopoietic 
“commitment”) and a more undifferentiated fraction (Lin−, which represents undifferentiated 
cells and those that have not undergone hematopoietic commitment). Lin− cells have been 
shown to contain a population of EPCs117. The osteoblastic niche provides a quiescent 
microenvironment for stem cell maintenance – stem cell niche – and since part of the resident 
HSCs/EPCs are believed to be in contact with cells in this niche, several molecules have been 
identified and thought to regulate HSC/EPCs retention and quiescence. The main molecules 
involved in HSC/EPC interaction with the osteoblastic niche are respectively: integrin β1 – 
Osteopontin; c-Kit – membrane-bound stem cell factor; Tie-2 – Angiopoietin2; N-Cadherin – N-
Cadherin; CXCR4 – SDF-1α and Notch1 – Jagged-1118. However the BM microenvironment 
might switch from a quiescent state to a proliferative state upon tissue injury that causes the 
release of hypoxia-induced soluble factors, for instance, (growth factors, cytokines, chemokines) 
into the PB. As these factors enter the BM there is an increase in the expression of proteases 
(enzymes with proteolytic activity: elastase, cathepsin G and metalloproteinases [MMPs]), 
adhesion molecules and angiogenic factors. Namely, there is the upregulation of angiogenic 
factors, such as SDF-1 (stromal derived factor-1), VEGF and PlGF that induce protease 
expression and activity, which in turn cleaves adhesive bonds on stromal cells, or factors that 
promote HSC/EPCs mobilization, resulting in HSC/EPCs release. In detail, MMP-9 released by 
BM stromal cells exposed to stress signals and/or factors that promote HSC mobilization, 
cleaves ECM-bound and membrane-bound Kit ligand (mKitL) releasing soluble Kit ligand 
(KitL; also known as stem cell factor) that transfers HSC/EPC from the quiescent osteoblastic 
niche into the proliferative vascular niche enabling their recruitment into the circulation119. 
Moreover, these upregulated proteinases cleave the cytokine SDF-1, which is released by 
stromal cells and its receptor CXCR4 on HSC/EPCs120. Decreased BM levels of SDF-1 and high 
levels of circulating SDF-1 (produced by damaged tissue) reverse the SDF-1 gradient across the 
BM barrier, forcing CXCR-4+ cells to exit the BM121. Another regulator of HSCs/EPCs 
mobilization from the BM is endothelial nitric oxide synthase (eNOS). eNOS is expressed by 
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BM stromal cells and directly regulates MMP-9 enzymatic activity thus regulating recruitment of 
HSCs/EPCs122. Altogether proteases will cause HSCs/EPCs to dissociate from the osteoblastic 
niche, start to proliferate locally, migrate into the vascular niche and selectively enter PB upon 
direct interaction with BM ECs via respectively: E-selectin/VLA4 – VCAM-1; Tie-2 – Ang-1 
and CXCR4 – SDF-1α interactions118. Interestingly angiogenic factors like VEGF may regulate 
the expression of adhesion molecules on BM EC and control the transendothelial migration of 
EPC123. 
 
2.2.1 – Molecular signals that regulate EPC mobilization from the BM 
There are numerous factors produced outside the BM niche that can induce EPC mobilization by 
interfering with BM endogenous regulation. These comprise cytokines, chemokines, angiogenic 
growth factors, hormones and pharmacological drugs. 
 
2.2.1.1 – Cytokines regulating EPC mobilization from the BM 
The main cytokines involved in EPC mobilization are GM-CSF (granulocyte-monocyte colony 
stimulating factor), G-CSF (granulocyte colony stimulating factor) and erythropoietin (Epo). G-
CSF is a major mobilizer of HSCs, which has been used in the setting of BM transplantation for 
years. G-CSF has been shown to recruit EPCs capable of stimulating vascularization in 
myocardial infarcts models124 and in tumor models125. More recently, it has been shown that G-
CSF can also mobilize EPCs in response to vascular disturbing agents126. Mechanisms regulating 
G-CSF induced mobilization of EPCs are indirect, since EPCs have not been shown to express 
G-CSF receptor127, and involve upregulation of proteases expression on the BM117. Another 
possible mechanism underlying the mobilization effects of G-CSF may involve modulation of 
BM SDF-1 levels120. Erythropoietin (Epo) has the main functions of inducing the proliferation of 
early erythroid precursors and the differentiation of late precursors of the erythroid lineage in the 
BM microenvironment. Interestingly Epo significantly increases EPC recruitment in 
experimental models in vivo128 and in humans129. 
 
2.2.1.2 – Angiogenic Growth factors regulating EPC mobilization from the BM 
The major angiogenic growth factors described to be involved in EPC mobilization are VEGF, 
PlGF and Ang-1. Increased levels of VEGF correlate directly with EPCs levels, as shown in 
vascular trauma patients (patients suffering acute vascular insult secondary to burns or coronary 
artery bypass grafting)130, patients with acute myocardial infarction131, patients with different 
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cancer types132-135 and also murine models of ischemia136 and cancer137. It is also possible to 
experimentally modulate EPCs mobilization in murine model, using recombinant VEGF protein 
or VEGF expressing plasmids121,138. VEGF induced recruitment is dependent on both receptors 
as demonstrated using neutralizing antibodies139. The mechanism by which VEGF induces EPC 
mobilization are believed to act trough MMP-9 activation in the BM but can be also due to 
increased BM vessel permebilization or increased expression of adhesion molecules on BM 
ECs123. A recent study shows that BM expression of integrin β3 regulates negatively VEGF-
induced EPCs mobilization140. Positive correlation between EPC PB levels and PlGF has also 
been observed in mouse models of skin cancer139. Similarly, PlGF-induced mobilization is 
mediated mainly via MMP-9141. bFGF is also a EPC mobilizer as shown in mouse models of  
corneal angiogenesis142. Angiopoietins (Ang), are also involved in EPC (Tie-2+ cells) 
recruitment to tumour blood vessels. In mouse brain tumour models, BM-derived EPC strongly 
localized to Ang-2-expressing areas, but not with Ang-1-positive cells, suggesting that increased 
Ang-2 activity provides a pro-angiogenic environment that enhances the recruitment of EPC into 
the tumour vessels143. 
 
2.2.1.3 – Chemokines regulating EPC mobilization from the BM 
SDF-1 and its receptor CXCR-4 are one of the main chemokine:receptor regulating EPC 
mobilization. Positive correlations between circulating EPCs and SDF-1 plasma levels have been 
show in models of arterial injury144, acute coronary syndrome145, response to vascular disrupting 
agents146, cancer models147-149, cutaneous wound healing150, burn patients151 and also tested in 
murine models receiving plasmids expressing SDF-1121. The mechanism by which SDF-1 
mobilizes EPCs involves reversing the SDF-1 BM gradient (which retains EPCs in the BM 
osteoblastic niche), releasing EPCs into circulation. The role of IL-8 and its receptor CXCR2 in 
EPC recruitment has been shown in model of myocardial acute ischemia and in patients with 
myocardial infraction152,153. According to these studies IL-8-mediated recruitment of EPC to the 
ischemic heart regulates their ability to induce myocardial neovascularization, protection against 
cardiomyocyte apoptosis, and functional cardiac recovery. In another study, blocking IL8 
receptor (CXCR2) inhibited incorporation of human EPCs expressing CXCR2 at sites of arterial 
injury in athymic nude mice154. 
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2.2.1.4 – Hormones and drugs regulating EPC mobilization from the BM 
Hormones can also mobilize EPC from the BM. Estrogens have been show to increase EPC 
levels, inhibiting apoptosis, in mice models of vascular injury155,156. Interesting women with high 
plasma levels of estrogen show increased mobilization of EPCs157. Insulin also increases EPC 
mobilization namely in models of arterial injury158. Besides the above-mentioned factors there 
are numerous pharmacological agents that can induce EPC mobilization namely, lipid-lowering 
agents – statins – (3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors159, antidiabetic 
and antiinflammatort peroxisome proliferator-activated receptor-γ agonists, among many 
others160-163. 
  
2.3 – Molecular regulation of EPC homing during vascular remodelling  
After being mobilized from the BM into the PB EPCs become a small percentage of circulating 
cell along with other hematopoietic populations. Considering this, EPCs must be specifically 
responsive to signals present at injury/remodelling ECs as opposed to signals present at 
normal/quiescent EC. Recognizing such signals enables EPC to home to sites of vessel 
injury/remodelling where they become activated by local chemo-/cytokines, adhere to activated 
ECs and incorporate and differentiate into newly formed vessels or act via paracrine/justacrine 
interactions on pre-existing ECs. Direct evidence of EPC homing and incorporation into tumor 
vasculature comes from a recent work by Vajkoczy et al using intravital fluorescence 
videomicroscopy and murine embryonic EPCs (eEPCs)164. According to this study EPCs home 
to the tumor vasculature where they become arrested, extravasate into the intersticium and 
incorporate new vessels. This study further suggests that eEPC homing to tumor vasculature 
occurs mainly by sticking (active adhesion to tumor without affecting blood flow) and not by 
plugging tumor blood vessels (size restrictions or dead-end vascular sprouts), contrarily to what 
happens in normal vasculature (Figure 5). The molecular mechanisms by which PB circulating 
cells home to specific sites have been well described during leukocyte homing into sites of 
inflammation. During inflammation the recruitment of leukocytes depends on a coordinated 
sequence of multistep adhesive and signalling events including: selectin-mediated rolling, 
activation by chemokines leading to activation of integrins, integrin-mediated firm adhesion to 
ECs monolayers, diapdesis trough ECs and finally migration/invasion into the extracellular 
matrix in a integrin/matrix-degrading proteases dependent way165. Evidence from recent studies 
suggests that the homing mechanisms of EPCs to angiogenic sites share commons features with 
the homing of leukcytes to sites of inflammation, namely: chemotaxis, adhesion, transendothelial 
migration and invasion. 
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Figure 5 – Experimental evidence of EPC interaction with the endothelium, extravasation and incorporation 
into tumor vasculature. 1. Circulating eEPCs interact with tumor endothelium (A) Tumor blood vessels before cell 
injection after contrast enhancement with FITC-conjugated dextran. Arrows indicate direction of microvascular 
blood flow. (B–E) Intravital microscopic sequence of two DiI-labeled eEPCs (1 and 2) interacting with the vessel 
wall of the identical vascular segment indicated in A. Cells adhere either permanently (1) or temporarily (2) to the 
endothelium. Numbers depict sequential time points in seconds (top right). 2. Extravasated eEPCs branch and 
interconnect tumor blood vessels. (A and D) Tumor microvasculature after contrast enhancement by FITC-dextran. 
(B and E) Same regions of interest as in A and D, demonstrating DiI-labeled eEPCs. (C and F) Superimposed FITC 
and DiI images after adding false colors to DiI images. eEPCs are marked with green false color. (A–C) eEPCs 
participate in angiogenic sprouting (arrow indicates vascular sprout; day 1 after injection). (D–F) eEPCs branch and 
span between individual tumor blood vessels interconnecting distant microvascular segments (arrows indicate 
vascular sprouts; day 1 after injection). 3. Bone-marrow derived EPCs are incorporated luminaly in tumor vessels. 
Image of a representative blood vessel showing an incorporated mature BM-derived GFP+ CD31+ VE-cadherin+-
coexpressing cell (arrow). The lumen of the vessel (L) and VE-cadherin staining the adherens junctions between 
ECs are shown. Bar, 20 µm. In the lower panel is the optical sectioning (Z-stack resolution, 0.275 µm) of the BM-
derived EPCs showing that GFP and CD31 signals are localized within the same individual cell (X–Z- and Y–Z-
axes are represented by the top and side panels). Figure 1 and 2 (and respective legend) taken from Vajkoczy, P., et 
al. Multistep Nature of Microvascular Recruitment of Ex Vivo-expanded Embryonic Endothelial Progenitor Cells 
during Tumor Angiogenesis. The Journal of Experimental Medicine 197, 1755-1765 (2003). Figure 3 (and 
respective legend) adapted from Nolan, D.J., et al. Bone marrow-derived endothelial progenitor cells are a major 
determinant of nascent tumor neovascularization.Genes & Development 21, 1546-1558 (2007). 
 
 
2.3.1 – Role of Chemo-/Cytokines in EPC homing 
EPC activation by chemokines is an essential step to recruit EPCs from the PB to ischemic tissue 
or to sites of tumor angiogenesis. Interestingly, factors that regulate EPC homing to angiogenic 
sites may be the same regulating HSCs BM engraftment. Namely SDF-1 has been shown to 
regulate both stem cell engraftment and recruitment of progenitor cells to ischemic tissue166-168 
where its expression is upregulated169-171. Accordingly to Abbot et al inhibition of the SDF-
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1/CXCR4 axis partially inhibits the homing of progenitor cells to the ischemic myocardium169. 
In vitro, inhibition of CXCR4 with an anti-CXCR4 antibody inhibits significantly SDF-1 
induced adhesion of EPCs to EC monolayers170 and in vivo reduces homing of EPCs to the 
ischemic limb in the model of hind limb171. Moreover, overexpression of SDF-1 enhanced stem 
cell homing and incorporation into ischemic tissues168,173. In accordance with this, CXCR4 gene 
transfer to EPCs enhances their reendothelization capacity in vivo174. Other chemokines such as 
IL-8/Gro-α and their receptors CXCR2 and CXCR1 mediate the homing of intravenously 
injected CD34+ progenitor cells to ischemic myocardium152. Also MCP-1 and interleukins 
produced by imuno competent cells that have invaded ischemic tissues can attract circulating 
progenitor cells including EPCs175. Interestingly Spring and colleagues demonstrated the 
expression of chemokine receptors CCR2 and CCR5 in EPCs and the expression of C-C 
chemokines in tumor vessels. According to the same study, inhibition of chemokine receptor 
signalling reduces significantly EPC homing and vessel incorporation176 supporting the 
involvement of G-protein coupled chemokines receptors in EPCs homing to tumor vessels. More 
recently CXCR2 expressed on EPCs and its ligands CXCL1 and CXCL2 have been shown to be 
essential in the homing of EPCs during allergic airways remodelling, namely in new 
peribronchial blood vessels formation177. Beside chemokines, other factors expressed at ischemic 
tissues may help recruitment of EPCs. Namely, high-mobility group box-1 (HMGB-1) that is a 
nuclear protein, is released upon cell activation by inflammatory cytokines and during cell 
necrosis and acts as a chemoattractant for inflammatory and stem cells in vitro and in vivo178,179. 
Indeed, HMGB1 induces migration of EPCs on FN and fibrinogen via integrins β1 and β2 
respectively. Also, short-term prestimulation of EPCs with HMGB1 also increases EPC adhesion 
to ICAM-1 and FN. In vivo EPCs treated with HMGB1 show increased homing to ischemic 
tissues and tumor vessels180. 
 
2.3.2 – Role of Adhesion molecules in EPC homing 
2.3.2.1 – Role of Selectins in EPC rolling 
The initial steps in leukocyte homing to inflammatory sites involve the rolling of leukocytes on 
the activated endothelium165. Rolling consists of brief low-affinity contacts with ECs, allowing 
leukocytes to become activated by cytokines and to become arrested in the inflammatory area. In 
circulating leukocytes rolling is mediated mainly by selectins and theirs ligands181 and also 
between integrin α4β1 and its ligand VCAM-1182. The selectin family consists of 3 related 
molecules: L-selectin (constitutively expressed in leukocytes), E-selectin (expressed on ECs 
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activated by inflammatory cytokines) and P-selectin (expressed in ECs and platelets). Selectins 
bind sialyl-Lewis-X-like carbohydrate ligands presented by sialomucin-like surface molecules 
such as P-selectin-glycoprotein ligand -1(PSLG-1)183. Although no rolling has been described in 
eEPCs interactions with tumor ECs, Vajkoczy et al shows that in vivo EPCs homing to tumor EC 
depends on an initial arrest mediated by E- and P-selectin and PSGL-1164. Moreover human 
CD34+ cells show efficient rolling on P-selectin, E-selectin and CD44 ligand hyaluronic acid 
under physiologicalshear flow in vitro184. Furthermore, L-selectin is expressed by EPC, and L-
selectin interactions with the respective ligands seems to support homing of EPCs to 
endothelioma tumors in SCID mice185. Additionally, a study also using intravital microscopy 
reports that BM-derived progenitor cells (Lin-Sca-1+) display rolling on the tumor vasculature 
before firm adhesion186. Besides the interactions with ECs during homing to sites of vascular 
remodelling or angiogenesis, EPCs can also interact with other cellular components. For instance, 
upon vascular injury, ECs detach exposing the underlying extracellular matrix this in turn 
recruits and activates platelets initiating the coagulation cascade. Consequently EPCs bind to 
platelets via P-selectin and GPIIb integrins. SDF-1 secretion by platelets further supports 
adhesion and migration of EPCs. Interestingly inhibition of platelet adhesion impairs EPC 
homing to sites of vascular injury187. Other haemostatic factors, like fibrin-containing thrombi, 
collaborate with platelets supporting EPC migration and differentiation on the site of vessel 
injury188. 
 
2.3.2.2 – Role of Integrins in EPC adhesion, transendothelial adhesion and migration of 
EPCs 
Since the process of rolling is reversible, leucocytes in circulation need to convert the weak 
interactions of rolling into high affinity adhesions, allowing them to stick on vessel lumens, 
resist detachment by disruptive shear stress forces and consequently migrate transendothelialy 
into the underlying tissue. Thus, the subsequent step of leukocyte adhesion consists of integrin 
activation by chemokines and the integrin-dependent arrest/firm adhesion of leukocytes on the 
endothelium. Leukocytes have a unique family of integrins, the β2 integrins (CD11a/CD18, 
CD11b/CD18 and CD11c/CD18), additionally many leukocytes also express integrin α4β1 and 
integrin α4β7, all of which bind to counter ligands expressed on EC surface. Regarding 
progenitor CD34+ cells it has been demonstrated that SDF-1 expressed on the surface of ECs is 
essential for the transition of rolling to firm adhesion by increasing the adhesivity of the integins 
α4β1 and LFA-1 (β2-integrin) to their respective endothelial ligands, VCAM-1 and ICAM-1184. 
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Recent evidence supports the involvment of integrins in the homing of EPCs and progenitor cells 
to sites of active neovascularization. Human adult PB-derived EPCs, murine adult BM-derived 
EPCs (VEGFR-2+/lin- cells) and BM-derived progenitor/stem cells (Lin-Sca-1+ cells) express 
β2 integrins186,189,190. In vitro adhesion studies show that β2 integrins mediate the adhesion of 
adult PB-derived EPCs to EC monolayers, while α4β1 integrin is not involved in this process214. 
Additionally β2 integrins play an essential role in the homing of murine BM Lin-Sca-1+ 
progenitors and murine BM Lin-VEGFR-2+ EPCs to ischemic tissues and for the 
neovascularization capacity of these cells in vivo180,190. However since β2 integrins inhibition 
leads only to a partial inhibition on homing to ischemic sites it is possible that other integrins 
may also regulate firm adhesion of EPCs/progenitor cells. Paradoxically, blockade of α4β1 
integrin does not inhibit BM-EPCs homing to ischemic tissues but rather increases their 
mobilization enhancing EPC-mediated neovascularization of ischemic tissue191. Contrarily to 
these results in vivo neutralization of integins α4β1 and LFA-1 functions reduces recovery of 
hind-limb blood flow, capillary density and incorporation of EPC into the vessel endothelium 
expressing their ligands, VCAM-1 and ICAM-1192. In another study using a model of breast 
cancer the inhibition of α4β1 integrin significantly blocks homing of BM-Lin-Sca1+ cells to 
sites of neovascularization expressing its ligands FN and VCAM-1186. Differences in the 
contribution of these integrin sub-units may result from the fact that different integrins may play 
distinct context-specific roles for progenitor cell homing. The role of integrin-mediated adhesion 
on EPC homing is further demonstrated in studies using pharmacological activators of Epac1, a 
nucleotide exchange protein for Rap-1 that activates integrin conformation. Carmona, G et al 
show that activation of Epac in EPCs increases β2-integrin-dependent adhesion to ICAM-1 and 
migrantion on fibrinogen. In the same study, the Epac activator enhances the β1-integrin-
dependent adhesion and migration of EPCs on FN. In addition, prestimulation of EPCs with the 
Epac activator increases homing to ischemic muscles and neovascularization-promoting capacity 
of intravenously injected EPCs in the model of hind limb ischemia193. Other integrin sub-units 
might be involved in EPCs adhesion directly to the ECM. Namely in in vivo models of artery 
reendothelization, EPC adhesion to denuded vessels appears to be mediated by vitronectin-
receptors (αvβ3- and αvβ5-integrins). Thus, inhibition of αvβ3- and αvβ5-integrins with cyclic 
RGD peptides blocked reendothelialization of denuded arteries, suggesting that these integrins 
are involved in the reendothelialization of injured carotid arteries. However, other integrins such 
as the β1-integrins may also mediate adhesion of progenitor cells to ECM components during 
reendothelialization of denuded arteries194. More recently new integrin sub-units have been 
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associated to EPCs homing, namely integrin α6 has been show to mediate migration, adhesion, 
recruitment at the site of ischemia, and the promotion of the post ischemic vascular repair195. 
After establishing adhesive contacts with ECs leukocytes move in a β2 dependent fashion from 
the site of firm adhesion to the nearest EC junction196, where they pass across the EC monolayer 
in a process called transendothelial migration or diapdesis. Moleculary this process depends on 
interactions between integrins expressed in leukocytes: VLA-1, α4β1, CD11a,b/CD18 and their 
ligands expressed in ECs like: ICAM-1, VCAM-1 and JAM197-199. Moreover homophilic 
interactions between PECAM-1 and CD99 have also been described during leukocyte 
diapdesis165. Concerning EPCs, very little is know concerning transendothelial migration. 
Diapdesis in human adult peripheral blood-derived EPCs appear to be mediated mainly by β2 
integrins and not α4β1, and depends on MCP-1 and VEGF180. This is further supported by a 
study showing that increased expression of ICAM-1, via Akt activation, in ECs increases EPC 
homing and transendothelial migration200. Another study indicates that CD99 expressed in 
subsets of CD34+ cells is essential for transendothelial migration of progenitors201. Also, a recent 
study provides evidence that CD34+ cells exposed to SDF-1 upregulate the expression of CD9, a 
member of the tetraspanin family proteins, which in turn regulates SDF-1 mediated 
transendothelial migration, regulating CD34+ homing to the BM202.  
 
2.4 – Molecular regulation of EPC invasion and migration 
Once circulating cells have crossed the endothelial monolayer they need to migrate trough the 
blood vessel basement membrane and trough the interstitial extracellular matrix in order to arrive 
at the specific niches where they can exert their functions. These processes require cell-matrix 
interactions. In leukoctytes the laminin binding integrin α6β1 mediates migration through the 
basement membrane203 while β2 integrins (CD11b/CD18) mediated migration through 
fibrinogen which is an extracellular component in the context of inflammation204. However the 
role integrins in the in vivo invasion and migration of EPC has not been established.  
 
2.4.1 – Role of proteases in EPC invasion and migration 
The role of extracellular proteases in EPC biology is very complex, involving different families 
of proteases, which regulate multiple steps of EPC function. Namely they can degrade ECM 
components, growth factors and cell surface receptors and also promote activation, release and 
modification of multiple vasculogenic/angiogenic growth factors. The matrix metalloprotease 
family (MMPs) are zinc-dependent endopeptidases that are either soluble or membrane-type. 
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Despite their function in EPC mobilization, MMP-9 appears to have no role in EPC homing, 
since MMP-9 deficient BM MNCs show no homing deficiency into ischemic hind limb205. 
Cathepsins represent another family of proteases, which is composed by endopeptidases 
containing disulfide-connected heavy and light chains. Cathepsin L appears to be required for 
EPCs-induced neovascularization. Indeed, EPCs activity of cathepsin L is essential for 
neovascularization after hind-limb ischemia since cathepsinL-/- EPCs were unable to home to 
sites of ischemia and to augment vascularization. This impairment was shown to result from 
reduced invasion and matrix-degrading activity of cathepsinL-/- EPCs206. Other proteases may 
also regulate EPC invasion and migration including serine proteases like urokinase-type 
plasminogen activator (u-PA) that proteolytically activates plasminogen into plasmin, and tissue-
type plasminogen activator (t-PA) that cleaves plasminogen in the presence of fibrin during 
fibrinolysis of blood. A recent study shows that EPC-derived ECs have high levels of u-PA and 
t-PA that upon inhibition with blocking antibodies reduce proliferation, migration and tube-
forming activity of EPC-derived ECs206. 
 
2.5 – Molecular regulation of EPC differentiation and paracrine/justacrine interactions 
The mechanisms that contribute to the functional activity of EPCs are still under intensive 
investigation. However functional activity of EPCs depends mainly on 2 processes: 
differentiation into mature ECs and direct incorporation into neovessels and/or production of 
paracrine/justacrine signals that promote interactions with pre-existing ECs and other cell types. 
Concerning EPC differentiation into EC, a recent study by our lab207 has shed some light into the 
molecular pathways that modulate the different steps of EPC differentiation. Accordingly, our 
lab defined a global gene-expression profile of CB-derived EPC (CD133+ CD34+ KDR+) 
during the process of endothelial differentiation in vitro and also defined molecularly freshly 
isolated EPCs versus differentiated EPCs. The gene profile data of EPC differentiation reveals a 
strict temporal regulation of endothelial differentiation, which can be divided into 3 sequential 
and distinct stages: integrin mediated adhesion to specific extracellular matrix component; 
growth factor induced proliferation and survival; maturation and functional acquisition of ECs 
properties (Figure 6). 
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Figure 6 – Steps involved in the differentiation of EPCs into ECs. Differentiation of EPCs into ECs is a 
multistep sequentical process that can be subdivided in 3 steps. 1.  In the presence of specific ECM components 
EPCs adhere via specific integrin subunits; 2. In response to specific endothelial growth factors and molecular cues 
provided by the underlying ECM differentiating EPCs become proliferative and more resistant to apoptosis; 3. Later 
on, concomitant with the expression of genes related to an endothelial phenotype, the cell acquires 
maturation and endothelial properties.  Figure adapted from Igreja, C. et al. Detailed molecular characterization 
of cord blood-derived endothelial progenitors. Experimental hematology 36, 193.e191-193.e115 (2008). 
 
 
2.5.1 – EPC differentiation: integrin-mediated adhesion to ECM 
EPC adhesion to the ECM is an essential step during differentiation, allowing cells to attach onto 
a substrate and to acquire proliferative and survival signals from the underlying matrix. EPCs 
express different sets of integrin throughout endothelial differentiation, for instance integrin α9 
is only expressed in freshly isolated EPCs, while β5 and β7 are only expressed later on. However 
integrins α5β1 and αVβ3 are expressed throughout EPC differentiation207. Interestingly, as 
observed during embrionary vasculogenesis, FN – integrin α5β1 interactions regulate EPC 
differentiation in adulthood. Indeed FN promotes VEGF-induced differentiation of EPCs into 
ECs via specific binding to integrin α5β1208. In another study the down regulation of the 
expression of integrin subunits α5 and αV using VEGI (vascular endothelial growth inhibitor), 
impairs EPCs adhesion to FN and vitronectin and consequently differentiation into mature 
ECs209. However complete understanding of signals provided by integrins-ECM interactions 
during EPC differentiation is still lacking. 
 
2.5.2 – EPC differentiation: growth factor induced proliferation and survival 
A critical step during EPC differentiation is proliferation and survival. In fact Tepper OM shows 
that once EPCs home to ischemic tissues they proliferate continuously, forming cell clusters that 
in turn differentiate into new vascular structures136. In the proliferative and survival stage of EPC 
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differentiation there is an increase in the expression of genes involved in promotion of the cell 
cycle, anti apoptotic genes (death receptors and associated proteins, caspases and BCL family 
proteins) and also genes regulating transcription, splicing and translation. This increase in 
proliferation and survival results probably from signals from integrins binding ECM but also 
growth factors and their receptors. One of the main factors regulating EPC proliferation is VEGF, 
acting via VEGFR-2. Lack of VEGFR-2 leads to severe defects in vasculogenesis due to a lack 
of angioblast formation32,210. In EPCs there is a sustained expression of VEGFR-2 throughout 
differentiation, possibly regulating multiple steps of this process207.  In fact all known endothelial 
differentiation assays are done in the presence of VEGF, although the precise mechanism by 
which it acts on EPCs is still under investigation. Other growth factor regulating EPC 
proliferation is the Ang-Tie receptors pathway. Interestingly Ang-1 has been showed to regulate 
initial EPC commitment whereas Ang-2 enhances expansion of adherent EPCs. Further 
confirming this is the fact that Ang-2 is highly expressed in proliferating EPCs211. 
  
2.5.3 – EPC differentiation: maturation and acquisition of endothelial properties 
After the proliferative stage, adherent EPCs acquire further endothelial-specific characteristics 
by expressing genes associated with endothelial maturation and function and loose the 
expression of stem markers. Histone deacetylases (HDAC) are a major regulator of EPC 
differentiation, mainly by regulating the expression of HoxA9. HoxA9 is one of the major 
factors regulating expression of typical endothelial proteins essential in EC function such as: 
endothelial nitric oxide synthase (eNOS), VEGFR-2 and vascular cadherin (VE-Cadherin)212. In 
another study histone deacetylase 3 (HDAC3) has been shown to be essential for VEGF induced 
EC differentiation from Sca-1+ progenitors213. Differentiating EPC also upregulated the 
expression of genes involved in invasion (e.g.: matrix metalloproteinases and their inhibitors), 
which are essential for migration, tube formation and consequently new vessel assembly. 
Maturation of EPCs is also associated with an increase in the synthesis of basement membrane 
components such as laminins that are essential for vessel stabilization207. 
 
2.5.4 - EPC and paracrin/juxtacrin regulation of pre-existing ECs and other cell types 
Regarding the production of paracrine factors by EPCs it has been show that EPCs can produce 
numerous factors such as VEGF, SDF-1 and IGF-1 that can stimulate angiogenesis and recruit 
other cell types214. In a cutaneous wound healing setting it has been shown that EPCs can 
produce MCP-1 (monocyte chemotactic protein 1) and MIP-1α (macrophage inflammatory 
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protein 1 alpha) that are the 2 major chemoattractants for monocytes/macrophages and play a 
key role in macrophage infiltration in the early phase of wound healing215. Also it was shown 
that conditioned media obtained from CB-EPCs is enough to increase wound healing in diabetic 
mice, mainly by production of PDGF-α, PDGF-β and KGF (keratinocyte growth factor) that 
mediate fibroblast and keratinocyte migration and proliferation216. Concerning the role of 
juxtacrine signaling pathways (namely the Notch-Delta pathway) in the communication between 
EPCs and ECs or other cell types it is still unkown, although EPCs express Dll4 ligand 
throughout differentiation suggesting that in fact Notch-Delta pathway might be involved in EPC 
differentiation and function207. 
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Section 3 – EPC contribution to postnatal vasculogenesis in different 
physiological and pathological settings 
 
Since the isolation and characterization of EPCs by Asahara and colleagues several studies have 
been realized in order to determine the exact contribution of these cells in different physiological 
and pathological settings. 
 
3.1 - EPC quantifications in healthy individuals 
Studies aimed at the quantification of EPCs in circulation have revealed that these cells represent 
only a small fraction of the total PB cells217. One study describes the isolation of 645 CD34+ 
cells per millilitre of blood using anti-CD34 antibody–coated magnetic microbeads217. According 
to Gill et al the percentage of circulating VEGFR2+CD15- cells in healthy donors is around 
0.10% of total PBMNCs130. Another study reports that the number of circulating 
CD133+CD34+VEGFR-2+ in healthy human subjects to be in the range of 0.002% of total 
PBMNCs241. Concerning the number of incorporated EPC in vessels of normal individuals it has 
been reported that the endothelium of mice, examined 16 weeks after BM transplantation, 
displayed low rates of BM incorporation in the brain, intermediate levels in the aorta, and higher 
levels in the skin where up to 2.5% of endothelial cells were bone-marrow derived218. In a 
similar study219 it is shown that BM derived flk-1+ and tie-2+ ECs are present in normal organs 
(BM, PB, spleen, lung, liver, intestine, skin, ovary and uterus) suggesting that these cells might 
be needed to ensure physiological maintenance of organ vasculature. 
 
3.2 - EPC quantifications in physiological/pathological conditions 
The incorporation of EPCs into blood vessels in different physiological and pathological 
conditions has been extensively quantified in numerous studies. However the incorporation rates 
of EPCs in neovessels is extremely variable depending on the physiological/pathological 
condition and the models where this was tested. This indicates that quantification of EPC 
incorporation is highly dependent on organ and condition specificities and also on the method 
and markers used for quantification (Table 5)124,137,139,143,176,219-234. 
 
 
 
 
 
 59 
Table 5 – Contribution of EPCs to different physiological/pathological conditions. 
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Altogether the above studies reveal that there is a variable but significant contribution of EPCs in 
different vascular related physiological and pathological settings. This indicates that in order to 
have a deeper understanding of the different physiological and pathological conditions 
mentioned in table 5 it is essential to address the exact mechanisms by which EPCs contribute to 
neovascularization and overall angiogenic response.  
 
3.3 – Contribution of EPCs during cutaneous wound healing 
3.3.1 – Cutaneous Wound Healing 
The mammalian skin is the largest the largest organ of the integumentary system and consists on 
three different layers: the epidermis (Merkel cells, keratinocytes, melanocytes, Langerhans cells 
and contains no blood vessels), dermis (connective tissue containning hair follicles, sebacious, 
apocrine glands, lymphatic vessels and blood vessels) and the hypodermis (fibroblasts, 
macrophages and adipocytes). The main functions of the skin are protection (anatomical barrier 
against pathogens and mechanical agression), sensation, heat regulation, synthesis and storage 
organ for different compounds. Considering the multiple functions of the skin it is essential that 
it heals and regenerates properly and efficiently upon external aggressions235. Clinically, skin 
wounds remain a challenging problem, with early and late complications presenting a frequent 
cause of morbidity and mortality236. The immense social and economic impact of wounds 
worldwide is a consequence of their high rate of occurrence and their increasing frequency in the 
ageing population. In addition to a high number of acute wounds, there are also a large number 
of chronic, hard-to-heal wounds associated with different pathologies (namely diabetes) that 
cause damage of the cutaneous coverage, including arterial, venous, diabetic and pressure 
ulcers237. In an attempt to reduce the wound burden, much effort has focused on understanding 
the physiology of wound healing. Considering this it is now established that the healing of an 
adult acute cutaneous wound is a very complex process that can be classically dived in to four 
phases: hemostasis, inflammation, proliferation, and remodeling238-240 (Figure 7). 
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Figure 7 – Cutaneous wound healing phases. A. Schematic representation of the main cellular processes 
determining each step of cutaneous wound healing: 1. Hemosasis comprises the formation of a fibrin clot together 
with other components such as platelts and eritrocytes that will immediately cover the open area exposed upon 
injury; 2. Immflamtion phase initiates with the arrival of neutrophils into the wound that will kill and phagocite 
bacteria as well as cellular debris. Later inflammatory stage occurs with the arrival of macrophages will further 
phagocyte cellular debris, bacteria and apoptotic cells present in the wound bed. 3. Proliferative stage involves 
reepithelization via active proliferation and migration of keratinocytes, increased vessel formation (angiogenesis and 
postnatal vasculogenesis) and increased proliferation and migration of mio-/fibroblasts, which also secrete collagens 
(type III and later type I) into the wound bed. Neo-blood vessels together with fibroblasts constitute the granulation 
tissue. 4. Maturation and emodeling phase initiates once the epidermis is re-established, there is increased apoptosis 
of excessive vessels and wound contraction via miofibroblast contraction and collagen type I deposition.  Figure 
adapted Epstein, F.H., Singer, A.J. & Clark, R.A.F. Cutaneous Wound Healing. New England Journal of Medicine 
341, 738-746 (1999). B. Schematic representation of the main steps of cutaneous wound healing pointing out the 
duration (time scale) of each step and each cell type present at the wound bed at every time point of the healing 
process. Image taken from the Wikimedia Commons. 
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3.3.1.1 – Cutaneous wound healing: Hemostasis and Inflamatory Phase 
Hemostasis occurs within the first minutes after wounding and is essential to stop hemorrage. It 
involves first the vasoconstriction induced by inflammatory factors (thromboxanes and 
prostaglandins) produced upon cell membrane rupture and secondly the initiation of the clotting 
cascade with the formation of a fibrin clot that serves as a temporary shield protecting the 
denuded wound tissues and provides a provisional matrix over and through which cells migrate 
during the repair process241. The clot consists of platelets embedded in a mesh of crosslinked 
fibrin fibers derived by thrombin cleavage of fibrinogen, together with smaller amounts of 
plasma FN, vitronectin, and thrombospondin. Importantly, the clot also serves as a reservoir of 
cytokines and growth factors that are released as activated platelets degranulate releasing 
proinflamatory compounds (seratonins, prostaglandins, prostacyclins, thromboxane, histamine 
and also VEGF) that increase vascular permeability increasing the afflux of blood proteins and 
cells into the wounding site thus initiating the inflammatory phase242. Within an hour of 
wounding, attracted by FN, growth factors and proteolitix fragments of bacteria and ECM 
components, polymorphonuclear neutrophils arrive at the wound site, extravasate blood vessels 
and become the predominant cells type243. Neutrophils phagocytise debris and bacteria, kill 
bacteria by releasing free radicals and secrete proteases that break down damaged tissue. 
Neutrophils usually undergo apoptosis once they have completed their tasks and are engulfed 
and degraded by macrophages. Macrophages accumulate in the wound by recruitment and 
differentiation of blood-borne monocytes and become the predominant cell type around day 2 
after wounding. Macrophage infiltration into the wound site is highly regulated by gradients of 
different chemotactic factors, including growth factors, proinflammatory cytokines, and 
chemokines such as monocyte chemotactic protein (MCP-1), macrophage inflammatory protein 
(MIP-1α), RANTES243. Macrophages have immunological functions as antigen-presenting cells 
and phagocytes, eliminating any remaining pathogenic organism or celular/matrix240. Once 
activated, macrophages also release numerous growth factors and cytokines at the wound site, 
thus amplifying the earlier wound signals released by degranulating platelets and neutrophils244 
(Table 6).  
 
3.3.1.2  – Cutaneous wound healing: Proliferative and Maturations phases 
The proliferative phase starts around two or three days after wounding. This phase is 
characterized by increased angiogenesis, fibroplasia and epithelization. Since the activity of 
fibroblasts and epithelial cells requires oxygen and nutrients, angiogenesis is imperative for both 
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fibroplasia and epithelization239. Wound adjacent ECs are attracted to the wound area by FN 
present in the fibrin clot and by angiogenic factors such as FGF-2, IGF and VEGF released by 
activated macrophages, platelets, keratinocytes and by damaged ECs244 (Table 6). EC 
proliferarion is further stimulated by hypoxia and lactic acid present in the wound245. In order to 
invade the fibrin clot ECs express collagenases and plasminogen activator to degrade the clot 
and part of the ECM and MMPS to digest the basement membrane and ECM. As new vessels 
invade the fibrin clot it becomes highly vascularized, termed granulation tissue, and normoxia is 
reestablished thus decreasing the overall production of angiogenic factors and new vessel 
formation. Fibroplasia initiates two to five days after wouding. In the presence of IGF, FGF, 
PDGF and TGF-β fibroblast proliferate and migrate from adjacent tissues or even from 
circulating fibroblast precursor cells, termed fibrocytes246. Fibrobaslt migrate over the fibrin 
fibers, adhere to FN on the wound bed and start producing ECM components (collagens type III 
and I, FN and hyaluronan) that form the granulation tissue. The formation of granulation tissue 
in an open wound allows the reepithelialization phase to take place, as epithelial cells migrate 
across the new tissue to form a barrier between the wound and the environment. The main factors 
regulating reepithelization are EGF, TGF-a, and FGF that stimulate epithelial cell migration and 
proliferation244 (Table 6). This process begins with the dissolution of cell–cell and cell–
substratum contacts followed by polarization and migration of keratinocytes over the provisional 
ECM. Once wound closure (100% epithelialization) is achieved, keratinocytes stop migrating via 
contact inhibition, undergo stratification and differentiation to restore the barrier247. The next 
step is called contraction in which miofibroblasts attach to ECM components like fibrin and FN 
on one side and to wound edges on the other side and contract pulling together the wound 
margins. The maturation stage starts once the levels of collagen production and degradation 
equalize in the wound bed.  During maturation, type III collagen, which is prevalent during 
proliferation, is gradually degraded and replaced by the stronger type I collagen248. As the 
maturation phase progresses, the tensile strength of the wound increases ultimately becoming as 
much as 80% as strong as normal skin. During the maturation phase there is a massive apoptosis 
of excessive blood vessels, fibroblasts and inflammatory cells, thus restoring the normal 
homeostasis of the skin249. 
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Table 6 – Major growth factors and cytokines that participate in wound healing with cell types and their 
respective roles in both acute and chronic wounds (Platelets – Pl; Macrophages – M; Fibroblasts – Fb; 
Keratinocytes – K; Mast Cells – MC; Smooth muscle cells – SMA; Lymphocites – L; Neutrophils – N; Monocytes – 
Mo). Table adapted from Barrientos, S., Stojadinovic, O., Golinko, M.S., Brem, H. & Tomic-Canic, M. 
PERSPECTIVE ARTICLE: Growth factors and cytokines in wound healing. Wound Repair and Regeneration 16, 
585-601 (2008). 
 
 
 
 
 
 
 
 
 
 
 
3.3.2 – Role of EPCs in cutaneous wound healing 
3.3.2.1 – EPC mobilization during wound healing  
Recent studies suggest that EPCs play an important role during cutaneous wound healing. 
Concerning EPC mobilization different studies have show that cutaneous aggressions such as 
burning or full thickness wounding induce a rapid and transient mobilization of EPCs into the PB. 
In burning patients, EPCs are mobilized within the first 24h is response to increased levels of 
VEGF and SDF-1, returning to basal levels after 72h130,151. In mice models of skin wound 
healing EPCs peak in PB around day 3 after wounding preceding increased levels of PB SDF-
1150. Altogether these results suggest that EPCs are recruited during the inflammatory phase of 
wound healing in response to SDF-1 and VEGF. 
 
3.3.2.2 – EPC homing signals during wound healing  
The signals mediating EPC homing to cutaneous wounds are still unclear, however a recent 
study describes a EPC homing mechanism by which overexpression of SDF-1 in the wound 
increases EC expression of E-selecting thus increasing EPC homing and wound 
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vascularization250. Hemostatic factors such as platelets and fibrin can also mediate EPC homing. 
Accordingly H.C. de Boer et al have shown in vascular injury models that platelets aggregates 
can increase tethering and rolling of CD34+ cells through interaction of P-selectin expressed by 
platelets and P-selectin glycoprotein ligand-1 (PSGL-1), expressed by CD34+ cells.  According 
to these authors fibrin-containing thrombi can support migration of CD34+ cells to the site of 
injury and subsequent differentiation toward a mature EC phenotype188. Another homing signal 
might be integrins-RGD sequences interactions. RGD sequences are specific amino acid 
sequences (Arg-Gly-Asp) present in different compounds (like FN, Fibrin among others) that 
mediating interactions with integrins α5β1; αvβ5; α8β1; αvβ5; αvβ6; αvβ8 and also αIIbβ357. 
In fact target delivery of EPCs in a RGD enriched biosynthetic scaffold into a cutaneous wound 
increases EPC survival, proliferation and vessel incorporation, thus increasing wound 
vascularization and closure251.  
 
3.3.2.3 – EPC differentiation and paracrine signals during wound healing  
Concerning EPC differentiation in a wound healing setting, it has been shown that, when 
transplanted, EPC can incorporate newly formed vessel contributing to increased vessel 
formation215,224. However the specific mechanisms regulating EPC endothelial differentiation 
during wound healing are still unclear. This pointed out the fact that another way by which EPC 
can enhance wound healing is via production of paracrine factors that will act on other cell types 
involved in wound healing. In fact EPCs have been shown to produce MCP–1, MIP–1α and 
PDGF increasing the recruitment of monocytes/macrophages into the wound, accelerating 
wound closure215. EPCs have also been known to release a variety of growth factors such as 
VEGF, HGF, G-CSF, GM-CSF252. In a more recent study, topical application of EPCs to 
ischemic wounds of diabetic mice resulted in accelerated wound closure with increased 
angiogenesis in the wound, and the action was abrogated by coadministering the Wnt antagonist 
secreted frizzled-related protein-1 or neutralizing antibodies against VEGF-a or IL-8, implying 
that EPCs stimulate wound healing by paracrine mechanisms that activate Wnt signaling 
pathway in recipients253. Consistent with the therapeutic effect of EPCs on wound healing in 
animals, reduced numbers and impaired function of circulating EPCs have been described in 
both type 1 and type 2 diabetic patients254,255. EPCs derived from diabetic mice exhibited 
impaired ability to participate in wound vascularization and healing256. Moreover, chronic 
wounds in patients with diabetes showed reduced chemoattractive ability to EPCs. In this cases 
administration of exogenous SDF-1a into the wound reversed EPC homing into the wound and 
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promoted wound closure257. Altogether these studies suggest that EPCs are essential during 
cutaneous wound healing via direct incorporation into neovessels and via paracrine action over 
other cell types. 
 
3.4 – Contribution of EPCs during tumor vascularisation 
3.4.1 - Tumor angiogenesis 
In 1986 Harold F. Dvorak defined tumors as wounds that do not heal. Dvorak proposed that by 
secreting VPF (vascular permeability factor, later termed VEGF) tumors induce angiogenesis by 
turning on the wound healing response. He noted that wounds, like tumors, secrete VPF, causing 
blood vessels to leak plasma fibrinogen, which stimulates blood vessel growth and provides a 
matrix on which they can spread. Unlike wounds, however, that turn off VPF production after 
healing, tumors did not turn off their VPF production and instead continued to make large 
amounts of VPF, allowing malignant cells to continue to induce new blood vessels and so to 
grow and spread258. Nonetheless it was Judah Folkman who first postulated the critical role of 
angiogenesis in tumor growth in 1971 when he published the hypothesis that “tumor growth is 
angiogenesis dependent”.  In this paper Folkman: 1) predicted that most tumors do not grow 
beyond a microscopic size of 1-2 mm3 without recruiting new blood vessels; 2) introduced the 
concept that tumors can produce diffusible angiogenic molecules; 3) described a model of tumor 
dormancy due to blocked angiogenesis; 4) proposed the term anti-angiogenesis to mean the 
prevention of new capillary sprouts from being recruited into an early tumor implant and 5) 
predicted the future discovery of an angiogenesis inhibitor, namely antibodies against tumor 
angiogenic factor (TAF)259. Later, Folkman defined the transition of a avascular (hyperplasia) to 
a vascular tumor (neoplasia) as the “angiogenic switch”260. Currently there have been proposed 4 
tumor strategies to enhance blood supply. Vascular co-option is the process by which a tumor 
grows along pre-existing blood vessels, using it for its own needs. The classic example of this 
strategy is provided by astrocytomas261. Another strategy is vasculogenesis, the process by which 
new vessels are formed by differentiation of mobilized BM-EPCs (Table 5). Besides these 
mechanisms, others have revealed different processes by which tumors achieve neo-
vascularization, including vascular mimicry, which is the process by which tumor cells form 
luminal network where blood cells circulate, without the presence of ECs, which has been 
observed in higly aggressive melanomas262. Despite these theories and mechanisms, the most 
frequent process by which tumors induce neo-vascularization is via angiogenesis. A tumor can 
induce angiogenesis by secreting pro-angiogenic factors and/or by reducing anti-angiogenic 
factors resulting in the induction of EC proliferation, migration leading to vessel sprouting and 
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tube formation. In addition vessels may increase in numbers by intussusception263. Tumor 
angiogenesis is considered one of the hallmarks of cancer264. Since the postulation that tumor 
growth is angiogenesis dependent by Folkman, numerous studies have been made in an attempt 
to identify pro-angiogenic and anti-angiogenic factors and also to completely comprehend the 
molecular mechanism regulating tumor angiogenesis (Table 6)265. 
 
Table 6 – Major molecular pathways regulating physiological and pathological (tumor) angiogenesis. Table 
adapted from Chung, A.S., Lee, J. & Ferrara, N. Targeting the tumour vasculature: insights from physiological 
angiogenesis. Nat Rev Cancer 10, 505-514 (2010). 
 
 
 
 
 
 
 
 
 
 
 
Interestingly most of the molecular pathways that regulate tumor angiogenesis have been 
described during physiological conditions suggesting that (as previously observed by Dvorak) 
tumor angiogenesis results from a deregulated physiological angiogenic process, derived by 
overproduction of proangiogenic and decreased production of antiangiogenic factors. It is now 
accepted that stromal cells of the tumor microenvironment exert an important role during the 
angiogenic switch. In addition to tumor cells, pro-angiogenic factors as well as justacrine signals 
are also produced by pericytes266, cancer-associated fibroblasts (CAFs)267 and cells of the immune 
system268. Among the immune system cells or BM-derived cells known to be involved in tumor 
angiogenesis are TAMs (tumor associated macrophages); MDSCs (Myeloid –derived surpressor 
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cells); MSC (mesenchymal stem cells); TEMs (Tie-2 expressing macrophages); Mast cells; 
Neutrophils; Pericytes; T cells; NK cells; vascular leukocytes; hemangiocytes and EPCs269. 
 
3.4.1.1 - Tumor angiogenesis: Notch-Delta pathway 
As could be expected from its role in developmental angiogenesis, the Delta-Notch pathway is 
also important in tumour angiogenesis. Several studies have documented the expression of Notch 
components in tumour vessels, most notably Dll4. Studies of tumours in mice and humans have 
shown that Dll4 is strongly expressed in tumour blood vessels compared to adjacent normal 
vessels270,271. Dll4 expression in tumour vessels appears to be directly regulated by VEGF since 
blockade of VEGF in tumour-bearing mice results in a rapid and profound reduction of Dll4 
expression by the tumour blood vessels272. Conversely, the levels of Dll4 expression in tumours 
correlate with the levels of VEGF expression273. The striking pattern of Dll4 expression in 
tumour vessels prompted several groups to target Dll4-Notch activity and provided insight into a 
role for Dll4-Notch in regulating VEGF-induced vascular sprouting. Local or systemic treatment 
of mice with Dll4-Notch inhibitors caused overgrowth of a non-functional tumour vasculature 
causing growth inhibition and increased tumor hypoxia in a variety of established human and 
rodent tumour models272,274-276. Other Notch ligands may also influence tumour angiogenesis 
namely Jagged1 has been shown to have an angiogenic role in head and neck tumours277. A 
similar conclusion was reached in a study of a novel Notch inhibitor, the Notch1 decoy, which 
has the ability to block Notch signalling via several different Notch ligands, including both Dll4 
and Jagged1. The Notch1 decoy was shown to block angiogenesis in both a VEGF-driven dermal 
angiogenesis model and a xenograft model of mammary tumour growth278. One molecular 
explanation of these phenotypes depends on the interaction between the Notch-Delta and the 
VEGFR-VEGF pathways. Recent data suggests that VEGF binding to VEGFR-2 increases Dll4 
expression on the VEGFR-2+ cell (tip cell) and this in turn increases N1 activation on the 
adjacent cell (stalk cell). On the other hand Notch activation leads to decrease in VEGFR-2 
expression and increases VEGFR-1 and 3 expression. In sum, these results suggest a complex 
interplay between Notch activity and expression of VEGF receptors, resulting in changes in how 
a particular EC will respond to VEGF signals279. Therapeutically the Notch-Delta and the 
VEGFR-VEGF pathway crosstalk is of enormous interest, as seen in recent studies where 
blockade of Dll4 can have potent antitumour effects on tumours that are resistant to VEGF 
inhibition272,274. In addition, the tumour vessels in this model show dramatic disorganization and 
dysfunction following Dll4-Notch blockade. Altogether these data suggests that full 
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understanding of the role of the Notch-Delta and its interacting pathways in tumor angiogenesis 
as well as vasculogenesis might provide new clues into the mechanism regulating tumor 
angiogenic switch and growth. 
 
3.4.2  – Role of EPCs in tumor vascularization: tumor vasculogenesis 
The contribution of EPCs to tumor vessel formation has been extensively studies and it is evident 
that the rates of EPC incorporation in tumor vessels are highly variable (Table 5). This 
variability might be due to several factors such as: the molecular markers used to define EPCs; 
the lack of definitive methods for distinguish incorporated or vessel associated perivascular cells; 
tumor type and stage as well as mouse genetic models used269. Nevertheless the first 
experimental evidence of EPC to tumor vasculature was described by Asahara et al in 1999, 
using a mouse model of syngenic colon cancer transplanted with BM cells expressing Lacz 
under the transcriptional control of an endothelial specific promoter (Tie-2 or Flk-1)219. Since 
this initial report many other authors have show the contribution of BM-EPCs in tumor 
vascularization and growth, in many different cancer models (Table5). However one of the most 
convincing evidence of EPC incorporation in tumor vessel has been shown in individuals who 
developed cancer after BM transplantation with donors of the opposite sex. Peters et al. revealed 
that BM-derived EPC contribution to tumour vasculature, ranging from 1% to 12%, average 
4.9%, was observed in different tumour types (Hodgkin lymphoma, head and neck spindle cell 
sarcoma, thyroid carcinoma, osteogenic carcinoma and mucoepidermoid carcinomas). BM-
derived EC were randomly distributed throughout the tissue and each vessel had no more than 
two transplant-derived EC280. 
 
3.4.2.1 - EPCs mobilization during tumor growth 
Increased levels of circulating EPCs have been reported in different cancer types. In fact, EPCs 
have been detected at increased frequency in the PB of patients with lung cancer281, 
hepatocellular carcinoma282, breast133,283 and colorectal cancer284 and myeloma multiplex285, 
myelofibrosis286, non-Hodgkin’s lymphoma287, acute myeloid leukemia288, and malignant 
gliomas289. Concerning the molecular signals responsible for EPCs mobilization in cancer 
patients VEGF is the most commonly described one. However erythropoietin and angiopoietin-2 
increases serum levels have been show to be correlated with increased EPC levels in breast 
cancer290. In mouse models VEGF, together with different types of CC chemokines (CCL2, 3 
and 5), is responsible for EPC mobilization and homing to hepatic tumors176.  
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3.4.2.2 – Signals determining EPC homing into tumor vessels 
Direct evidence of EPC homing and incorporation into tumor vasculature was provided by 
Vajkoczy et al (2003) using intravital fluorescence videomicroscopy and murine eEPCs. 
According to this study eEPCs home to the tumor vasculature where they become arrested, 
extravasate into the intersticium and incorporate new vessels. Expression analysis and in vivo 
blocking experiments provided evidence that the initial cell arrest of eEPC homing is mediated 
by E- and P-selectin and P-selectin glycoprotein ligand 1164. These results where further 
confirmed in another study showing that L-selectin interactions support homing of EPCs to 
endothelioma tumors in SCID mice185. Moreover, the inhibition of α4β1 integrin significantly 
blocked homing of BM-Lin-Sca1+ cells to sites of neovascularization expressing FN and 
VCAM-1 in a model of breast cancer186. More recently, Gao et al has reported that tumor vessel 
VCAM-1 and EPC α4β1integrin interaction is involved in the recruitment of BM-derived EPCs 
to the neovessels in lung metastatic lesions228.  
 
3.4.2.3 - EPCs are functionally required tumor vessel formation and growth 
The numerous studies relating EPC incorporation with tumor growth suggest that EPCs are 
necessary for tumor vessel formation. However there is still much uncertainty regarding the 
functional role of EPCs in supporting tumor angiogenesis. Studies aimed at the functional 
characterization where first preformed by Lyden, D et al.  It was shown that the recruitment of 
BM-derived EPCs is essential for tumor angiogenesis and growth in a adult Id-mutant mice 
(which do not support tumor neoangiogenesis). In fact, transplantation of wild-type (wt) BM or 
of VEGF-mobilized progenitors restored tumor angiogenesis and growth, suggesting that the Id 
transcriptional factor is essential for BM derived EPC tumor vascularization. In this study EPCs 
incorporated tumor vessels at a frequency of 50-100% of the total EC number in 
xenotransplanted tumors137. Consistent with this model, acute and conditional shRNA-mediated 
silencing of Id1 mRNA in the adult BM resulted in EPC mobilization defects associated with 
severe angiogenesis inhibition and impaired growth of primary tumors and metastatic lesions, 
suggesting a crucial role for these cells in angiogenesis-mediated tumor growth228. More recent 
studies suggest that Id1 is required in early hematopoietic stem cells to restrain the commitment 
to the myeloid lineage and preserve a pool of cells that give rise to endothelial progenitors in 
response to vasculogenic growth signals291. Concerning other intracellular molecular pathways 
regulating EPC function in tumor vascularization it has been showed that cell cycle inhibitors 
p130 and p27 are essential for EPC BM mobilization and for tumor neoevascularization292. The 
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essential role of EPCs in tumor neovessel formation has also been showed in studies targeting 
transiently expressed monomeric VE-cadherin specifically on EPCs using radiolabeled anti-VE-
cadherin antibody. Interestingly administration of these antibodies resulted in severe 
angiogenesis inhibition and impaired tumor growth associated with decreased EPCs levels in 
tumors293,294. Besides direct evidence of tumor vessel incorporation, EPCs might also regulate 
tumor neoangiogenesis via paracrine effects. Indeed, in their unincorporated state, tumor-
recruited EPCs secreted numerous pro-angiogenic factors that could be essential in EC migration 
and proliferation in early stages of tumor growth229. 
 
3.4.2.4 - EPCs protect tumor ECs from radio and chemotherapeutic agents 
Besides having a direct role in tumor vessel formation EPCs have also been shown to be 
essential in protecting tumor and tumor vasculature against ionizing radiation, chemotherapeutic 
and vessel disrupting agents. Interestingly it was reported that tumors grown in apoptosis-
resistant acid sphingomyelinase (asmase)-deficient or Bax-defecient mice display markedly 
reduced endothelial apoptosis after ionizing radiation and increased growth than wt. Furthermore 
transplantation of asmase-deficient BM into tumor-bearing wt mice significantly reduced the 
radiation sensitivity of xenotransplanted tumors to ionizing treatment233. This suggests that BM-
EPCs incorporating tumor vessels might actually protect tumor vessels from radiotherapy 
treatment. In a separate study Shaked Y et al reported that chemotherapeutic agents like 
paclitaxel (taxol containing drug) induced a rapid increase in the mobilization and homing of 
EPCs into tumor vessels, via upregulation of systemic SDF-1. Interestingly coadministration of 
anti-VEGFR2 blocking antibodies or paclitaxel treatment in EPC-deficient Id mutant mice 
resulted in enhanced antitumor effects mediated by paclitaxel146. The same author further 
observed G-CSF mediated mobilization of EPCs upon treatment of tumor bearing mice with 
vascular disrupting agents (OXi-4503), thus protecting tumor vasculature126. These results point 
out for a vascular protective effect of EPCs during vascular and tissue aggression, suggesting 
that coadministration of EPC blocking agents might improve radio- and chemotherapeutic 
approaches to cancer treatment reducing the probability of tumor recurrence295.  
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3.5 - Contribution of other BM derived cell types during tumor angiogenesis 
3.5.1- Tumor-mediated systemic activation of the BM compartment 
In the past three decades there has been emerging evidence from murine models suggesting that 
tumor specific factors can interfere with different BM populations inducing their expansion, 
mobilization and recruitment into PB and into the tumor. In fact BM-derived populations 
contribute to tumor microenvironment by controlling multiple aspects of tumor progression such 
as the modulation of tumor proliferation, angiogenesis, inflammation and immune suppression. 
More recently, clinical studies began to reveal that increased BM recruitment into tumors is 
associated with poor prognosis. Thus, the BM-derived tumor microenvironment has emerged as 
an attractive therapeutic target determining the clinical outcome of many cancer patients296. The 
intricate communication between tumor (breast carcinomas) and BM compartment has been 
addressed by McAllister et al. These authors show that human breast carcinomas instigate the 
growth of otherwise-indolent tumor cells, micrometastases, and human tumor surgical specimens 
located at distant anatomical sites. Interestingly systemic instigation is accompanied by 
incorporation of undefined BM cells (BMCs) into the stroma of the distant, once indolent tumors. 
The authors show that secretion of osteopontin by instigating tumors is required for BMC 
activation, recruitment and subsequent outgrowth of the distant otherwise-indolent tumors. In 
fact, when coinjected with indolent cells, these activated BMCs mimic per se the systemic 
effects induced by instigating tumors297. Besides this groundbreaking study many others have 
been done in order to determine BM populations able to interact with tumors and interfere with 
its properties and progression (Figure 8). 
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Figure 8 – Schematic diagram showing discrete subsets of BM-derived cells that are recruited to the tumor 
and contribute to tumor progression. Discrete subsets of BM-derived cells characterized by cell surface markers 
(in brackets) are shown, and these are recruited to the tumor and contribute to tumor progression. These include 
GR1+CD11b+ myeloid progenitors, F4/80+CD11b+ TAMs of M1 and M2 phenotype, TEMs, PDGFR+ pericytes, 
VEGFR2+, VE-cadherin+ EPCs, MSCs infiltrating mast cells and pre-metastatic-niche cells (associated with tumor 
metastasis). The cells secrete a variety of factors (shown in boxes) that mediate angiogenesis, inflammation, 
immunity, invasion and metastasis. Figure adapted from Gao, D. & Mittal, V. The role of bone-marrow-derived 
cells in tumor growth, metastasis initiation and progression. Trends in Molecular Medicine 15, 333-343 (2009). 
 
 
3.5.2 – Roles of BM-derived populations in tumorigenesis 
3.5.2.1 – Tumor associated macrophages (TAMs) 
Macrophages are one of the main cell type of the immune system recruited to tumors in response 
to gradients of chemoattractants including colony stimulating factor (CSF-1), chemokines CCL2, 
3, 4, 5 and 8 and VEGF298. Increased macrophage infiltration correlates with tumor stage and 
poor survival in different cancer types299,300. TAMs are CD11b+ CD45+ VEGFR1+ F4/80+ 
CD14+ CD68+ CD133- CD31- cells that can be either classically activated (M1) or alternatively 
activated (M2). M1 macrophages are essential for tumor rejection and are activated trough type I 
cytokines (IFN-γ, LPS). On the other hand M2 macrophages represent “tumor educated” 
macrophages activated by type II cytokine (such as IL-10, IL-4, and IL-13) and promote tumor 
progression enhancing angiogenesis, metastasis and suppressing immune responses301. The 
mechanism by which M2 macrophages promote tumor progression are: 1) protease production 
namely MMP and cathepsin B that breakdown the basement membrane around areas of 
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proliferating tumor cells thereby prompting their escape into the surrounding stroma where they 
show deregulated growth; 2) release of proangiogenic cytokines and growth factors, such as 
VEGF, TNF-α, IL-8, and bFGF and expression of MMPs (namely MMP-9) that increase tumor 
angiogenesis; 3) tumor growth via production of factors that stimulate tumor cell proliferation 
and survival, including EGF, PlGF, TGF-β1, HGF and bFGF; 4) production of factors such as 
EGF that guide tumor cells in the stroma and into the blood vessels302. 
 
3.5.2.2 – Myeloid-derived suppressor cells (MDSCs)  
MDSCs are a heterogeneous group of GR1+ CD11b+ CD33+ cells often elevated in cancer 
patients and recruited preferentially by interleukin-1β303,304. These cells contribute to tumor 
escape, immune tolerance and suppression, and have been shown to contribute to TGF-β-
mediated metastasis305. MDSCs also produce VEGF-A promoting tumor growth and their own 
expansion, generating a vicious cycle of tumor growth and myeloid-cell expansion. In another 
study, MDSCs were found to enhance the growth of mammary tumors in mice by interacting 
with M1 macrophages and converting them to the M2 type306.  
 
3.5.2.3 –Mesenchymal stem cells (MSCs)  
MSCs are CD29+ CD44+ CD51+ CD73+ CD105+ CD166+ CD45- CD14- cells that selectively 
proliferate and contribute to the formation of tumor-associated stroma307. Recent studies have 
shown that recruitment of BM-derived human MSCs in breast carcinomas facilitates metastatic 
spread. Accordingly, it was shown that breast cancer cells stimulate de novo secretion of the 
chemokine CCL5 from MSCs, which then acts in a paracrine fashion via CCR5 present on the 
cancer cells to enhance their motility, invasion and metastasis308. 
 
3.5.2.4 –Tie-2 expressing monocytes (TEMs), mast cells and neutrophils 
TEM are Tie2+ CD11b+ CD14+ CD45+ CCR1+ VEGFR2- CD31-cells that are recruited to 
tumor stroma where they stabilize neovessels and promote angiogenesis by secreting pro-
angiogenic factors309. Mast cells are CD43+ CD123+CCR3+ ckit+ cells that positively correlate 
with increased vasculature and poor prognosis in a wide variety of human tumours. Recruitment 
of these cells to a tumour is mediated by stem cell factor (SCF), IL-3 and adrenomedullin310. 
These cells, which are preferentially localized at the tumour periphery, are a major pro-
angiogenic source of VEGF, FGF2, IL-8, TGFβ, TNFα, Ang-1 and serine proteases311. Mast 
cells promote MMP9-dependent neovascularization of dysplastic tissue and are necessary for 
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triggering the angiogenic switch in a mouse model of skin cancer312. Neutrophils are CD11b+ 
GR1+ CXCR1+ CXCR2+ cells. Recruitment of neutrophils is associated with poor prognosis in 
lung cancer. Neutrophils enhance angiogenesis and metastasis in animal model of multistage 
carcinogenesis313. Interestingly IL-8 mobilized neutrophils have been shown to interact with 
transiently entrapped circulating melanoma tumor cells facilitating their extravasation and lung 
metastasis formation314. 
 
3.5.2.5 – Pericyte progenitor cells (PPCs), T-Cells and NK-Cells 
BM-derived PPPs are Desmin+ NG2+ aSMA+ Sca1+ PDGFRb+ CD11b+ cells that associate 
perivasculary with nascent tumor vessels stabilizing and increasing vessel survival315,316. T-cells 
are CD3+ CD4+/CD8+ CD45+ cells that have been described has major effectors of anti-tumor 
immune responses. Namely CD8+ T cells specifically recognize and destroy cancer cells317. 
Another BM-derived population that is associated to tumor stroma are NK-cells (natural killer) 
which are CD11b+ CD27+ CD3+ CD56+ cell that monitor cell surfaces of autologous cells for 
an aberrant expression of MHC class I molecules and cell stress markers. NK cells are cytotoxic 
to cancer cells, in fact the number of NK cells in tumors serve as prognostic markers317. 
 
3.5.2.6 – Pre-metastatic niche cells 
Pre-metastatic niche cells where first characterized in 2005 by Kaplan et al being described as 
CD11b+ VEGFR1+ VLA4+ cells that are recruited distant organs to sites with increased 
expression of FN, mediated by tumor specific growth factors. Once at this discrete sites CD11b+ 
VEGFR1+ VLA4+ contribute for the formation of a permissive local microenvironment adjusted 
for the incoming tumor cells, leading to the initiation and establishment of micrometastases318,319. 
Recently, another mechanism of pre-metastatic niche formation was elucidated, in which lysyl 
oxidase (LOX) secreted by hypoxic breast tumor cells accumulated at pre-metastatic sites, where 
it crosslinked collagen IV in the basement membrane, which was essential for the recruitment of 
CD11b+ myeloid cells. CD11b+ cells adhere to crosslinked collagen IV and produce matrix 
MMP-2, which cleaves collagen, enhancing the invasion and recruitment of BM-derived cells 
and metastasizing tumor cells320. 
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3.5.3 – Approaches for targeting BM-derived cells in tumor stroma 
In the last three decades there has been a significant increase in the development of compounds 
aimed at cancer treatment, however few of them have show success treating solid tumors. 
Considering this there has been a recent interest in developing agents against cell types within 
the tumor stroma instead of tumor cells alone (Table 7). 
 
Table 7 – Agents used to target different types of tumor stromal cells. Table adapted from Gao, D. & Mittal, V. 
The role of bone-marrow-derived cells in tumor growth, metastasis initiation and progression. Trends in Molecular 
Medicine 15, 333-343 (2009). 
 
 
Bevacizumab (humanized antibody against VEGF-A) was the first FDA approved anti-
angiogenic drug. Clinical data shows increased survival rates in metastatic colorectal, colon and 
breast and renal-cell carcinoma patients when administered in combination with standard 
chemotherapy321,322. Although tumor vessel normalization has become the most accepted 
explanation for this observed synergy323, pre-clinical and early clinical evidence suggests that 
one potential mechanism by which bevacizumab enhances the activity of certain 
chemotheraputics is through reducing chemotherapy-induced BM-derived EPC mobilization. In 
contrast to bevacizumab, VEGFR2 kinase inhibitors have failed to enhance the efficacy of 
conventional chemotherapy in clinical trials322, possibly owing to the inability to block the 
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chemotherapy-induced EPC mobilization. Another BM-derived population that is a potential 
target in cancer treatment are MDSCs. One method has exploited the fact that MDSCs are 
developmentally immature and, therefore, promoting their differentiation using all-trans-retinoic 
acid (ATRA) might be a viable approach to overcome their immunosuppressive property during 
cancer vaccination324. In another approach, the administration of a drug that inhibits MMP9 
activity was found to reduce VEGF concentrations and the number of circulating MDSCs in 
mice that have mammary tumors. The drug also enhanced immune responses directed against the 
tumor325. Another emerging concept in anticancer therapy involves the mobilization and 
recruitment of BM-derived cells that provide resistance to cancer therapeutics, namely 
administration of certain chemotherapy drugs is associated with an increase in levels of BM-
derived cells including EPCs and VEGFR1+ cells that stimulate tumor progression and 
metastasis146. Similarly, BM-derived GR1+ myeloid cells have been implicated in tumor 
refractoriness to anti-VEGF treatment326, by avoiding the need for VEGF-A signaling and 
reinitiating angiogenesis. However, when the anti-VEGFA antibody was combined with an anti-
GR1 antibody, tumor growth was effectively reduced. Notably, tumor-promoting functions of 
recruited BM cells have been shown in several clinicopathological studies in which increased 
number of these cells in tumors correlated with increased angiogenesis and metastasis, leading to 
reduced patient survival. However the complete comprehension of the molecular mechanisms 
involved in the tumor-BM molecular communication as well as the identity of BM-populations is 
still lacking and might provide new targets in cancer treatment. 
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Chapter 2 - Aims and outline of the thesis 
 
In the last decade there has been an increase interest in the comprehension of the mechanisms 
regulating the interaction between cell populations derived from the bone marrow (BM) and 
physiological and pathological angiogenic processes occurring in adult individuals. One such 
population is composed by endothelial progenitor cells (EPCs) and the molecular mechanisms 
that regulate their function are still unclear. Considering this, the experimental data presented in 
this PhD thesis focuses mainly on the molecular mechanisms that regulate the multiple steps of 
EPC endothelial differentiation and paracrine/justacrine interactions during cutaneous wound 
healing and tumor progression. In detail, the aims of this thesis are: 
1. To understand the role of integrin:ECM interaction on the initial steps of the endothelial 
differentiation of EPCs (Chapter 3); 
2. To determine the contribution of the Notch-Delta signalling pathway on the endothelial 
differentiation of EPCS (Chapter 4); 
3. To understand the Notch-Delta signalling pathway as a justacrine signal regulating the 
interaction of EPCs with ECs during neo-vessel formation (Chapter 4 and 5); 
4. To understand the contribution of paracrine factors produced by EPCs during cutaneous 
wound healing (Chapter 3 and 4); 
 
Besides focusing on the comprehension of the role of the Notch-Delta pathway and its 
interacting pathways (namely integrins:ECM) on EPCs biology this thesis also attempts to 
understand how this pathway is involved in the communication between tumor cells and other 
BM-derived cell populations (besides EPCs) recruited during tumor growth and progression 
(Chapter 6). Considering this, the overall aim of this thesis is to contribute to a deeper 
comprehension of the role Notch-Delta pathway and its interacting pathways on the function of 
BM-derived populations, thus allowing more specific and efficient targeting of these pathways in 
the clinical setting. 
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Abstract 
Severe skin loss constitutes a major unsolved clinical health problem worldwide. For this reason, 
in the last decades there has been a major push towards the development of novel therapeutic 
approaches to enhance skin wound healing. Neo-vessel formation through angiogenesis is a 
critical step during the wound healing process. Besides the contribution of pre-existing 
endothelial cells (EC), endothelial progenitor cells (EPCs) have also been implicated in wound 
healing and believed to act either by differentiating into EC that incorporate the neo-vessels, or 
via the production of paracrine factors that improve angiogenesis. In the present work we tested 
the importance of different extracellular matrices (ECM) in regulating the angiogenic and wound 
healing potential of cord blood-derived EPC (CB-EPC). In detail, we compared the properties of 
several ECM and particularly of fibrin fragment E (FnE) in regulating EPC adhesion, 
proliferation, differentiation and healing-promotion in vitro and in vivo. Our results show that 
CB-EPC present increased adhesion to FbnE compared to other substrates (collagens, fibronectin 
and fibrin). As shown by the use of integrin neutralizing antibodies, EPC adhesion to FnE is 
mediated by integrin α5β1. In addition, CB-EPC plated on FnE show increased differentiation 
into CD31+ vWF+ EC. Gene expression analysis of CB-EPC plated on different substrates 
revealed that CB-EPC grown on FbnE show increased expression of paracrine angiogenic factors 
such as VEGF-A, TGF-β1, SDF-1, IL-8 and MIP-1α. Accordingly, conditioned medias from 
CB-EPC grown on FnE induced EC tube formation and monocyte migration in vitro. To test the 
wound healing effects of FnE in vivo we used a FnE-enriched scaffold termed Smart Matrix 
(SM) in a cutaneous wound healing mouse model. We observed that SM placement on wounds 
together with EPC inoculations accelerated wound closure and wound vascularization 
significantly, compared to SM alone or to using collagen based scaffolds (with or without 
addition of CB-EPC). Taken together, our results show that FnE modulates several CB-EPC 
properties in vivo and in vitro, therefore FnE based scaffolds represent a promising approach to 
resolve wound healing complications. 
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Introduction 
Over the past three decades, there have been extraordinary advances in our understanding of the 
cellular and molecular processes involved in acute wound healing and in the pathobiology of 
chronic wounds1-3. The process of wound healing is very complex involving multiple cell types, 
extracellular matrices (ECMs) and growth factors/chemokines interactions. The healing can be 
divided into 4 phases: hemostasis, inflammatory, proliferative and maturation phases1,4. One of 
the critical steps of wound healing involves new blood vessel formation in the wound 
granulation tissue, which occurs during the proliferative phase and allows oxygen, nutrient and 
immune cell delivery into the wound tissue5. New blood vessel formation may occur via 2 
interdependent processes: angiogenesis5 and post-natal vasculogenesis6. Post-natal 
vasculogenesis is the process by which new blood vessel from via differentiation of endothelial 
progenitor cells (EPCs)7. A putative role for EPCs in wound healing has been extensively 
documented and depends on both direct differentiation of EPCs into vessel incorporated 
endothelial cells6,8,9 or via production of paracrine factors that act on other cells types namely 
monocytes/macrophages, endothelial cells, fibroblasts and keratinocytes10,11. Thus the use of 
EPCs in wound healing therapies represents a possible approach in the clinical settings, namely 
in patients with chronic ulcerations secondary to diabetes mellitus, pressure, and venous 
stasis9,12,13. 
The increased knowledge of the wound healing process has led to wound care innovations that 
facilitate wound treatment. Nevertheless, the use of conventional surgical reconstruction using 
skin allo or autografts has shown limited application14, which led to the development of a new 
research area focusing on the generation of synthetic skin substitutes15. However the success of 
most synthetic skin substitutes has been limited by a varying incidence of infection at the wound 
site16. An underlying reason for these problems is the limiting rate of neo-vascularization. In 
order to increase the vascularization of synthetic skin substitutes it is necessary to engineer 
compounds that are able to increase endothelial cell migration and blood vessel formation17. One 
such compound is fibrin, a potent inducer of endothelial cell migration18. Enzymatic cleavage of 
fibrin yields a variety of fibrin degradation products (D dimers, D and E fragments and also 
smaller fragments like the peptide Bβ15-42), particularly in areas of intense angiogenesis such as 
in healing wounds and active atherosclerotic plaques19. One of these, fibrin fragment E (FnE), is 
a potent angiogenic factor recapitulating the effect of whole fibrin on endothelial cell migration20. 
FnE induces proliferation, migration and differentiation of human microvascular endothelial 
cells in vitro independently on the presence of angiogenic factors like VEGF or bFGF21. In the 
present study, we addressed the role of FnE fragment on EPC function, neo-vascularization of 
wound tissue and wound healing. 
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Materials and Methods 
 
The procedures involving mice were performed following Institutional (Instituto Gulbenkian de 
Ciencia) and National Guidelines. All experiments were approved by an Institutional Review 
Committee. 
 
Immunomagnetic isolation of EPC 
All human umbilical cord blood samples were obtained from the OB/GYN Department of 
Hospital de Santa Maria, Lisbon after informed consent. To understand the molecular features 
that regulate EPC differentiation, EPC (CD133+CD34+KDR+ cells) were isolated from human 
umbilical CB mononuclear cells (MNC) after Ficoll (Histopaque-1077, Sigma Diagnostics, St. 
Louis, USA) separation. CD133+ cells were positively isolated using the mini-MACS 
immunomagnetic separation system (Miltenyi Biotec, Bergisch Gladbach, Germany), according 
to the manufacturer's instructions. CD133+ cells were subjected to a second round of magnetic 
isolation for VEGFR-2 using the PlusCellct Kit against human VEGFR-2 (R&D systems) 
according to the manufacturer's instructions. 
 
Cell Culture and Reagents 
Isolated cord blood-derived EPCs (CB-EPCs) were transferred onto 1% gelatine (Sigma-
Aldrich), Fibronectin (10µg/ml, Sigma-Aldrich), Colagen I (10µg/ml, Cell Adhesion), Laminin 
(10µg/ml, Sigma-Aldrich), Plasmin activated Fibrinogen (10µg/ml, Sigma-Aldrich) or Fibrin 
fragment E (provided by Julian Dye, RAFT institute) coated 24-well plates (1-2,5x105 cells/well). 
FbnE was prepared as follows: Fibrinogen was dissolved in Dulbeccos PBS with calcium & 
magnesium pH7.4 (10 mg/ml) filtred 0.2: and coagulated with thrombin (30 U, 3ml at 10 U/ml in 
PBS), for 1 hr, 37ºC. Plasmin (8U, Calbiochem) was added to the clot, with initial mechanical 
dissagregation with a pipette-tip into small fragments, and incubated for 1hr, 37ºC, to achieve 
complete clot lysis. This was stopped by addition of 100 U aprotinin. (This lysis step could be 
extended to 12hr with little further effect on the yield or MW of FnE.) The lysate was incubated 
at 60ºC for 1hr, which yielded a floculum (FnD and larger fragments) that was precipitated by 
centriguagtion at 100,000g, 30min. The supernatant was recovered and buffer-exchanged into 
PBS/aprotinin using a 10kD molecular cutoff filter (VivaSpin). The resultant FnE was divided 
into 100ug aliquots, frozen and lyophilised (yield measured by Biorad protein assay). In 
endothelial differentiation assays cells where incubated in endothelial differentiation medium 
consisting of EBM-2 medium supplemented with 2% FBS, ECGS (20µg/ml, Sigma-Aldrich), 
Heparin (5U/ml, Sigma-Aldrich), VEGF (20ng/ml, Sigma-Aldrich), HEPES buffer (ph=7,5, 
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25mM) and antibiotics. Every 3 days the medium was supplemented with 1µl VEGF (20ng/ml, 
Sigma-Aldrich) and 1µl Heparin (5U/ml). Around day 8 of differentiation non-adherent cells 
were washed off and new media was added. Cells were allowed to differentiate for 15-20 days 
under these conditions. Concerning other assays besides the endothelial differentiation assay 
EPCs where cultures in complete EBM-2 medium supplemented with 5% fetal bovine serum 
(Lonza). Human dermal microvascular endothelial cells (HDMECs), passages 3 to 6, were 
cultured and maintained following standard procedures and culture conditions in MCDB 105 
media (Sigma-Aldrich) containing Hidrocortisone (Lonza) and EGF (50ηg/ml, Lonza). 
 
Quantitative Reverse-Transcription Polymerase Chain Reaction (qRT-PCR) 
RNA extraction (Trizol, Invitrogen), cDNA synthesis (Reverse-transcription with Superscript II 
reverse transcriptase (Invitrogen)) and oligo (dT) primer (Roche) were performed following 
standard protocols. mRNA levels were measured by real time RQ-PCR  on the ABI Prism® 
7900HT Sequence Detection System (Applied Biosystems) using the following primers human 
VEGF-A (cgaagtggtgaagttcatggact; ttctgtatcagtctttcctggtg) PlGF (gtcatgaggctgttcccttg; 
gggtaccacttccacctctg), TGF-β1 (gtacctgaacccgtgttgct; cacaactccggtgacatcaa) PDGF 
(cgatccgctcctttgatgat; tccaactcggccccatct) IGF (gaaagtgacgtcctgcattt; ccggtgccaggttatgatg), FGF-
6 (gagaagtgcctcttcgttg; ttacccgtccgtatttgctc) ANG-2 (ggaacactccctctcgacaa; attcaccgtggcagtcacta), 
SDF-1 (cagatgcccatgccgatt; agtttggagtgttgagaattttgaga), IL-8 (ctggccgtggctctcttg; 
ccttggcaaaactgcacctt), MIP-1α (gctgtcctcctctgcaccat; gcggtcggcgtgtca) and MCP-1 
(tcgctcagccagatgcaat; gcctctgcactgagatcttcct). The housekeeping gene used to normalize the 
samples was hrRNA 18s (gccctatcaactttcgatggta; ccggaatcgaaccctgatt). Each sample was 
analyzed in duplicate and each PCR experiment included at least one non-template control well. 
PCR products were electrophoresed through 2% agarose gel and analyzed by staining with 
ethidium bromide. 
 
Immunocytochemistry 
Cells were fixed in 2% paraformaldehyde for 15 minutes at 4ºC, permeabilized for 20 minutes at 
room temperature using PBS + 0,02% Triton-X (only for P-H3 nuclear stinning), blocked with 
PBS + 0,1% BSA for 45 minutes at room temperature and incubated with primary antibody 
overnight (diluted in PBS + 0,1% BSA). Antibodies used were von Willebrand Factor (vWF - 
1:200, A0082, Dako), CD31 (1:100, JC70A, Dako), P-H3 (1:100, 06-570, Upstate – Cell 
Signaling Solutions). Secondary antibodies used: anti-rat/goat/rabbit FITC/PE-coupled IgG 
(Alexa fluor 488/594, Molecular Probes, US). Cells were examined by standard fluorescence 
microscopy using a fluorescence microscope (Axioplan Microscope, Zeiss, Germany).  
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Flow cytometric acquisition and analysis 
CB- EPCs purity was determined by FACS (Becton Dickinson) with CD34-R-PE conjugated 
mouse anti-human monoclonal antibody (BD Biosciences Pharmingen), CD133-PE anti-human 
monoclonal antibody (Miltenyi Biotec) and anti-human KDR-APC (R&D Systems, Inc). 
Determination of integrins expressed by EPCs was determining using primary antibodies (diluted 
in PBS + 0,5% BSA) against integrin subunits α2 (1:100, 611016, BD Biosciences Pharmingen), 
α3 (1:100, MAB1952Z, Chemicon), α5 (1:100, sc-13547, Santa Cruz), αV (1:100, 407286, 
Calbiochem), β1 (1:100, AF2405, R&D) and β3 (1:100, sc-20058, Santa Cruz). After 30 minutes 
incubation at 4ºC, samples where washed in PBS + 0,5% BSA and incubated with secondary 
antibodies anti-rat/goat/rabbit FITC/PE-coupled IgG (Alexa fluor 488/594, Molecular Probes, 
US). All flow cytometric acquisitions were performed using a FACS Calibur (BD Biosciences, 
San Jose, CA, USA) with a minimum of 10,000 events adquired for each sample. Live cells used 
for the analysis, were gated based on forward angle light scatter (FSC) and side angle light 
scatter (SSC) characteristics and further analyzed using the Cell Quest Pro software (Becton 
Dickinson). 
 
Adhesion Assays  
Isolated CB-EPCs where transferred onto 1% gelatine (Sigma-Aldrich), Fibronectin (10µg/ml, 
Sigma-Aldrich), Colagen I (10µg/ml, Cell Adhesion), Laminin (10µg/ml, Sigma-Aldrich), 
plasmin activated Fibrinogen (10µg/ml, Sigma-Aldrich) or Fibrin fragment E (10µg/ml provided 
by Dr.Julian Dye, RAFT institute) coated 24-well plates (1,5x105 cells/well) and incubated in 
complete EBM-2 medium. 48h after seeding, non-adherent cells were removed (using sterile 
PBS) and adherent cells were counted in 6 random high power fields (x200). The number of 
adherent cells was normalized relatively to the control (gelatine) condition. In adhesion 
inhibition assays CB-EPCs where pre-incubated for 45 minutes at 4ºC with anti-α5β1 
neutralizing antibody (1:100, MAB1969, Millipore) before being plated. 
 
In Vitro Endothelial Tube Formation Assay 
HMECs were seeded on Matrigel (BD Bioscience) – coated wells (24 well plate) at a density of 
1x105 cells per well in complete EBM-2 medium with 2%FBS in control conditions and in 
conditions media collected from CB-EPCs plated on Gelatin/Fibronectin/Fibrin fragment E for 
16-18h at 37ºC. After endothelial cell tube formation was observed the cells were fixed in 
paraformaldehyde (2%). Photographs were taken at 40x magnification using an Olympus 
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Microscope. Tubes and bifurcation quantifications were done using the NIH Image J analyzer 
and expressed as number per 40x high power field (HPF). 
 
In vitro preparation of dermal substitute INTEGRA and Smart Matrix 
IntegraJ (commercial dermal scaffold consisting of an inner layer of porous 3-dimensional 
cross-linked collagen and chondroitin sulphate, and an outer layer of silicone) and Smart 
MatrixJ (porous cross-linked fibrin alginate dermal scaffold, under development at RAFT) were 
pre-incubated for 1 week in complete EBM-2 medium plus 5% FBS together with or without 
CB- EPC (2-3x105 cells/well) in a 24-well plate. 
 
In Vivo Wound Healing Model and Wound Closure Analysis 
In vivo wound healing model was established using Balb-SCID mice. Briefly, female mice, 8 
weeks old, body weight 20-33 grams, were anesthetized with intraperitoneal injection of a 
combination of xylazine (10mg/kg) and ketamine (100 mg/kg). After shaving the hair, 2 single 
full thickness, 6-mm diameter excisional wounds were performed in the dorsolumbar skin with a 
sterile biopsy punch. INTEGRA and Smart matrix substitutes with or without CB-EPCs where 
subsequently added to the wound and sewed into the adjacent dermis. Mice were individually 
caged. Photos were taken every 3 days starting on day 1 and wound perimeter was calculated 
using Image J software. Wound perimeter at each time point was represented relatively to the 
area obtained at day 1.  
 
Wound histology and Immunohistochemistry 
Animals were sacrificed at day 13 post-wounding. 8mm diameter skin biopsy samples centred on 
the wound bed was collected, fixed in 10% formalin for a maximum of 48 hours and embedded 
in paraffin. Wounds were serially sectioned (3 µm) perpendicular to the wound surface, rostral to 
caudally, with a 500µm intermission, and stained with haematoxylin and eosin (H&E). The 
number of levels analysed ranged from 8-10 per wound.  
To visualize blood vessels, sections adjacent to those stained for H&E were labelled for VE-
cadherin (1:300, A0082, Dako). Briefly, sections were deparaffinised and immersed in methanol 
with 0.3% hydrogen peroxide for 30 minutes. Microvessel density (MVD) was evaluated 
through VE-cadherin immunoreactivity. At low power field (x 40), tissue sections were screened 
and 5 areas with the most intense neovascularization (hot spots) were selected. Microvessel 
counts of these areas were performed at high power field (x 200). The mean microvessel count of 
the five most vascular areas was taken as the MVD, which was expressed as the absolute number 
of microvessels per 0.74 mm2 (x 200 field). Staining for human EPCs in the wound bed was 
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performed using CD31 staining (1:100, M0823, Dako). Quantification of miofibroblast at the 
wound bed was done by Muscle Actin staining (1:100, HHF35, Dako). Quantification of 
pericytes at the wound bed was done by Smooth Muscle Actin staining (1:100, M0851, Dako). 
At low power field (x 40), tissue sections were screened and 5 areas with the most intense 
staining (hot spots) were selected counts of these areas were performed at high power field (x 
200). The mean number of positive cells in the five hot spots areas was expressed for each 
condition. 
 
Statistical Analysis 
Differences between the experimental groups (cell numbers, migrated distances, wound size 
among other parameters) were calculated using ANOVA or T student test. 
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Results 
 
CB-EPCs express mainly integrin sub-units α5 and β1 
CB-EPC isolation was based on the expression of specific markers; specifically, isolated cells 
were CD133 positive (95±2%), CD34 positive (96±1%), VEGFR-2 positive (75±12%) and 
CXCR4 positive (82±5%) (Figure 1). Relevant to the present study, we also determined the 
integrin expression profile of CB-EPCs. As determined by FACS analysis, 80±5% CB-EPCs 
express integrin sub-unit α5 and 74±7% express integrin subunit β1 (Figure1). In addition, a 
small fraction of CB-EPCs expresses α2 (7±3%) and α3 (less than 5%), αV (8±1%) and β3 
(22±6%). Altogether these data indicate that CD133+CD34+VEGFR-2+CXCR4+ CB-EPCs 
express mainly the fibronectin (FN) receptor integrin α5β1. 
 
 
Figure 1 - CB-EPC are CD133+ CD34+ KDR+ CXCR4+ cells that express mainly integrin 
α5β1. FACs analysis of freshly isolated CB-EPCs. Analysis of side and forward scatter 
parameters and analysis of the levels of expression of CD133, CD34, KDR, CXCR4 and integrin 
sub-units (α2, α3, αV, α5, β1, β3). Flow cytometric histograms from one representative 
experiment are shown (n = 3). At least 10,000 live gated cells were analyzed for FITC, PE, 
PerCP or APC expression. Isotype controls (unstainned cells) are shown as green lines. 
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FnE increases CB-EPCs adhesion and endothelial differentiation in vitro 
Next, we determined the effect of FnE on CB-EPC adhesion, proliferation and endothelial 
differentiation. To determine the effect of FnE on adhesion, CB-EPCs were plated onto different 
types of extracellular matrices and the number of adherent cells was quantified. The number of 
adherent CB-EPCs was highest on FnE-coated plates compared to fibronectin or gelatin (Figure 
2A). Neutralization of α5β1 integrin reduced adhesion of CB-EPC to FN and to FnE (Figure 2B), 
confirming the specificity of the integrin expression profile. 
Next we sought to determine whether FnE influenced endothelial differentiation of CB-EPCs, by 
affecting cell proliferation and acquisition of endothelial markers. Proliferation of CB-EPCs in 
vitro was not affected by the different matrices (data not shown). To test the effect of FnE on 
CB-EPCs endothelial differentiation, these were plated onto the different matrices and cultured 
under endothelial differentiation conditions for 3 weeks, after which cells where fixed and 
stained for endothelial markers (Von Willebrand factor (vWF) and PECAM (CD31)). After the 
differentiation period, the number of vWF and CD31 expressing cells was higher on FnE coated 
plates (Figure 2C), suggesting that FnE promotes CB-EPCs endothelial differentiation. Taken 
together, these data suggest that FnE increases CB-EPC adhesion via α5β1 integrin and 
consequently promotes endothelial differentiation in vitro. 
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Figure 2 - CB-EPCs show increased integrin α5β1 mediated adhesion and endothelial 
differentiation on FnE. A. Quantification of adherent CB-EPCs 72h after being plated on 
gelatine (Gel), Collagen type I (Col I), Fibronectin (FN), Fibrin E fragment (FnE) and Fibrin 
(Fib). Cells were quantified per 40x high power field (HPF). Error bars indicate SD. B. 
Quantification of adherent CB-EPCs plated on FN and FnE in the presence (anti-a5b1) or 
absence (C) of an integrin α5β1 neutralizing antibody. Cells were quantified per 40x high power 
field (HPF). The lower pannels shows representative images of the conditions quantified in the 
upper graph. Scale bar: 100 µm. Error bars indicate SD. C. Quantification of CB-EPCs 
expressing CD31 and VWF after 3 weeks of culture on on gelatine (Gel), Collagen type I (Col I), 
Fibronectin (FN), Fibrin E fragment (FnE) and Fibrin (Fib) in the presence of endothelial 
differentiating media. Error bars indicate SD. Each experiment was performed in triplicate and 
the mean presented (n=3). 
 
 
FnE induces expression of pro-angiogenic and pro-inflamatory paracrine factors on CB-
EPCs 
EPCs have been show to participate in new vessel formation by differentiating into endothelial 
cells and incorporating neo-vessels but also by producing paracrine factors that can in turn 
induce angiogenesis. Considering this we tested whether culturing CB-EPCs onto different 
matrices could influence the production of angiogenic and/or inflammatory 
cytokines/chemokines by these cells. As shown in Table 1, CB-EPCs cultured on FnE coated 
plates express increased levels of VEGF-A, TGF-β1, SDF-1, IL-8, MIP-1α and MCP-1. Since 
VEGF-A, TGF-β1, SDF-1, IL-8 are well known angiogeninc factors, next we tested whether 
adding conditioned media from CB-EPCs cultured on gelatin, FN or FnE affected endothelial 
tube formation on matrigel. Conditioned media from CB-EPCs cultured on FnE-coated plates 
increased HDMECs tube formation and bifurcation compared to the other conditions (Figure 3A). 
In addition, culturing CB-EPCs in FnE seems also to promote the production of pro-
inflammatory cytokines and chemokines such as SDF-1, IL-8, MIP-1α and MCP-1. Considering 
this we tested the effect of CB-EPC conditioned media on transwell migration of human 
peripheral blood derived monocytes (isolated for the CD14 marker). Interestingly as observed in 
figure 3B, condition media collected from CB-EPCs cultured on FnE increase significantly 
CD14+ monocyte migration compared to the other conditions. 
These data suggest that CB-EPCs adhesion and differentiation in the presence of FnE leads to 
increased production of multiple angiogenic and proinflammatory factors that in turn may 
promote both angiogenesis and inflammatory cell recruitment in a paracrine manner.  
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Table 1 Relative expression levels (determined by qRT-PCR) of different growth factors, 
chemokines and citoknes expressed by CB-EPCs cultured on gelatine (Gel), fibronectin (FN) or 
fbrin-fragment E (FnE). 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3 FnE induces expression of pro-angiogenic and pro-inflamatory paracrine factors 
on CB-EPCs. A. Quantification of the number of bifurcation (white bars) and tubes (black bar) 
formed by HDMECs on matrigel in the presence of control media or conditional media collected 
from CB-EPCs cultured on Gel, FN and FnE. Right panel shows representative images of the 
conditions quantified on the graph on the left. Scale bar: 100 µm. Error bars indicate SD. B. 
Quantification of the number of CD14+ monocytes that migrated toward control media or 
conditional media collected from CB-EPCs cultured on Gel, FN and FnE. Error bars indicate SD. 
Each experiment was performed in triplicate and the mean presented (n=3) 
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FnE enriched scaffold (Smart Matrix) containing CB-EPCs enhancing cutaneous wound 
healing in in vivo models 
Considering the in vitro effect of FnE on CB-EPC adhesion, differentiation and paracrine factor 
production we next sought to determine the in vivo wound healing potential of an FnE enriched 
scaffold termed smart matrix (SM) pre-incubated or not with CB-EPCs (SM+E and SM 
respectively). In order to validate the effect of SM on wound healing we compared its effect to 
the one of INTEGRA also pre-incubated or not with CB-EPCs (INT+E and INT respectively). 
An additional control group was used with no addition of any scaffold into the wound (C). As 
depicted on figure 4A comparison of the wound perimeters measured at different time points of 
the healing process shows that SM+E mice group showed enhanced wound healing 10 and 13 
days after wounding compared to SM alone and C groups. SM group alone showed no 
significant increase in wound closure compared to C, revealing that adding CB-EPCs is essential 
for SM-mediated wound closure. Surprisingly all mice treated with Integra (total of 8 
individuals) died with suspected panniculitis (infection and inflammation of subcutaneous 
adipose tissue) on day 7 after wounding. Histological measurement of the distance between the 
wound margins further confirms the increased wound closure observed on SM+E group (Figure 
4B). Direct observation of wound tissue H&E shows that the cellular density in C and SM+E 
groups is higher than that of SM groups, further suggesting that besides the direct contribution of 
CB-EPCs to increase the cellular density they might be recruiting via paracrine action other cell 
types into the wound granulation tissue (Figure 4B).  
Further characterization of the wound cellular components revealed that wounds in mice of the 
SM-E group have increased number of vessels (VE-Cadherin+ structures) relatively to the other 
groups (Figure 4C). Interestingly a small fraction (not quantified) of the vessels in the SM-E 
group were of human origin (recognized by a mouse anti-human CD31 antibody) suggesting 
direct differentiation of exogenous CB-EPC into neo-vessels (Figure 4D). Concerning the 
number of pericytes (smooth muscle actin + cells) associated with blood vessels there were no 
significant differences between the 3 groups (Figure 4E). On the other end the number of 
myofibroblasts (muscular specific actin + cells not associated with vessels) was significantly 
higher in the C group compared to the SM and the SM+E groups. Taken together, these data 
shows that addition of CB-EPC to FnE-rich matrix promotes wound healing by modulating neo-
vessel formation, cell infiltration, ultimate scarring and wound resolution. 
 
 
 
 107 
 
 
 
 
 
 108
 
Figure 4 - FnE enriched scaffold (Smart Matrix) containing CB-EPCs enhancing cutaneous 
wound healing in in vivo models 
A. Quantificiation of the wound perimeters on days 0 (day when the wound was performed), 4, 7, 
10 and 13 (day when mice where sacrificed). Mice were group as C (wound no scaffold addition), 
INT (wound with INTEGRA scaffold), INT+E (wound with INTEGRA and EPCs), SM (wound 
with smart-matrix scaffold) and SM+E (wound with smart-matrix and EPCs). Wound perimeter 
at each time point was divided by the respective perimeter at day 0 and represented as a 
percentage. Error bars indicate SD. B. Representative histological images of wounds collected at 
day 13 after wounding. Hematoxilin and Eosin staining. Graph on the right represents the 
quantification of the distance between wound margins in the different groups. Scale bar: 100 µm. 
Error bars indicate SD. C. Representative histological images of wound microvessel density with 
imunostainning against VE-Cadherin. Graph on the right represents the quantification of the 
number of vessels in the wounds of the different groups. Scale bar: 100 µm.. Error bars indicate 
SD. D. Representative histological images of a CB-EPC-derived blood vessel in the wounds by 
immunostainning against human CD31 (arrow points positively stainned cells). Scale bar: 100 
µm. Error bars indicate SD. E. Upper panel: representative histological images of muscel 
specific actin positive (MSA+) cells in the wounds of the different groups. Graph on the right 
represents the quantification of MSA+ cells in the wounds of the different groups. Lower panel: 
representative histological images of smooth muscle actin positive (SMA+) cells in the wounds 
of the different groups. Graph on the right represents the quantification of SMA+ cells in the 
wounds of the different groups. Scale bar: 100 µm. Error bars indicate SD. Each experiment was 
performed in triplicate and the mean presented (n=3) 
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Discussion 
In the last decades the incidence of pathologies that cause skin loss is rising and the treatment of 
these pathologies represents nowadays a major costs to European healthcare systems22, 23. Recent 
data reveals that the most common single cause of significant skin loss is thermal injury. Other 
causes include trauma and chronic ulcerations secondary to diabetes mellitus, pressure and 
venous stasis. In Europe the annual incidence of severe burns is 0.2 to 2.9/10,000 inhabitants, 
with mortality rates between 1.4% and 18%24. Chronic ulceration affects around 1% of the 
European population25 and is rising due to increased life span and incidence of diabetes, with 
40,000 to 50,000 lower extremity amputations occurring each year, 30-40% of which result in 
death22. Considering these rising numbers there is an urge to further comprehend the cellular and 
molecular mechanisms that regulate wound healing in order to development new cellular and/or 
molecular centered approaches that will allow a more efficient healing with reduced mortality 
rates and with reduced costs to the public healthcare systems. 
The formation of a functional vessel network into the wound tissue, via angiogenesis, represents 
a crucial and critical step in the wound healing process1-5. Effective angiogenesis occurs as a 
result of the proliferation of pre-existing EC in response to stimuli released in the wound bed, but 
may also involve the direct or indirect action of EPC. Direct incorporation of EPC (from 
different sources) into neo-vessels in wounds has been demonstrated, but it is now increasingly 
accepted that EPC, and other cells recruited in response to systemic signals, may promote neo-
angiogenesis during wound healing via the production of paracrine signals released at the wound 
site10,11,13. Moreover, given the potential of EPC and other cells at inducing neo-angiogenesis, 
great efforts have been put forward to improve their recruitment and incorporation into sites 
where angiogenesis is needed, such as during wound healing. One mechanism by which 
incorporation and fixation of EPC into wounds may be improved could involve the addition of 
substrates that promote EPC adhesion. In the present study we investigated the potential of 
different matrices/substrates at modulating pro-angiogenic properties of EPC in vitro and in vivo 
In detail, we tested the effect of Fibrin fragment E (FnE) on the adhesion, proliferation, 
endothelial differentiation and paracrine factor production of CB-EPCs. Accordingly to our 
results CB-EPCs where characterized as CD34+ CD133+ KDR+ CXCR4+ cells that express 
mainly integrin subunits α5 (80±5%) and β1 (74±7%). Integrin α5β1 has been shown to be a FN 
binding integrin, interacting with RGD sequences present on FN26. Besides integrin α5β1 CB-
EPCs show also a reduced expression of integrin αV (8±1%) and β3 (22±6%), which bind 
vitronectin and also FN, also by interacting with RGD sites27. Regarding CB-EPC adhesion 
assays we have shown that these cells adhere preferentially to FnE and also to FN although at a 
significantly lower frequency, suggesting that CB-EPCs have higher affinity for FnE. Using 
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neutralizing antibodies against integrin α5β1 we show that adhesion of CB-EPCs to FnE is 
mediated mainly but not totally by integrin α5β1. Indeed the inhibition was only partial 
suggesting that there might be other integrins (for instance αVβ3) mediating CB-EPC adhesion 
to FnE or that the dosage of neutralizing antibody used was not enough to completely block 
integrin α5β1 mediated adhesion. Interestingly α5β1 integrin has been shown to be essential for 
vascular smooth muscle cells interaction with FnE together with integrin αVβ328. In another 
study it was shown that microvascular dermal endothelial cells interaction with FnE is mediated 
mainly by αVβ3 integrin21. Altogether these data suggests that CB-EPC interaction with FnE is 
mediated mainly by integrin α5β1 but might also depends on integrin αVβ3, possibly due to the 
fact that both these integrins have high affinity for RGD binding sites which is found on FnE21. 
After determining the effect of FnE on CB-EPC adhesion we next sought to determine the effect 
of FnE on endothelial differentiation. Interestingly we observed that FnE increases the number of 
CD31+ vWF+ cells obtained at the end of the endothelial differentiation assay, suggesting that 
this fragment provides essential signals, possibly adhesion signals associated with integrin α5β1 
that promote endothelial commitment of CB-EPCs. In accordance integrin α5β1 has been shown 
to be essential for CD34+ VEGF-induced endothelial differentiation into endothelial cells29.  
Recent data suggests that EPC can increase wound healing by differentiating into ECs but also 
by producing paracrine factors that can interact with other cell types directly involved in wound 
healing10, 11, 30. Considering this we determined the expression of different paracrine factors by 
CB-EPCs when grown on gelatin, FN and FnE. CB-EPCs grown on FnE express increased levels 
of VEGF-A, TGF-β1, SDF-1, IL-8, MIP-1a and MCP-1 relative to CB-EPCs cultured on other 
substrates. Concerning wound healing VEGF-A promotes the early events in angiogenesis, 
particularly endothelial cell migration31 and proliferation32, being essential for wound 
angiogenesis. In fact experimental data shows that VEGF-A improves reepithelialization of 
diabetic wounds associated with enhanced vessel formation33. In wound healing TGF-β1 is 
important in inflammation, angiogenesis34, reepithelialization35 and connective tissue 
regeneration36. SDF-1 plays essential roles on wound healing namely by recruiting bone-marrow 
derived cells such as lymphocytes and progenitor cells37, inducing proliferation and migration of 
endothelial cells38 and also by enhancing keratinocyte proliferation39. IL-8 has been shown to be 
essential for the recruitment of neutrophils40, keratinocytes proliferation41 and angiogenesis42. 
Interestingly the proangiogenic effect of EPC-produced IL-8 has been shown in vitro43. MIP-1α 
(CCL3) is a major monocyte/macrophage-attractant chemokine, however MIP-1α (-/-) mice 
show normal wound healing suggesting that this chemokine is not essential for wound healing44. 
MCP-1 (CCL2) is a chemoattractant for monocytes/macrophages, T-cells, and mast cells. The 
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essential role of this chemokine during wound healing is pointed by the fact that MCP-1 (-/-) 
mouse show delayed reepithelialization, angiogenesis, and collagen synthesis thus impairing 
wound healing44. Altogether these results suggests that direct interaction of CB-EPCs with FnE 
induces expression of multiple factors, which is in accordance with other studies showing that 
FnE induces macrophage IL-6 production45 and monocyte IL-1b production46.  
Having shown the beneficial effect of FnE on CB-EPC adhesion, endothelial differentiation and 
pro-angiogenic and pro-inflammatory factor production we tested the effect of an FnE enriched 
scaffold – termed Smart-matrix (SM) on in vivo mouse cutaneous wound healing. Interestingly 
we observed that mice receiving SM had a rate of wound closure similar to the one of control 
mice (mice receiving no scaffold) suggesting that SM per se is not enough to increase wound 
healing in mouse models of acute wound healing. In fact we observed that the wounds receiving 
SM had a reduced cellular density compared to the control group, suggesting a retarded cellular 
invasion of this scaffold. On the other hand mice receiving SM together with CB-EPCs (SM+E) 
show increased wound closure compared to control and SM groups. This higher wound closure 
rate is associated with an increased wound vascularization (quantification of VE-Cadherin + 
vessels) in SM+E group compared with control an SM groups. Interestingly the increased 
number of vessel may result from both an indirect (as a result of pro-angiogenic and pro-
inflammatory paracrine factors produced by CB-EPCs) and direct effects of CB-EPC 
(differentiation of CB-EPCs into vessel incorporated endothelial cells).  Altought the vessel 
number was higher in SM-E groups the number of vessels associated pericytes (SMA+ cells) 
was not, suggesting that in SM-E group there is a reduced pericyte coverage and possibly an 
increased responsiveness to angiogenic factors compared to the other groups. Regarding the 
number of myofibroblasts in the wound we observed that control wounds have significantly 
higher levels of these cells than both SM and SM+E, suggesting that SM does not efficiently 
recruit this cell type. 
In conclusion the data presented on this paper suggests a new approach to deal with cutaneous 
wounds at a clinical level by combining the use of a synthetic scaffold enriched for FnE together 
with the addition of CB-EPCs. While the use of a synthetic scaffold can reduce wound infection 
(by reducing the wound area exposed to external agents) and provide a physical support for cell 
migration and invasion, the addition of both FnE and CB-EPCs can act synergistically to 
increase wound vascularization and consequent closure and healing. 
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Abstract 
Bone marrow (BM) derived vascular precursor cells (BM-PC, endothelial progenitors) are 
involved in normal and malignant angiogenesis, in ischemia and in wound healing. However, the 
mechanisms by which BM-PC stimulate the pre-existing endothelial cells at sites of vascular 
remodelling/recovery, and their contribution towards the formation of new blood vessels are still 
undisclosed. In the present report, we exploited the possibility that members of the Notch 
signalling pathway, expressed by BM-PC during endothelial differentiation, might regulate their 
pro-angiogenic or pro-wound healing properties. We demonstrate that Notch pathway modulates 
the adhesion of BM-PC to extracellular matrix (ECM) in vitro via regulation of integrin α3β1; 
and that Notch pathway inhibition on BM-PC impairs their capacity to stimulate endothelial cell 
tube formation on matrigel and to promote endothelial monolayer recovery following wounding 
in vitro. Moreover, we show that activation of Notch pathway on BM-PC improved wound 
healing in vivo through angiogenesis induction. Conversely, inoculation of BM-PC pre-treated 
with a gamma secretase inhibitor (GSI) into wounded mice failed to induce angiogenesis at the 
wound site and did not promote wound healing, presumably due to a lower frequency of BM-PC 
at the wound area. Our data suggests that Notch pathway regulates BM-PC adhesion to ECM at 
sites of vascular repair and that it also regulates the capacity of BM-PC to stimulate angiogenesis 
and to promote wound healing. Drug targeting of the Notch pathway on BM-PC may thus 
represent a novel strategy to modulate neo-angiogenesis and vessel repair.    
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Introduction 
The vertebrate skin represents a major barrier against external damage. Maintenance of a 
functional/undamaged skin namely through an efficient cutaneous wound healing is essential. 
Cutaneous wound healing involves an inflammatory response, formation of granulation tissue, 
angiogenesis and tissue remodelling1,2. During these processes there is interplay between 
different cell types or between cells and the extracellular matrix (ECM) which are mediated by 
chemokines/growth factors and integrins, respectively3,4. Angiogenesis, the process by which 
new capillaries are formed, is a fundamental step in wound healing. The formation of new 
vessels at the wound site allows the inflammatory cells to migrate into the wound, but also 
supply the oxygen and nutrients necessary to sustain the growth of the granulation tissue and 
epidermis5. 
Bone marrow derived progenitor cells (BM-PC) with vasculogenesis/angiogenesis potential have 
been proven essential in a variety of models of post-natal angiogenesis6. Despite the 
heterogeneity of BM-PC populations, it is now accepted that bone marrow derived endothelial 
progenitor cells (EPC) and bone marrow derived mesenchymal stem cells (MSC) can enhance 
angiogenesis and promote vascular healing in different models, such as in cutaneous wound 
healing. Accordingly, it has been shown that BM-PC can improve angiogenesis at the wound site 
by differentiation and incorporation into mature vessels and production of pro-angiogenic 
factors7,8,9. In addition, recruited BM-PC may promote endothelial cell migration and 
proliferation via the production of IL-8, VEGF, angiopoietin-1 or stromal derived factor-1, 
among other facors10,11,12. 
The Notch signalling pathway involves the activity of Notch transmembrane receptors 1, 3 and 4, 
which interact with membrane-bound ligands, Delta1, 2 and 4 and Serrate/Jagged 1 and 2. 
Ligand binding induces proteolytic cleavage of Notch receptor by a gamma-secretase complex 
causing the subsequent translocation of the Notch intracellular domain (NICD) to the nucleus, 
where it will activate the transcription of downstream target genes such as Hes1 (hairy enhancer 
of split homolog-1) and Hey1 and Hey2 (Hes related protein)13. Deficient Notch signalling 
impairs normal vascular development in the embryo14,15,16,17,18. More recently involvement of the 
Notch pathway in cutaneous wound healing was demonstrated, since Notch antisense transgenic 
mice and normal mice treated with gamma-secretase inhibitors have impaired healing due to 
defective endothelial and keratinocyte cell migration19. However the contribution of BM-PC in 
these settings was not addressed. Considering this, besides regulating arterial/venous fate20,21, the 
role of the N/D pathway in regulating BM-PC differentiation and function during angiogenesis is 
still elusive.  
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In the present study, we hypothesized that the Notch pathway might be involved in the 
communication between recruited BM-PC and endothelial cells during wound healing. To test 
this hypothesis, we employed gamma-secretase inhibitors to block Notch activity and 
overexpression of the Notch ligand Dll4 to address how Notch signalling contributes to the 
function of BM-PC in vitro and during the angiogenic response in cutaneous wound healing. 
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Materials and Methods 
 
The procedures involving mice were performed following Institutional (Instituto Gulbenkian de 
Ciencia) and National Guidelines. All experiments were approved by an Institutional Review 
Committee. 
 
BM-PC Isolation 
To isolate BM-PC, four-to-eight-week-old male BALB/c mice were sacrificed and their bones 
collected in DMEM (Gibco) supplemented with 10%FBS (foetal bovine serum, Sigma-Aldrich, 
Germany). Bone-marrow was flushed-off using PBS with 2%FBS and then ficol (Histopaque-
1077, Sigma Diagnostics, St. Louis, USA) was used to isolate total mononuclear cells (MNC). 
The lineage negative (lin-) fraction was isolated using mini-MACS immunomagnetic separation 
system (Mylteni Biotec, Bergish Gladbach, Germany), according to the manufacturer 
instructions, and was cultured overnight in RPMI 10%FBS with stem cell factor (Sigma-Aldrich, 
1ng/ml). Sca-1+ cell isolation was subsequently done using mini-MACS immunomagnetic 
separation system. Purity of the isolated cells was determined by FACS analysis using anti-Sca-1 
antibodies (BD Pharmigen); isolated BM-PC were used in further experiments if their purity was 
above 95%. 
 
Cell Culture and Reagents 
Isolated BM-PC were transferred onto 2% gelatine (Sigma-Aldrich), Fibronectin (10µg/ml, 
Sigma-Aldrich), Colagen I (10µg/ml, Cell Adhesion) or Laminin (10µg/ml, Sigma-Aldrich) 
coated 24-well plates (1,5x105 cells/well) and incubated in endothelial differentiation medium 
consisting of EBM-2 medium supplemented with 2% FBS, ECGS (20µg/ml, Sigma-Aldrich), 
Heparin (5U/ml, Sigma-Aldrich), VEGF (20ng/ml, Sigma-Aldrich), HEPES buffer (ph=7,5, 
25mM) and antibiotics.. Every 3 days the medium was supplemented with 1µl VEGF (20ng/ml) 
and 1µl Heparin (5U/ml). Around day 8 of differentiation non-adherent cells were washed off 
and new media was added. Cells were allowed to differentiate for 15-20 days under these 
conditions. RNA samples were collected at different time points and imunofluorescence staining 
was preformed at the end of the differentiation assay. 
Human umbilical vein endothelial cells (HUVEC), passages 3 to 6, were cultured and maintained 
following standard procedures and culture conditions in complete EBM-2 medium (Clonetics). 
The γ-secretase inhibitor (DAPT, Sigma-Aldrich) was diluted in dimethyl sulfoxide (DMSO, 
Sigma-Aldrich) and used at a final concentration of 10µM. In most experiments DMSO was used 
as control. Soluble Delta Ligand 4 (BD Pharmigen) was used at a concentration of 2µg/ml. 
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Plasmids, Antisense Oligonucleotides, and Cell Transfection 
The plasmids bearing distinct forms of murine Notch4 were a gift from Tom Maciag Lab: 
constitutively active Notch 1 and Notch4 – CAN1 and CAN4 (C-terminal intracellular domain 
Int3 cloned into XhoI site of pcDNA3.1 hygro). Plasmid transfections were preformed using 
Lipofectamine (Invitrogen) accordingly with manufacturer’s instructions. The antisense 
nucleotides (Applied Biosystems-Ambion) against integrin sub-units α3 
(uuccgcugaaucauguacgtg) and β1 (ggauaaucayaguaauggctc) were used to transfect BM-PC using 
Oligofectamine (Invitrogen) accordingly with manufacturer instructions. 
 
Reverse-transcription Polymerase Chain Reaction (RT-PCR) 
RNA extraction (Trizol, Invitrogen), cDNA synthesis (Reverse-transcription with Superscript II 
reverse transcriptase (Invitrogen)) and oligo (dT) primer (Roche) were performed following 
standard protocols. mRNA levels were measured by real time RQ-PCR on the ABI Prism® 
7900HT Sequence Detection System (Applied Biosystems) using the following primers mHes1 
(tctacaccagcaacagtgg; tcaaacatctttggcatcac), mHey1 (tgagctgagaaggctggtac; 
accccaaactccgatagtcc), mHey2 (tgagaagactagtgcaacag; tgggcatcaaagtagccttta), mNotch1 
(cggtgaacaatgtggatgct; actttggcagtctcatagct), mNotch4 (attgaattcggataaagatgcc; 
agcgttagcaggtcccagtgac), mDll4 (ctgtccttatggctttgtgg; gctccttcttctggtttgtg), mDll1 
(acagaaacaccagcctccac; gccccaatgatgctaacaga), mJagged1 (ccagccagtgaagaccaagt; 
tcagcagaggaaccaggaaa), mJagged2 (gaggtcaaggtggaaacagt; tgtccaccatcagcagataa), mITGA3 
(tgtgtacctgtgtcccctca;atgccggtctgcaagtagtc), mITGB1 (ccaaatcttgcggagaatgt; 
cattcatcaaatccgttcca). The housekeeping gene used to normalize the samples was mß-actin 
(agccatgtacgtagccatcc; ctctcagctgtggtggtgaa). Each sample was analyzed in duplicate and each 
PCR experiment included at least one non-template control well. PCR products were 
electrophoresed through 2% agarose gel and analyzed by staining with ethidium bromide. 
 
Immunofluorescence 
Cells were fixed in 2% paraformaldehyde for 15 minutes at 4ºC, blocked with PBS + 0,1% BSA 
for 45 minutes at room temperature and incubated with primary antibody overnight (diluted in 
PBS + 0,1% BSA + 0,1% Triton X-100). Antibodies used were von Willebrand Factor (vWF, 
1:200, A0082, Dako, Germany), Flk-1 (5µg/ml, AF644, R&D Biosystems), CD31 (1:100, 
553370, BD Pharmigen), P-H3 (1:100, 06-570, Upstate – Cell Signaling Solutions), VE-cadherin 
(1:100, sc-6458, Santa Cruz Biotechnology), integrin α3 (1:100, sc-7019, Santa Cruz 
Biotechnology) and integrin β1 (1:100, AF2405, R&D systems, Inc.). For LDL incorporation 
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cells were cultured in FITC-conjugated acetylated LDL (ac-LDL, 1:1000, L23380, Invitrogen – 
Molecular Probes) during 4h before fixation. Secondary antibodies used: anti-rat/goat/rabbit 
FITC/PE-coupled IgG (Alexa fluor 488/594, Molecular Probes, US). Cells were examined by 
standard fluorescence microscopy using a fluorescence microscope (Axioplan Microscope, Zeiss, 
Germany).  
 
Adhesion Assays  
Isolated BM-PC were transferred onto 2% gelatine, Fibronectin (10µg/ml), Colagen I (10µg/ml) 
or Laminin (10µg/ml) coated 24-well plates (1,5x105 cells/well) and incubated in complete 
EBM-2 medium. 72h after seeding, non-adherent cells were removed (using sterile PBS) and 
adherent cells were counted in 6 random high power fields (x200). The number of adherent cells 
was normalized relatively to the control (gelatine) condition.  
 
In Vitro Wound Healing Assays 
HUVEC were harvested by brief trypsin digestion and seeded at a density of 5x104 cells  per cm2 
on a 24-well plate, allowed to grow to a confluent monolayer, and then a scratch wound with a 
yellow tip (0,1 mm in diameter) was made at the length of the plate. After the scratch, the wells 
were rinsed with PBS to remove detached cells and EBM-2 medium (2%FBS) was replaced. To 
determine the effect of BM-PC on HUVEC monolayer recovery/wound healing, 1,5x105 BM-PC 
untreated or treated with DAPT were added. To determine the effect of secreted factors by 
adherent or non-adherent BM-PC in wound healing we added their conditioned medium 
(collected after 24h) to wounded HUVEC, using EBM-2 alone as a control. The total distance 
migrated by wounded HUVEC was evaluated using computer image analysis (NIH Image J 
analyzer) and expressed as percentage of control (without BM-PC). The distance between the 
wound edges was measured immediately after wounding and 8h later. The difference between 
the 2 measurements was considered as the total distance migrated by the wounded HUVEC. 
Adherent BM-PC quantification was obtained by counting the number of BM-PC at the wound 
site (adherent to exposed extracellular matrix or to HUVEC at the wound edge) versus the 
number of BM-PC adherent to HUVEC away from the wound. Data is represented relative to the 
wound or monolayer area. 
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In Vitro Tube Formation Assay 
HUVEC were seeded on Matrigel (BD Bioscience) – coated wells (24 well plate) at a density of 
1x105 cells per well in EBM-2 medium (2%FBS). Untreated, DMSO and DAPT treated BM-PC 
were added at a density of 1,5x105 cells and then incubated for 16-18h at 37ºC. To determine the 
localization of BM-PC during the assay, we first incubated these with FITC-conjugated ac-LDL 
for 4h to allow further visualization. After endothelial cell tube formation was observed the cells 
were fixed in paraformaldehyde (2%). Photographs were taken at 10x and 20x magnification 
using an Olympus Microscope. Branch quantification was done using the NIH Image J analyzer 
and expressed as a percentage of the control condition (without BM-PC). 
 
In Vivo Wound Healing Model and Wound Closure Analysis 
In vivo wound healing model was established using Balb-SCID mice. Briefly, female mice, 8 
weeks old, body weight 20-33 grams, were anesthetized with intraperitoneal injection of a 
combination of xylazine (10mg/kg) and ketamine (100 mg/kg). After shaving the hair, 2 single 
full thickness, 6-mm diameter excisional wounds were performed in the dorsolumbar skin with a 
sterile biopsy punch. Mice were individually caged. BM-PC were injected in the tail vein on the 
day of wound infliction (day 0) and at day 4 post-wounding. For each injection 2,5x105 BM-PC 
untreated or treated with DAPT or sDll4 were used. Photos were taken every 2 days starting on 
day 0 and wound area was calculated (Π.r1.r2). Wound area at each time point was represented 
relatively to the area obtained at day 0.  
 
Wound histology and Immunohistochemistry 
Animals were sacrificed at days 7 and 14 post-wounding. 8mm diameter skin biopsy samples 
centred on the wound bed was collected, fixed in 10% formalin for a maximum of 48 hours and 
embedded in paraffin. Wounds were serially sectioned (3 µm) perpendicular to the wound 
surface, rostral to caudally, with a 500µm intermission, and stained with haematoxylin and eosin 
(H&E). The number of levels analysed ranged from 8-10 per wound.  
To visualize blood vessels, sections adjacent to those stained for H&E were labelled for 
vWF(1:300, A0082, Dako) and laminin (1:200; L9393 Sigma-Aldrich, Germany). Briefly, 
sections were deparaffinised and immersed in methanol with 0.3% hydrogen peroxide for 30 
minutes. Antigen retrieval was achieved in protease K for 30 minutes, followed by blocking with 
0.1% BSA in PBS and overnight incubation with the primary antibodies. Immunolocalization 
was achieved using biotinylated swine anti-rabbit IgG antibody (Dako) and peroxidase-
conjugated streptavidin, 30 min each, and visualized with DAB (Dako) counterstained with 
Mayer's hemalumen (Merck, Germany). 
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Microvessel density (MVD) was evaluated through laminin and vWF immunoreactivity. At low 
power field (x 40), tissue sections were screened and 5 areas with the most intense 
neovascularization (hot spots) were selected. Microvessel counts of these areas were performed 
at high power field (x 200). The mean microvessel count of the five most vascular areas was 
taken as the MVD, which was expressed as the absolute number of microvessels per 0.74 mm2 
(x 200 field).  
 
ImunoFISH detection of transplanted BM-PCs within wound sections 
Wound sections were deparaffinised and antigen retrieval was achieved in 0,01M sodium citrate 
buffer followed by 15 minutes Pepsin 0,4% digestion. Sections were immunostained for Colagen 
IV (1:100, AB769, Chemicon International), and secondary antibody anti-goat-Alexa 488. 
Following immunoflorescence, the sections were hybridized with a probe against the Y 
chromosome (Cambio, UK) using a denaturation temperature of 75-80ºC for 5 minutes and 
hybridization temperature of 37ºC overnight. 
 
Statistical Analysis 
Differences between the experimental groups (cell numbers, migrated distances, wound size 
among other parameters) were calculated using ANOVA or T student test. 
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Results 
 
BM-derived progenitors express Delta-Notch members and show evidence for Notch 
pathway activation in vitro 
BM-PC (lin-sca1+) cells were cultured on endothelial-differentiation medium and the expression 
of Delta-Notch members and their target genes was determined by RT and semi-quantitative 
(RQ) PCR, throughout endothelial differentiation. As shown in Figure 1A, BM-PC express 
Delta-like 4, Delta 1 and Notch 1 but do not express Notch 4. The expression of Notch 
downstream target genes Hes 1, Hey 1 and Hey 2 increases throughout endothelial 
differentiation (Figure 1B), as the majority of the cultured cells differentiate and acquire 
endothelial markers and properties (at day 20 of culture, Figure 1C and D and Supplementary 
Figure 1). These results suggest that BM-PC give rise to endothelial cells in vitro and that this 
process is accompanied by activation of the Notch signalling pathway and transcription of Notch 
target genes.  
 
 
 
Figure 1 - BM-PC express Notch pathway ligands/receptors and show increased expression 
of notch downstream targets during endothelial differentiation. A. Expression of Notch 
receptors and ligands in BM-PC was detected by RT-PCR. Error bars indicate SD. B. Expression 
of Notch downstream targets (Hes 1, Hey 1 and 2) was detected at different time points during 
BM-PC endothelial differentiation by quantitative real-time PCR. C. Representative images 
(x200) of BM-PC at day 20 of culture showing positivity for endothelial lineage specific markers, 
acetylated  LDL, CD31 , Flk-1 and vWF with DAPI nuclear counterstaining in blue. 
Quantification of BM-PC positive cells for acetylated  LDL, CD31 , Flk-1 and VWF after 20 
days of culture. Error bars indicate SD.  Each experiment was performed in triplicate and the 
mean presented (n=3). 
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BM-PC adhesion to ECM in vitro is impaired by gamma-secretase inhibition of Notch 
pathway and integrin alpha3beta1 modulation 
Having shown activation of Notch signalling on BM-PC under endothelial differentiation 
conditions in vitro, we asked what aspect of the endothelial differentiation process would be 
affected by inhibiting the Notch pathway. As shown in Figure 2, Notch pathway inhibition by a 
gamma-secretase-inhibitor (GSI, also known as DAPT) reduced the activation of Notch target 
genes on BM-PC (Fig 2A), impaired their adhesion to different ECM components (Fig 2B,C,E) 
and reduced the percentage of endothelial cells obtained under endothelial differentiation 
conditions in vitro (Fig 2D). Importantly, Notch pathway inhibition with GSI did not affect BM-
PC survival or proliferation (data not shown).  
Next, we asked if inhibition of the Notch pathway affected BM-PC adhesion to ECM by 
reducing the expression of specific integrins. As shown in Fig3 and Table 1, GSI-treated BM-PC 
showed a significant reduction in the expression of alpha3beta1, while beta 3, alpha5 and alpha v 
expression levels remained unaffected by GSI treatment. These results demonstrate that the GSI 
inhibition of BM-PC adhesion to different ECM involves the selective down-regulation of 
integrins alpha 3 beta 1. Accordingly, siRNA against integrin alpha 3 decreased the number of 
adherent BM-PC (Fig 3 D,E). 
 
Notch pathway inhibition on BM-PC reduces their pro-angiogenic properties in vitro 
After showing that Notch inhibition impairs BM-PC adhesion to ECM and their endothelial 
differentiation in vitro, we tested whether it also impaired their angiogenesis-stimulation 
capacity. As shown in Figure 4, endothelial cells co-cultured with control (untreated and DMSO 
treated) BM-PC for 18 hours on Matrigel formed significantly more endothelial branches 
(quantified as branch points per high power field) than those resulting from endothelial cells co-
cultured with GSI-treated BM-PC (the effect of GSI is dose-dependent, Fig 4 C). Since this pro-
angiogenic effect of BM-PC could result from direct contact with endothelial cells or from 
paracrine (indirect) stimulation, we next quantified the number of BM-PC (labelled with ac-
LDL) in contact with endothelial cells and those spread throughout the matrigel. As shown in 
Figure 4C and quantified in Figure 4D, the majority of untreated BM-PC are found in contact 
with the endothelial cells, in close proximity to branch points; in contrast, GSI-treated BM-PC 
are predominantly found throughout the matrigel (Fig 4D). Therefore, GSI treatment impairs the 
direct contact between BM-PC and endothelial cells. Importantly, the total number of BM-PC in 
contact with endothelial cells or adherent to the ECM is reduced by GSI treatment (not shown), 
highlighting the global role of Notch pathway in regulating BM-PC:endothelial cell adhesion and 
BM-PC:ECM adhesion.  
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Figure 2 - Notch pathway early inhibition impairs BM-PC adhesion and spreading to 
extracellular matrix, reducing the number of mature cells obtained at the end of the 
differentiation A. Expression of Hes 1 and Hey 2 72h after GSI (10uM) treatment was detected 
by RT-PCR. Error bars indicate SD. B. Quantification of adherent BM-PC 72h after treatment 
with DMSO, GSI at 10ηM or 10µM, on 2% gelatin coated wells. Error bars indicate SD. C. 
Quantification of adherent BM-PC 48h after treatment with DMSO and GSI at 10µM, on 2% 
gelatin, fibronectin, collagen or laminin coated wells. Error bars indicate SD. D. Quantification 
of control or GSI BM-PC expressing double EC – lineage specific markers (acLDL/FLK-1 or 
acLDL/VWF) after 20 days of endothelial differentiation. E. Representative image (100x) of 
adherent cells under the different conditions. *P<0,05, **P<0,01. Error bars indicate SD. Each 
experiment was performed in triplicate and the mean presented (n=3) 
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Figure 3 - Regulation of the Notch pathway interferes with expression levels of integrin 
sub-units α3 and β1 in BM-PC. A. Expression of integrin sub-units α3 and β1 determine by 
real-time PCR on BM-PC after treatment with DMSO or GSI. Error bars indicate SD.  B. 
Quantification of α3 expressing BM-PC after treatment with DMSO or GSI. Error bars indicate 
SD. C. Representative images (200x) of adherent BM-PC imunostained for integrin α3 and β1 in 
control and GSI treated BM-PC. D. Quantification of adherent BM-PC after 48h of transient 
transfection with siRNA against integrin sub-unit α3 at concentrations of 100 or 200 ηM. Error 
bars indicate SD. E. Expression of integrin sub-units α3 determine by real-time PCR on BM-PC 
after transient transfection with siRNA against integrin sub-unit α3 at concentrations of 100 or 
200 ηM . *P<0.01. Error bars indicate SD. Each experiment was performed in triplicate and the 
mean presented (n=3). 
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Table 1. Integrin sub-units β3, α5 and αv expression on BM-PC after treatment with DMSO or 
GSI, as determined by FACS analysis. 
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Figure 4 - Notch pathway inhibition on BM-PC reduces their pro-angiogenic properties in 
vitro 
 A. Quantitative analysis of Matrigel-induced tube branching of HUVEC untreated or GSI-
treated monoculture and co-cultured with control and GSI-treated BM-PC. Results show the 
average number of branch points in 5 high power fields. Error bars indicate SD. B. 
Representative images of HUVEC tube formation in monoculture and co-cultured with control 
and GSI treated BM-PC. Phase contrast microscopy (original magnification, 40x). C. 
Quantitative analysis of Matrigel-induced tube branching of HUVEC untreated or GSI-treated 
monoculture and co-cultured with control and GSI-treated BM-PC, using different doses of GSI 
treatment. Error bars indicate SD. D. Representative images of HUVEC tube structures in the 
presence of control or GSI BM-PC acetylated LDL-FITC labelled (original magnification, 40x). 
Arrows identify acetylated LDL-FITC labelled control or GSI BM-PC. E. Quantification of 
control or GSI BM-PC found in or out of endothelial tubular structures. Results expressed 
relatively to the total number of BM-PC counted.*P<0.05. Error bars indicate SD. Each 
experiment was performed in triplicate and the mean presented (n=3). 
 
 
Notch pathway inhibition on BM-PC reduces their wound healing properties in vitro 
Since treating BM-PC with GSI impaired their adhesion to ECM and their capacity to induce 
endothelial branching, next we asked whether it also inhibited their wound healing properties. As 
shown in Figure 5, the capacity to restore an endothelial monolayer (in a “wound healing” assay) 
is significantly improved upon the addition of control BM-PC to the wounded endothelial 
monolayer (Fig 5A). Control BM-PC predominantly adhered to the exposed ECM and to 
endothelial cells at the wound edge (Fig 5B). In contrast, GSI treatment reduced BM-PC 
adhesion to ECM and to the endothelial cells at the wound edge (Fig 5B). Importantly, 
supernatants obtained from adherent BM-PC also accelerated wound healing/endothelial 
monolayer recovery while supernatant obtained from non-adherent BM-PC failed to do so (Fig 
5C). Taken together, these data suggest that BM-PC may promote wound healing by direct 
contact with endothelial cells at the wound edge and by adhering to the exposed ECM, but also 
that paracrine factor(s) released by the adherent BM-PC may stimulate endothelial cells during 
the wound healing process. These results also suggest that Notch pathway inhibition with GSI, 
by blocking BM-PC adhesion to ECM and activated endothelial cells, impairs BM-PC wound 
healing properties in vitro. 
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Figure 5 - Notch pathway inhibition on BM-PC reduces their wound healing properties in 
vitro 
A.Quantification of HUVEC migration during wound healing in vitro. HUVEC were cultured 
alone or in the presence of C/GSI treated BM-PC. Distance was measured in pixels using ImageJ 
software. Error bars indicate SD. Representative image of HUVEC at the beginning and at the 
end of the wound healing assay, in the presence of Control or GSI treated BM-PC. Phase 
contrast microscopy (original magnification, 200x). B. Quantitative analysis of Control and GSI 
treated BM-PC localization during HUVEC wound healing. BM-PC were classified has being on 
the wound site or over the HUVEC monolayer. Error bars indicate SD. Representative confocal 
image (x400) of BM-PC stained with acetylated LDL (FITC) and HUVEC (nuclear staining with 
DAPI). Dashed line represents the HUVEC wound edge. C. Quantitative analysis of HUVEC 
migration during wound healing assay. HUVEC were cultured with un-conditioned media or 
with conditioned media from adherent (Ad) /non-adherent (Nad) BM-PC.*P<0,05. Error bars 
indicate SD. Each experiment was performed in triplicate and the mean presented (n=3). 
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Notch pathway modulation on BM-PC regulates their angiogenic and their wound healing 
properties in vivo  
After showing that blocking the Notch pathway on BM-PC impairs their differentiation, 
adhesion to ECM, angiogenesis and wound healing promotion in vitro, next we tested the 
importance of these observations in a wound healing model in vivo.  
As quantified and shown in Figure 6A and B, injection of normal BM-PC to wounded mice 
improved wound healing significantly, while BM-PC pre-treated with GSI showed no effect 
(mice in this group showed similar rate of wound healing to PBS/non-injected mice). 
Importantly, the pro-wound healing property of BM-PC involved an angiogenesis response at the 
wound site. As shown and quantified in Figure 6D,E, mice injected with normal BM-PC showed 
a higher microvessel density at the wound site on days 7 and 14, while those that received BM-
PC pre-treated with GSI showed a similar wound microvessel density to control (untreated) mice 
(Data shown for day 14, Figure 6D, E). The increase in angiogenesis at the wounds after BM-PC 
injection was detected using laminin as a microvessel basement membrane marker and von 
wilebrand factor as an endothelial marker (Fig 6 D,E) and also using desmin as a smooth muscle 
cell marker (data not shown). These results suggest that BM-PC stimulate endothelial sprouting 
and smooth muscle cell recruitment to the wound site. Taken together, these data suggest that 
Notch pathway inhibition with GSI impairs the capacity of BM-PC to promote wound healing 
and angiogenesis in vivo. In contrast, activation of the Notch pathway on BM-PC using soluble 
Delta-like 4 further improved their wound healing capacity (Fig 6A and Supplementary Fig 3), 
strongly suggesting that Notch signalling pathway activation on BM-PC may be used to 
stimulate wound healing.  
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Figure 6 - Notch pathway modulation on BM-PC regulates their angiogenic and their 
wound healing properties in vivo  
A. Quantification of wound area in Balb-C mice injected with PBS, control BM-PC, GSI BM-PC 
or sDll4 BM-PC. Area at each time point is expressed relatively to the area measured 
immediately after wounding. Error bars indicate SD. B. Representative images of the wounds at 
days 0, 4, 8 and 12. C. Representative histological images of wounds collected at day 14 after 
wounding. Hematoxilin and Eosin staining. Scale bar represented. D. Quantification of vessel 
basement membrane immunostaining for laminin in the wound tissue of PBS, C-BM-PC or GSI 
BM-PC injected mice at day 14 post-wounding. Error bars indicate SD. E. Representative image 
of laminin and VWF immunostaining (* identifies VWF positive staining) in wounds of PBS, C-
BM-PC or GSI BM-PC injected mice. Scale bar represented. *P<0.05. Each experiment was 
performed in triplicate and the mean presented (n=3). 
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GSI-treated BM-PC are found at lower frequencies in wound tissues 
Having demonstrated that Notch pathway inhibition with GSI impaired the capacity of BM-PC 
to stimulate angiogenesis and to promote wound healing in vivo, we asked whether the frequency 
at which BM-PC are detected at the wound site might account for the differences observed. First, 
we verified that the number of BM-PC detected at the wound site on days 7 and 14 after 
wounding is very low (Fig 7 B). Nevertheless, as exemplified in Figure 7A, GSI treatment 
significantly reduced the frequency at which BM-PC are found in wound tissues. Moreover, as 
above, activation of the Notch pathway on BM-PC using soluble Delta-like 4 resulted also in 
higher numbers of BM-PC at the wound sites (Fig 7 B). These results suggest that Notch 
pathway inhibition by GSI, by impairing BM-PC adhesion to ECM and to endothelial cells in 
wounds, results in a lower frequency of BM-PC at the wound site and incorporated into neo-
vessels. 
 
 
Figure 7 – Control BM-PCs are found at greater frequencies in wounds. A. Representative 
image of injected C, GSI – or sDll4 treated BM-PC at the wound site. BM-PCs are identified as 
positive for Y-chromosome probe (white arrow). Immunostainning for collagen IV identifies 
vessel basement membrane. Scale bar represented. B. Quantification of BM-PC present at the 
wound. 10 slides per wound were used for BM-PC quantification. *P<0.05. Error bars indicate 
SD. 
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Discussion 
A putative role for BM-derived progenitors in neo-vessel formation (angiogenesis) and vessel 
repair has been under intense scrutiny for the last decade. Numerous studies have argued that the 
contribution of this rare and heterogeneous cell population is essential for vessel activation and 
repair, although their precise function or the mechanisms involved remain elusive22, 23. Direct 
incorporation of BM-progenitor cells has been extensively shown in diverse models24 but the low 
and variable frequency at which BM-progenitors are found incorporated into vessels is 
suggestive of an indirect (possibly paracrine or justacrine) role during the neo-angiogenesis 
processes. Therefore, it is of extreme importance to understand the mechanisms involved in the 
communication between BM-progenitors with angiogenic potential and endothelial cells at sites 
of neo-angiogenesis.  
In the present work we used lin-sca1+ BM mononuclear cells (termed BM-PC throughout the 
manuscript), which under well defined pro-endothelial differentiation culture conditions25 
generate over 70-80% mature endothelial cells, to study their importance in angiogenesis and 
vessel repair during wound healing. Previous studies suggested that sca1+ cells are recruited into 
sites of vessel damage and ischemia and contribute to vessel healing and formation26, 27. 
We have previously characterized the gene expression profile of endothelial progenitors under 
pro-endothelial differentiation conditions25, and observed the expression of members of the 
Notch pathway. In the present report, we exploited the hypothesis that this signalling pathway 
might be involved in the differentiation and, more importantly, in the function of BM-PC during 
neo-angiogenesis and vessel repair. The Notch pathway has been implicated in vasculogenesis in 
the embryo14-18, as well as in adult tumor angiogenesis28 and wound healing19, although BM-
derived progenitors were not studied in these settings. Considering that various components of 
the Notch pathway are expressed in BM-PC as well as in activated endothelial cells29, we also 
explored the possibility that this pathway might promote the communication between the 2 cell 
types during physiological angiogenesis. 
In the present work, we show expression of Notch1, Jagged 1 and Delta-like 4 on BM-PC and 
activation of Notch signalling during endothelial differentiation in vitro. We also demonstrate 
that inhibiting this pathway using the gamma secretase inhibitor (GSI) DAPT reduces the 
number of mature endothelial cells generated at the end of the differentiation assay. In addition, 
we reveal for the first time the importance of Notch pathway in BM-PC adhesion to different 
extracellular matrices. Treatment of BM-PC with GSI inhibited their adhesion to fibronectin, 
collagen, laminin and gelatin, suggesting this effect might be specific of BM-PC adhesion to the 
basement membrane. GSI treatment was shown to significantly reduce the expression of 
integrins alpha3 beta1 (which has affinity to the above mentioned ECM components), both at the 
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transcriptional as well as protein level, and thus regulated BM-PC adhesion to the ECM. 
Moreover, siRNA against integrin alpha3 significantly reduced the adhesion of BM-PC during 
endothelial differentiation. There is some literature suggesting that the Notch pathway modulates 
integrin activity on endothelial cells30 although only at the conformational level and not at the 
transcription and translational level. Interestingly, previous studies have shown that various 
components of the basement membrane are expressed in the vessel lumen during tumor 31 
angiogenesis and also during wound healing 4. These sites probably represent the preferential 
sites for BM-PC adhesion during vascular remodelling. Taken together, we suggest that BM-PC 
may interact with extracellular matrix exposed at sites of angiogenesis or vessel repair, and that 
the Notch pathway is involved in this interaction by modulating integrin expression. Although 
we cannot disregard other, off-Notch, effects in integrin modulation and BM-PC adhesion and 
differentiation, our data strongly suggests that this important signalling pathway is involved. In 
agreement, in vitro transfection of BM-PC with a constitutively active form of Notch 4 promoted 
their adhesion and augmented endothelial differentiation (Supplementary Fig 2).  
Next, we tested the role of the Notch pathway on the ability of BM-PC to induce endothelial cell 
activation, migration and tube formation. Notch inhibition with GSI reduced the capacity of BM-
PC to stimulate endothelial tube formation in vitro, suggesting it affects their capacity to 
stimulate angiogenesis. In this tube formation assay, Notch pathway inhibition reduced the 
capacity of BM-PC to interact (incorporate?) with endothelial cells during angiogenesis in vitro. 
Since endothelial cells during angiogenesis and wound healing express members of the Notch 
pathway29, we suggest this may be one mechanism by which BM-PC and activated endothelial 
cells interact.  
Next, we tested the importance of the Notch pathway in the function of BM-PC in wound 
healing in vitro and in vivo. We demonstrate that normal BM-PC adhere to the ECM at the 
wound site and enhance endothelial migration and wound closure. On the other hand, GSI 
treatment reduced the adhesion of BM-PC to extracellular matrix, reduced their interaction with 
endothelial cells at the wound edge and failed to induce endothelial migration in vitro. Notably, 
supernatants collected from adherent BM-PC also improved wound healing, suggesting their 
adhesion may result in the production of pro-angiogenic growth factors such as VEGF, IL-8, 
among others that promote endothelial cell activation. Taken together these results show that 
Notch activity on BM-PC is necessary (via integrin modulation) for their ability to recognize and 
adhere to exposed ECM and activated endothelial migration. These results also suggest that the 
interaction between BM-PC and activated (wounded) endothelial cells is exerted in a 
direct/justacrine (Notch pathway) and indirect/paracrine fashion. 
 135 
In vivo, intravenous injection of normal BM-PC in wounded mice increased angiogenesis at the 
wound site and improved wound healing, while pre-treatment with GSI reduced BM-PC homing, 
resulting in a decreased angiogenic response and delayed wound healing. These results imply 
that in the absence of Notch activation BM-PC lose their wound healing properties in vivo. 
Inefficient cutaneous wound healing represents a serious medical challenge, namely in chronic 
wounds such as in diabetic32, 33 and morbid obese patients34. Moreover, chronic or dysfunctional 
wound healing has been partially attributed to a lack of an appropriate vascular response32, 33, and 
also to dysfunctional BM-derived endothelial progenitors35, 36, 37. Therefore, there has been 
considerable interest in modulating the vessels response during impaired wound healing for 
therapeutic purposes, namely via the use of BM-PC38, 39. In the present study, we reveal a crucial 
and previously undisclosed role of the Notch pathway in the function of BM-PC in angiogenesis 
responses during wound healing in vitro and in vivo.  
Taken together, we propose a model which may explain the involvement of the Notch pathway 
in the function of BM-PC during wound healing (Fig 8): 1. Wounding promotes sca1+ BM-
derived progenitor mobilization to the peripheral blood; 2. Activated endothelial cells at the 
wound site express Notch ligands, namely Jagged 1 and 229 which may activate Notch signalling 
on circulating BM-PC; 3. Notch pathway activation on BM-PC up-regulates integrin alpha3beta1 
and promotes BM-PC adhesion to extracellular matrix components at the wound site; 4. 
Adherent BM-PC stimulate endothelial activation (angiogenesis) in a justacrine and paracrine 
manner, resulting in improved wound healing. 
We suggest that modulating the Notch pathway on BM-PC may be used to stimulate their wound 
healing potential, and further foster their use in chronic or delayed wound healing.  
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Figure 8 – Proposed model of the mechanisms modulated by the Notch-Delta pathway on 
BM-PC during wound healing. 1. Wounded endothelial cells produce chemoattractant signals 
that recruit BM-PC into the wound site; 2. As a result of injury/wounding endothelial cells die, 
exposing extracellular matrix components in the vessel lumen; activated endothelial cells near 
the wound edge overexpress ligands of the Notch-Delta pathway, namely Jagged 1 and 2; BM-
PC interact with endothelial cells at the wound site, and as a result of Notch-Delta activation 
these recruited cells overexpress integrin alpha3beta1, and bind the exposed extracellular matrix; 
as a result of BM-PC activation and adhesion, there is an angiogenesis induction (vessel 
sprouting) at the wound site. 3. Following angiogenesis activation and re-absortion of the wound 
tissue/scar, a small proportion of endothelial cells at the wound site derive from the recruited 
BM-PC, while the great majority derives from activated pre-existing endothelial cells. Following 
the pro-angiogenic response induced by BM-PC, vessel stabilization is promoted by recruitment 
of smooth muscle cells (desmin+). 
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Supplementary Figures 
 
 
 
Supplementary Figure 1. Differentiated BM-PC form tubes on Matrigel. 
A. Quantification of tube formation on day 0 or day 20 BM-PC plated or matrigel for 16h. 
*P<0.05. Error bars indicate SD. Each experiment was performed in triplicate and the mean 
presented (n=3). 
 
 
 
Supplementary Figure 2. Wounds induce mobilization of sca1+ cells in vivo. 
A. Quantification of Sca-1+ cells in the peripheral blood of wounded Balb-SCID mice. Results 
represented relatively to control/not wounded at given time points. 
 
 
 
 
 140
 
 
Supplementary Figure 3. Pre-treatment of BM-PC with soluble Dll4 improves wound 
healing in vivo. 
A. BM-PC pre-treated with soluble Dll4 show evidence for transcription of Notch pathway 
downstream targets. Error bars indicate SD. Each experiment was performed in triplicate and the 
mean presented (n=3). 
 
 
  
 
 
 
Supplementary Figure 4. Constitutively active Notch 4 activates the Notch pathway on 
transfected BM-PC, promotes their adhesion. A. Activation of the Notch pathway, as shown 
by expression of downstream targets, on BM-PC transfected with constitutively active Notch 4. 
Error bars indicate SD.  B. Constitutively active Notch 4 increases BM-PC adhesion relatively to 
control (100%) during in vitro endothelial differentiation. Error bars indicate SD. Each 
experiment was performed in triplicate and the mean presented (n=3). 
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Abstract 
Neo-blood vessel growth (angiogenesis), which may involve the activation of pre-existing 
endothelial cells (EC) and/or the recruitment of bone marrow-derived vascular precursor cells 
(BM-VPC), is essential for tumor growth. Molecularly, besides the well established roles for 
Vascular endothelial growth factor (VEGF), recent findings show the Notch signalling pathway, 
in particular the ligand Delta-like 4 (Dll4), is also essential for adequate tumor angiogenesis; 
Dll4 inhibition results in impaired, non-functional, angiogenesis and reduced tumor growth. 
However, the role of BM-VPC in the setting of Notch pathway modulation was not addressed 
and is the subject of the present report. Here we show that SDF-1 and VEGF, which are 
produced by tumors, increase Dll4 expression on recruited BM-VPC. Mechanistically, BM-VPC 
activated, in a Dll4-dependent manner, a transcriptional program on mature EC suggestive of EC 
activation and stabilization. BM-VPC induced ICAM-2 and Fibronectin expression on EC, an 
effect that was blocked by a Dll4-specific neutralizing antibody. In vivo, transplantation of BM-
VPC with decreased Dll4 into tumor-bearing mice resulted in the formation of microvessels with 
decreased pericyte coverage and reduced fibronectin expression. Consequently, transplantation 
of BM-VPC with decreased Dll4 resulted in impaired tumor angiogenesis, increased tumor 
hypoxia and apoptosis, and decreased tumor growth. Taken together, our data suggests that Dll4 
expression by BM-VPC affects their communication with tumor vessel endothelial cells, thereby 
modulating tumor angiogenesis by affecting vascular stability.   
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Introduction 
Besides sprouting of pre-existing endothelium, tumor angiogenesis may require also the 
contribution of bone marrow-derived endothelial progenitor cells (EPC)1, previously shown to be 
recruited into tumors (reviewed in 2) and proven essential for tumor angiogenesis3. However, the 
mechanisms by which EPC contribute towards angiogenesis still remain largely undisclosed, 
mainly because of the very low number of EPC found within tumor biopsies, in or around 
vessels4,5.  
Notch signalling is crucial during embryonic development, for the differentiation of different 
tissues, and also in adult homeostasis. Notch ligands (Delta like 4, Dll4) and receptors (Notch 1 
and Notch 4) have been shown to be involved in the differentiation and function of the 
vasculature, during embryogenesis and in adults. In detail, Dll4 deficient mice have severe 
vascular defects, similar to Notch 1 and 4 knockouts6,7. More strikingly, in inbred genetic 
backgrounds Dll4 heterozygous embryos (in haploinsufficiency) die at mid gestation due to 
severe vascular effects, highlighting its importance in vasculogenesis and its role over other 
members of the Notch pathway8,9. Notably, similar vascular defects are observed in 
haploinsufficient VEGF mouse embryos10. Consequently, a putative role for Dll4 in tumor 
angiogenesis has been under intense scrutiny11,12,13,14. However, it is still unclear whether Dll4 is 
only expressed on tumor vessels or other cell types, and what role it plays during angiogenesis. 
Given its crucial role in modulating vessel formation and function, in the present study, we 
hypothesized Dll4 expressed on bone marrow derived vascular progenitor cells (BM-VPC) might 
play a role in tumor angiogenesis, either by activating the pre-existing endothelium or by 
promoting vessel stabilization following sprouting and proliferation.  
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Materials and Methods  
 
Mouse strains 
Dll4 +/- mutant mice are kept on a CD1 outbred background. Dll4GOF mice are heterozigous 
double mutants for TetO7-Dll4 [15] and 
Tie2-rtTA-M2 [16], in C57/BL6 background. Transgene induction was performed 5 days before 
BM recovery, by adding doxycycline (4mg/ml) (Sigma-Aldrich) in drinking water containing 
4% sucrose (Sigma-Aldrich), ad libitum delivery.  
 
Mouse BM-VPC isolation  
We obtained BM cells and isolated Lin- cells (which are negative for the following markers CD5, 
CD45R(B220), CD11b, Gr-1 (Ly-6G/C), 7-4, and Ter-119) using magnetic sorting (Miltenyi 
Biotec-MACS). For in vitro experiments, Lin- cells were isolated from balbC, Dll4+/-, Dll4GOF 
and respective WT counterparts. For in vivo experiments Lin- cells from Dll4+/- mice and 
corresponding WT counterparts were then sorted by FACS for Flk1 expression (PE conjugated 
Flk1 antibody from Pharmingen). Lin-Flk1+ cells (96-99% purity, as determined by FACS 
sorting) were defined as BM-VPC-WT or Dll4+/- BM-VPC and were injected intravenously 
(1x104 cells per injection) into mice without further culture.  
To determine Dll4 induction by VEGF and SDF1, we cultured BM Lin- cells isolated from 
BalbC mice (with 4 to 6 weeks of age) in RPMI medium (Gibco) without any supplements in 
presence of VEGF (20ng/ml, Sigma-Aldrich) and Heparin (5U/ml, Sigma-Aldrich) or SDF1 
(50ng/ml, R and D Systems). To inhibit SDF1 activation we incubated BM-VPC with SDF1 and 
CXCR4 antagonist (5µg/ml AMD3100, Sigma-Aldrich). 
 
In vitro co-culture assays  
HUVEC were cultured at 1x104/cm2 cell density using EBM2 supplemented medium (Lonza) 
with 5% FBS (foetal bovine serum, Sigma-Aldrich), in 0,2% gelatine (Sigma-Aldrich) coated 
plates. After 24h, medium was change to EBM2 supplemented medium (Lonza) with 2% FBS 
(foetal bovine serum, Sigma-Aldrich) and 1x105 mBM-VPC from Dll4+/-, Dll4GOF and 
respective WT, were put over cultured HUVEC monolayer. Cell contact was maintained for 18h. 
After this period mBM-VPC were washed from the cultures and HUVECs collected for mRNA 
extraction. Neutralizing antibodies anti-mDll4 were added to co-cultures at 50ug/ml (kindly 
provided by Dr. Hideo Yagita). The cultures using mDll4GOF BM-VPC and respective controls 
were maintained in presence of doxycyclin (1µg/ml) (Sigma-Aldrich) for transgene induction.    
Endothelial cell biology microarray 
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We used Oligo GEArrays HybTube Format from SABiosciences. Total mRNA was isolated 
from HUVEC obtained from co-culture experiments with BM-VPC-Dll4+/-, MDll4GOF BM-
VPC and respective WT counterparts. mRNA was obtained from 3 independent experiments and 
pooled together in similar proportions. cDNA synthetisis and array hybridization was performed 
as recommended by manufacturer instructions. 
 
Gene expression by RQ-PCR 
mRNA levels were measured by real time RQ-PCR on the ABI Prism® 7900HT Sequence 
Detection System (Applied Biosystems) using the following primers and probes: hHey2, hHes1, 
hFibronectin1, hVE-Cadherin,  hICAM2, mDll4 .The housekeeping gene used to normalize the 
samples was 18S (human18S rRNA - 20x, Applied Biosystems) or ß-actin 
(agccatgtacgtagccatcc; ctctcagctgtggtggtgaa) (mouse). Each sample was analyzed in triplicate 
and each PCR experiment included at least one non-template control well. Membrane arrays 
were analysed using ImageJ. 
 
In vivo tumor formation assays  
We performed two types of in vivo assays, one reconstituting mouse bone marrow with mBM-
VPC with altered expression of Dll4 and the other introducing exogenous human progenitor cells 
expressing Dll4. In the first case, we used female NOD-SCID mice as recipients. NOD-SCID 
mice were sublethally irradiated (200 rads) and were intravenously injected after 24 hours with 
BM-VPC-WT or BM-VP C-dll4+/- (n=6 in each experiment, for each condition). Control mice 
were not injected with BM-VPC. After three days, controls, BM-VPC-WT and BM-VPC-dll4+/- 
reconstituted mice were subcutaneously injected with 6x106 Human HL60 cell line (myeloid 
leukemia, which forms chloromas). Tumor volume was determined at different time points. The 
mice were sacrificed 15 days or 25 days after tumor implantation and blood samples were 
collected. Tumors were both frozen and fixed for posterior analysis. In the second in vivo assay, 
we used NOD-SCID mice that were subcutaneously injected with 4x106 mouse breast cancer cell 
line (HTH-K29,30). After 6 days, we divided the tumor injected mice in three groups, no cell 
treatment (n=4), WT BM-VPC treated mice (n=4) and mDll4GOF BM-VPC treated mice (n=4). 
BM-VPCs (3x105 cells per injection) were administered intravenously (obtained from 
mDll4GOF mice bone-marrow by Ficoll density gradient centrifugation and isolated as Lin- 
population; see BM-VPC isolation) at day 6, 8 and 10 after tumor inoculation. Mice were killed 
at day 11 after tumor inoculation.  
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Fluorescent in situ hybridization (FISH) 
Fixed blood samples and frozen BM sections were used. Frozen sections were rehydrated in PBS, 
and then hybridized with a specific probe for mouse Y chromosome (Cambrio, UK). Frozen 
sections and blood samples were denaturation at 85ºC for 5 minutes. Hybridization was carried 
out at 37ºC overnight.  
 
Tumor microvessel determination, TUNEL, Proliferation, Hypoxia 
Tumours cryosections were blocked with a 5% FBS / 0,1% BSA solution in PBS for 30 minutes. 
Slides were then covered with primary antibodies (rat anti-PECAM from Pharmingen), mouse 
anti-alpha-SMA (DAKO) or rabbit anti-Histone 3 (Chemicon) overnight at 4ºC. After 3 brief 
washes in PBS, secondary antibodies from Invitrogen (anti-rat-FITC, anti-mouse-Alexa568, anti-
rabbit-Alexa488, respectively) and incubated for 2 hours. For the quantification of stable 
(CD31+ and SMA+) versus unstable (CD31+SMA-) vessels, stained sections were visualized, 
and the total number of vessels was determined in 5 high power fields (x400 magnification). For 
hypoxia determination we used Hypoxyprobe kit (Chemicon) and performed the immunostaining 
as indicated by the manufacturer. After briefly washing the slides in PBS, the slides were 
mounted in fluorescence mounting medium from DAKO. Slides were photographed using a 
standard fluorescence microscope. Hypoxia tumor area was determined by visualizing stained 
sections and quantifying the number of stained/unstained cells in 5 high power fields (x400 
magnification). 
 
Statistical Analysis 
Differences in tumor growth, proliferation, apoptosis, hypoxia and stable versus unstable vessels 
were analysed by ANOVA.  
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Results 
 
SDF1 and VEGF induce Dll4 expression on BM-VPC 
BM-VPC have been shown to be recruited into the peripheral blood in response to VEGF and 
SDF1 produced by tumors and to express Notch signalling pathway components, such as Dll417. 
We investigated whether these factors were able to regulate the expression of Dll4 on BM-VPC.  
BM-VPC were cultured in presence of VEGF or SDF1 for 18 hours. Dll4 expression was 
analysed by RQ-PCR and flowcytometry. Dll4 expression was significantly increased on BM-
VPC cultured in presence of both VEGF and SDF1 compared to the control condition (Figure 
1A), although comparatively SDF1 induced a greater increase in Dll4 expression. We also 
verified that Dll4 regulation by SDF1 was mediated via its receptor, CXCR4. We incubated BM-
VPC with SDF1 alone or in the presence of a CXCR4 inhibitor for 18h and analysed the cells by 
flowcytometry. As shown in Figure 1B, CXCR4i prevents Dll4 induction by SDF1 (Figure 1B). 
The results show that the expression of Dll4 on BM-VPC is induced by VEGF and by SDF1; the 
latter effect is mediated through its receptor, CXCR4.  
 
 
Figure 1. Dll4 expression on BM-VPC is induced by VEGF and SDF1. A. Expression of Dll4 
in BM-VPC was detected by RT-PCR. B. BM-VPC were incubated with SDF1 (50ng/ml) or 
SDF1 and CXCR4 inhibitor (5ug/ml) The number of Dll4 positive cells was quantified by flow 
cytometry using anti-Dll4 mouse specific. Each experiment was performed in triplicate and the 
mean represented n=3. (values show the mean plus s.e.m. *: P<0.05.) 
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Dll4 induces a vascular activation and stabilization program on mature EC in vitro 
We hypothesized that DLL4, driven by BM-VPC, could signal on EC, inducing molecular 
changes that may lead to an angiogenic response in vitro and in vivo. To test this hypothesis, we 
cultured HUVEC together with BM-VPC isolated from mDll4 overexpression (mDll4GOF BM-
VPC) or heterozygous (low expression) Dll4+/- (Dll4+/-BM-VPC) mice and used HUVEC co-
cultured with WT BM-VPC as control. After overnight contact, we removed BM-VPC and 
compared HUVEC gene expression using a microarray containing 113 genes related to EC 
biology. In particular, the expression of ICAM2, FN1 and VE-Cadherin increased in HUVEC 
cultured in presence of mDll4GOF BM-VPC and decreased in case of Dll4+/- BM-VPC (Figure 
2A).  
To further demonstrate that the regulation of these genes on EC was Dll4-specific we co-cultured 
HUVEC and mouse BM-VPC, in presence or absence of a mouse Dll4-specific inhibitor 
antibody (mDll4i). Hey2 and Hes1 quantification was used to confirm the activation state of the 
Notch signalling pathway on HUVEC. As shown in Fig 2B, Dll4 inhibition on BM-VPC 
decreased Hey2 but not Hes1 expression by co-cultured HUVEC; in contrast, the gamma-
secretase and Notch signalling inhibitor, GSI, inhibited both downstream Notch target genes 
(Figure 2B). Quantitative Q-PCR was used to determine the differences in the expression of 
ICAM2, FN1 and VE-Cadherin, in co-cultured HUVEC. Notably, FN1 and ICAM2 expression 
on induced by BM-VPC on HUVEC decreased in the presence of the Dll4 inhibitor (n=3, 
P<0,05)(Fig 2c). In contrast, VE-Cadherin expression was not altered by Dll4 inhibition (Figure 
2C). Inversely, when HUVEC were co-cultured with mDll4GOF BM-VPC, the expression of 
FN1 and ICAM2 decreased, while VE-Cadherin was not altered (Figure 2D). Taken together, 
these in vitro data indicate that Notch signalling pathway activation of EC by Dll4 driven by 
BM-VPC induces gene expression changes on EC, namely of genes linked to endothelial 
activation and stability such as fibronectin and ICAM2.  
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Figure 2. Dll4 expressed on BM-VPC stimulate a vascular activation and stabilization 
program on endothelial cells. A. Genes differently expressed on HUVEC after co-cultered with 
BM-VPC-WT, BM-VPC-Dll4 or mDll4GOF BM-VPC. These results were obtained from one 
hybridization using pooled samples from 3 experiments. B. Expression of Hey2 and Hes1 in 
HUVEC co-cultured with mouse isolated BM-VPC in presence of mouse specific neutralizing 
antibody for Dll4 (mDll4i) or γ-secretase inhibitor (γSi). C. ICAM2, FN1 and VE-Cadherin 
expression in HUVEC co-cultured with mouse BM-VPC or BM-VPC in presence of mouse 
specific neutralizing antibody for Dll4 (mDll4i). D. ICAM2, FN1 and VE-Cadherin expression 
in HUVEC co-cultured with mouse BM-VPC-WT or MDll4GOF BM-VPC. Gene expression 
was quantified by RT-PCR in B,C and D. (values show the mean plus s.e.m. *: P<0.05). 
Dll4 expression by BM-VPC is essential for tumor angiogenesis and growth  
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Next, to test whether the role of Dll4-expressing BM-VPC was essential to tumor angiogenesis, 
we developed an in vivo approach in which we reconstituted NOD-SCID mice BM with BM-
VPC obtained from Dll4+/- (heterozygous, with reduced Dll4 levels) or from WT (normal Dll4 
levels) mice. As shown by fluorescent in situ hybridization using a Y chromosome probe, WT 
BM-PC and Dll4+/- BM-VPC engraft the bone marrow of irradiated recipient mice, are recruited 
into the peripheral blood 2 weeks after tumor implant and incorporate the tumor mass at 
approximately the same rates and frequency (Figure 3) 
Normal BM-VPC (male lin-flk1+) or from Dll4+/- mice (Dll4+/- BM-VPC) were used in 
transplantation experiments into recipient female mice. Next, we analysed tumor angiogenesis 
using a well established in vivo model of human chloroma (solid leukemia-derived tumor, 
previously shown to be very efficient at recruiting BM-VPC2). Tumor microvessel density was 
determined by immunofluorescence staining against PE-CAM. As seen in Figure 4, Human 
tumors growing in mice transplanted with Dll4+/- BM-VPC had a significantly higher 
microvessel density than those with BM-VPC-WT.  
However, if tumors were allowed to grow beyond 15 days, there was a significant growth delay 
of tumors in BM-VPC-Dll4+/- transplanted versus control mice or those with WT BM-VPC 
(Figure 5A). As determined by Tunel (to identify apoptotic cells) and phospho-histone H3 
(which identifies proliferating cells) staining, tumors with Dll4+/- BM-VPC showed significantly 
a higher apoptosis index and lower proliferation rate than control and WT BM-VPC (Figure 5B-
C). 
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Figure 3. BM-VPC-Dll4 engraft bone-marrow of NOD-SCID mice and are recruited to 
peripheral blood during tumour growth. BM-VPC-WT and BM-VPC-Dll4 are equally present 
in bone marrow and peripheral blood 15 days after inoculation of cells. BM-VPC were identified 
using FISH to Y chromosome. 
 
 
 
 
Figure 4. Dll4+/-BM-VPC increase tumour vessel density in tumors. Endothelial cells were 
identified by immunofluorescence using anti-CD31 (PE-CAM) in tumor cryosections from mice 
inoculated with BM-VPC-WT or BM-VPC-Dll4. Scale Bar indicates 250µm. Graphs show the 
number of microvessels per section (values show the mean plus s.e.m. *: P<0.05). 
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Figure 5. Dll4+/-BM-VPC tumors have a smaller growth rate than WT BM-VPC tumors, 
and increased apoptosis. A. Tumor volume ((LxW2)/2) in control, WT BM-VPC and Dll4+/- 
BM-VPC-Dll4 tumors. B. As determined by TUNEL staining, tumor apoptosis index 15 days 
after inoculation, in control, WT BM-VPC and Dll4+/- BM-VPC tumors. C. Tumor proliferation 
index (number of phosphor-histone 3 (pH3) per section) pH3 staining in tumor cryosections. 
These quantifications were done in triplicate, in tumor sections obtained from 2 independent 
experiments. Scale bar indicates 150µm. (values show the mean plus s.e.m. *: P<0.05). 
 
 
Dll4 expression by BM-VPC affects the stability of tumor vessels 
We assessed vessel stability as determined by immunofluorescence staining against fibronectin 
(FN1) and SMA (smooth muscle actin, which identifies pericytes). We observed that tumors 
with Dll4+/- BM-VPC had significantly lower FN1 content (Figure 6A) in the vessels and these 
had significantly less pericyte coverage, suggesting these would likely be more unstable (the 
PECAM/SMA ratio of the tumors is shown in Figure 6B; the higher the ratio the less 
pericyte/SMA coverage of tumor vessels). Moreover, as determined by staining tumor frozen 
sections with hypoxiprobe (which labels hypoxic tumor areas), tumors with Dll4+/- BM-VPC had 
significantly greater proportion of hypoxic areas, which strongly suggests that the vessels in 
these tumors were less functional (Figure 6C). Taken together, these data show the tumor vessels 
grown in BM Dll4+/- BM-VPC transplanted versus control mice or those with BM-VPC-WT are 
non-functional, leaky vessels. 
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Figure 6. Dll4+/-BM-VPC regulates vessel stability in tumors. A. FN1 expression was detected 
by immunofluorescence (FN1) endothelial cells were stained using anti-PE-CAM antibody. B. 
Quantification of the number of PE-CAM+SMA+ and PE-CAM+SMA- vessels, (PECAM/SMA 
ratio of 2.2±0.9 versus 4.6±2.3, respectively, * P<0.05). Error bars indicate SD. Scale Bar 
represents 350µm. C. Hypoxia index 15 days after inoculation (number of hipoxyprobe positive 
cells per section) (* P<0.05). Scale bars represent 350µm. These quantifications were done in 
triplicate, in tumors from 2 independent experiments. Error bars indicate SD. 
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Dll4 expression on BM-VPC affects vessel stability in late stages of tumor growth  
Having shown the relevance of Dll4 expression on BM-VPC for EC behaviour in vitro, next we 
investigated whether these effects were also observed in vivo during tumor growth and 
specifically dependent on Dll4 expression in BM-VPC using a xenograft tumor model of mouse 
breast carcinoma (HTH-k). For that we increased the number of circulating BM-VPC by 
administering mouse BM-VPC derived from Dll4GOF mice with induced Dll4 over-expression 
(mDll4GOF BM-VPC) or normal Dll4 expression (WT BM-VPC) after tumor establishment 
during a restricted period of time. We analysed subcutaneous tumor xenografts of mice injected 
at day 6, 8 and 10 with BM-VPC, compared with mice in the same experimental conditions but 
without BM-VPC administration (Figure 7). 
To assess vessel stability we quantified Fibronectin 1 content in blood vessels of controls, WT 
BM-VPC and mDll4GOF BM-VPC tumors. We identified endothelial cells by immunostaining 
with PE-CAM. To assess vessel stability we quantified Fibronectin 1 content and blood vessel 
diameter in blood vessels of tumors. Fibronectin 1 expression and vessel diameter were 
significantly higher in tumors treated with mDll4GOF BM-VPC than WT BM-VPC (Figure 7A-
7C). However, the vessel density and tumor volume (data not shown) were similar between 
controls, WT BM-VPC and mDll4GOF BM-VPC tumors (Figure 7D). Taken together, this data 
suggest that specific expression of Dll4 on BM-VPC modulates vessel morphology at tumor site, 
increasing fibronectin1 content.  
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Figure 7. Increased expression of Dll4 in circulating blood cells regulates vessel stability in 
early stages of tumor development. A. Fibronectin 1 (FN1) and PECAM expression were 
detected by immunofluorescence. Scale bar indicates 50µm B. FN1 staining quantification was 
performed using ImageJ. Error bars indicate SD. C. Vessel diameter was quantified measuring 
the smallest distance between two nuclei in opposing vessel sides at more than 4 different vessel 
levels. Error bars indicate SD. D. Vessel density was obtained counting the number of vessel per 
section. Error bars indicate SD (values show the mean plus s.e.m. *: P<0.05). 
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DISCUSSION  
Therapeutic approaches to target tumor angiogenesis have shown promising pre-clinical 
results18,19,20, although some studies have reported significant side effects, while others have 
suggested better and more detailed molecular studies are still needed given the relatively modest 
therapeutic benefits observed21,22. It is now well established that VEGF is not the only factor 
essential for tumor angiogenesis, and that other signalling pathways play a crucial role during the 
initial (sprouting) and the late (stabilization) phases of this intricate and complex process. 
Moreover, the role for, and the importance of, the endogenous (pre-existing) and the “external” 
(BM-recruited progenitors, termed VPC throughout this manuscript) factors that regulate 
endothelial cells during tumor angiogenesis is still largely undisclosed and has been the theme of 
some controversy.  
Recent studies revealed that the Notch signalling pathway, and specifically its ligand Dll4, is 
crucial for adequate tumor angiogenesis14,23,24. In detail it was shown that therapeutic strategies 
aimed at neutralizing Dll4 binding to its receptor (with Dll4 neutralizing antibodies) resulted in 
inefficient angiogenesis due to vessel instability. A putative role for BM-VPC in the setting of 
Notch:Dll4 signaling during tumor angiogenesis has not been studied and was the subject of the 
present report.  
Our results demonstrate that BM-VPC are activated during tumor growth by SDF1 and VEGF 
resulting in increased Dll4 expression. VEGF and SDF1 produced in the tumor 
microenvironment, and released systemically, have been implicated in BM-VPC recruitment and 
retention in perivascular sites25. In this paper, we demonstrate that these cytokines are also 
responsible for the activation of BM-VPC.  It has already been described that SDF1 increases 
BM-VPC-dependent vasculogenesis26. However, the molecular mechanism responsible for this 
effect was unknown. Here we show that SDF1 is able to regulated Dll4 expression in BM-VPC 
altering the angiogenic response. Therefore, the Dll4 expression levels might be considered as a 
general marker for vascular responses, such as during tumor angiogenesis or vascular 
remodelling events. 
Dll4 expression on EC activates the Notch signalling pathway resulting in the regulation of 
tumor angiogenesis in a VEGF-independent manner23,24,27. In the present paper, we show that 
BM-VPC also regulates Notch signalling activity on EC via Dll4 expression. Dll4 expressed by 
BM-VPC was able to regulate FN1 and ICAM2 (among other genes) expression on mature EC, 
suggesting it might modulate vessel stability and activation programs. As already described in 
the context of the Dll4 overexpression mutant, Notch signalling activation by Dll4 on EC was 
able to regulate the expression of several components of the extracellular matrix including FN115, 
suggesting it modulates vessel stability by controlling the expression of ECM components of the 
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basement membrane. Moreover, it was already shown that the overexpression of Dll4 on EC 
increases the expression of VE-cadherin, a cell-to-cell adhesion molecule15. Our results do not 
show any difference in endothelial cell VE-cadherin expression with our without Dll4 inhibition 
on BM-VPC. This might indicate that VE-cadherin regulation on endothelial cells is a cell-
autonomous mechanism, since in our experiments Notch activation by Dll4 expressed on EC was 
not tested. Besides promoting leukocyte adhesion during inflammatory responses, ICAM2 is also 
implicated in angiogenesis, where it was shown to promote tube formation28. Taken together, 
Dll4 expression on BM-VPC is able to activate mature EC, which strongly suggests the cross-
talk between these 2 cell types is crucial for adequate tumor angiogenesis. 
In vivo, we observed that reduction of Dll4 expression on BM-VPC, and subsequent 
transplantation into tumor bearing mice, decreased tumor vessel stabilization resulting in the 
formation of unstable vessels. Dll4 reduction on BM-VPC (Dll4+/- BM-VPC) and their 
transplantation into tumor-bearing mice resulted in the formation of unstable vessels, as 
evidenced by the reduced pericyte coverage, reduced Fibronectin expression; this led to 
appearance of more hypoxic areas and consequently decreased tumor growth. Vessel instability 
has been previously observed in other studies looking at the importance of Dll4 during tumor 
angiogenesis and also embryonic vasculogenesis23,24, but this effect was not related to the 
contribution/involvement of BM-VPC. In addition, we also demonstrate that specifically 
modulating Dll4 expression on BM-VPC is sufficient to affect vascular stability of tumor vessels 
during a restricted period throughout tumor development.  Globally, the results presented here 
show that gene expression alterations in the ligand Dll4 on BM-VPC regulate angiogenesis at the 
tumor site. Nevertheless, we cannot exclude the possible contribution/involvement of other 
Notch ligands in the communication between BM-VPC and resident tumor endothelial cells.  
Taken together, our data further supports the concept that Dll4 expression and Notch signalling 
pathway activation must be tightly controlled to produce a normal and functional vessel network. 
Our data shows that BM-VPC may be essential in the control of this signalling pathway at 
different stages of tumor angiogenesis. Dll4 expression by BM-VPC may therefore be 
considered as an important regulator of vessel stabilization, essential for tumor angiogenesis but 
also in other vascular pathologies.  
 
 
 
 
 
 
 
 157 
References 
1. Asahara T, Masuda H, Takahashi T, Kalka C, Pastore C, et al. (1999) Bone marrow origin of 
endothelial progenitor cells responsible for postnatal vasculogenesis in physiological and 
pathological neovascularization. Circ Res 85: 221-228. 
2. Rafii S, Lyden D, Benezra R, Hattori K, Heissig B (2002) Vascular and haematopoietic stem 
cells: novel targets for anti-angiogenesis therapy? Nat Rev Cancer 2: 826-835.Review 
3. Lyden D, Hattori K, Dias S, Costa C, Blaikie P, et al. (2001) Impaired recruitment of bone-
marrow-derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and 
growth. Nat Med 7: 1194-1201. 
4. Larrivee B, Niessen K, Pollet I, Corbel SY, Long M, et al. (2005) Minimal contribution of 
marrow-derived endothelial precursors to tumor vasculature. J Immunol 175: 2890-2899. 
5. Peters BA, Diaz LA, Polyak K, Meszler L, Romans K, et al. (2005) Contribution of bone 
marrow-derived endothelial cells to human tumor vasculature. Nat Med 11: 261-262. 
6. Krebs LT, Xue Y, Norton CR, Shutter JR, Maguire M, et al. (2000) Notch signaling is 
essential for vascular morphogenesis in mice. Genes Dev 14: 1343-1352. 
7. Uyttendaele H, Ho J, Rossant J, Kitajewski J (2001) Vascular patterning defects associated 
with expression of activated Notch4 in embryonic endothelium. Proc Natl Acad Sci U S A 98: 
5643-5648. 
8. Duarte A, Hirashima M, Benedito R, Trindade A, Diniz P, et al. (2004) Dosage-sensitive 
requirement for mouse Dll4 in artery development. Genes Dev 18: 2474-2478. 
9. Gale NW, Dominguez MG, Noguera I, Pan L, Hughes V, et al. (2004) Haploinsufficiency of 
delta-like 4 ligand results in embryonic lethality due to major defects in arterial and vascular 
development. Proc Natl Acad Sci U S A 101: 15949-15954. 
10. Carmeliet P, Ferreira V, Breier G, Pollefeyt S, Kieckens L, et al. (1996) Abnormal blood 
vessel development and lethality in embryos lacking a single VEGF allele. Nature 380: 435-439. 
11. Mailhos C, Modlich U, Lewis J, Harris A, Bicknell R, et al. (2001) Delta4, an endothelial 
specific notch ligand expressed at sites of physiological and tumor angiogenesis. Differentiation 
69: 135-144. 
12. Oliner J, Min H, Leal J, Yu D, Rao S, et al. (2004) Suppression of angiogenesis and tumor 
growth by selective inhibition of angiopoietin-2. Cancer Cell 6: 507-516. 
13. Patel NS, Li JL, Generali D, Poulsom R, Cranston DW, et al. (2005) Up-regulation of delta-
like 4 ligand in human tumor vasculature and the role of basal expression in endothelial cell 
function. Cancer Res 65: 8690-8697. 
14. Williams CK, Li JL, Murga M, Harris AL, Tosato G (2006) Up-regulation of the Notch 
ligand Delta-like 4 inhibits VEGF-induced endothelial cell function. Blood 107: 931-939. 
15. Trindade A, Kumar SR, Scehnet JS, Lopes-da-Costa L, Becker J, et al. (2008) 
Overexpression of delta-like 4 induces arterialization and attenuates vessel formation in 
developing mouse embryos. Blood 112: 1720-1729. 
16. Deutsch U, Schlaeger TM, Dehouck B, Doring A, Tauber S, et al. (2008) Inducible 
endothelial cell-specific gene expression in transgenic mouse embryos and adult mice. Exp Cell 
Res 314: 1202-1216. 
17. Caiado F, Real C, Carvalho T, Dias S (2008) Notch pathway modulation on bone marrow-
derived vascular precursor cells regulates their angiogenic and wound healing potential. PLoS 
One 3: e3752. 
 158
18. Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, et al. (2007) Sorafenib in advanced 
clear-cell renal-cell carcinoma. N Engl J Med 356: 125-134. 
19. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, et al. (2008) Sorafenib in advanced 
hepatocellular carcinoma. N Engl J Med 359: 378-390. 
20. Motzer RJ, Bukowski RM (2006) Targeted therapy for metastatic renal cell carcinoma. J Clin 
Oncol 24: 5601-5608. 
21. Bergers G, Hanahan D (2008) Modes of resistance to anti-angiogenic therapy. Nat Rev 
Cancer 8: 592-603. 
22. Verheul HM, Pinedo HM (2007) Possible molecular mechanisms involved in the toxicity of 
angiogenesis inhibition. Nat Rev Cancer 7: 475-485. 
23. Noguera-Troise I, Daly C, Papadopoulos NJ, Coetzee S, Boland P, et al. (2006) Blockade of 
Dll4 inhibits tumour growth by promoting non-productive angiogenesis. Nature 444: 1032-1037. 
24. Ridgway J, Zhang G, Wu Y, Stawicki S, Liang WC, et al. (2006) Inhibition of Dll4 
signalling inhibits tumour growth by deregulating angiogenesis. Nature 444: 1083-1087. 
25. Moore MA, Hattori K, Heissig B, Shieh JH, Dias S, et al. (2001) Mobilization of endothelial 
and hematopoietic stem and progenitor cells by adenovector-mediated elevation of serum levels 
of SDF-1, VEGF, and angiopoietin-1. Ann N Y Acad Sci 938: 36-45; discussion 45-37. 
26. Yamaguchi J, Kusano KF, Masuo O, Kawamoto A, Silver M, et al. (2003) Stromal cell-
derived factor-1 effects on ex vivo expanded endothelial progenitor cell recruitment for ischemic 
neovascularization. Circulation 107: 1322-1328. 
27. Leslie JD, Ariza-McNaughton L, Bermange AL, McAdow R, Johnson SL, et al. (2007) 
Endothelial signalling by the Notch ligand Delta-like 4 restricts angiogenesis. Development 134: 
839-844. 
28. Huang MT, Mason JC, Birdsey GM, Amsellem V, Gerwin N, et al. (2005) Endothelial 
intercellular adhesion molecule (ICAM)-2 regulates angiogenesis. Blood 106: 1636-1643. 
29. Dias S, Thomas H, Balkwill F (1998) Multiple molecular and cellular changes associated 
with tumour stasis and regression during IL-12 therapy of a murine breast cancer model. Int J 
Cancer. 1998 Jan 5;75(1):151-7.	  
30. Scott KA, Holdsworth H, Balkwill FR, Dias S (2000) Exploiting changes in the tumour 
microenvironment with sequential cytokine and matrix metalloprotease inhibitor treatment in a 
murine breast cancer model. Br J Cancer. 2000 Dec;83(11):1538-43. 
 
 
 
 
 
 
 
 
 159 
Chapter 6 - Bone marrow-derived cells contribute towards tumor epithelial to 
mesenchymal transition and metastases onset  
 
Francisco Caiado#*, Tânia Carvalho#*, Ana Costa#*  and Sérgio Dias#* 
# Angiogenesis Laboratory, CIPM/Portuguese Institute of Oncology, Lisboa, Portugal; * 
Instituto Gulbenkian de Ciência, Oeiras, Portugal; 
 
Manuscript under preparation 
 
 
Abstract 
The tumor stroma, namely the bone marrow (BM)-derived components of the stroma plays an 
important role in tumor incidence, progression and metastasis. However the contribution of BM-
derived tumor stroma on epiyhelial-to-mesenchymal transitions (EMT) in primary epithelial 
tumors remains largely unknown. Using ectopic models of colon carcinoma tumor in mice 
bearing actin GFP+ BMs, we characterized the contribution of BM-derived cells to colon 
carcinoma progression and EMT. Accordingly to our results comparing early stage tumor with 
late stage tumors we observed that in later stage tumors there is significant contribution of BM-
derived myeloid cells (CD11b+) to the stroma. Interestingly in later stage tumors we observed 
the localization of BM-derived cells in close contact with tumor cells (Cytokeratin 19+) 
undergoing EMT, as characterize by immunoflorescence against epithelial marker E-Cadherin 
and the mesenchymal marker Vimentin. In vitro, co-culturing tumor associated BM-derived cells 
with colon carcinoma cells (HCT15 cell line) induced a significant decrease of E-cadherin levels 
while increasing Vimentin expression in tumor cells, further supporting the in vivo observations. 
Interestingly we observed that BM-derived cell induced EMT on tumor cells was dependent on 
Notch signalling activation, further confirming this was the observation that tumor associated 
BM-derived expressing Jagged-2 induced, per se, EMT in HCT15 cells. Characterization of the 
tumor associated BM-derived Jagged-2+ population revealed that this cells are CD11b+ F4/80+, 
further suggesting that the EMT inducing cells are in fact tumor associated macrophages 
(TAMs). Indeed co-culture of tumor associated BM-derived CD11b+ Jagged-2+ with HCT15 
induced EMT in HCT15 cells. Moreover immunostainnig of tumor samples revealed that 
CD11b+ Jagged-2+ cells localize in tumor regions undergoing EMT. In conclusion, we describe 
the contribution of a BM-derived myeloid (CD11b+) population to tumor progression, showing 
that these cells can in fact mediate tumor cell EMT via Jagged-2 mediated Notch activation. 
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Introduction 
Metastatic disease is the major cause of cancer-associated mortality. In fact most metastatic 
lesions are resistant to current treatments such as irradiation and chemotherapy as well as the 
more recent targeted biological therapies. The lack of an efficient therapeutical approach for 
metastasis treatment reflects a defective understandment of the molecular and cellular 
mechanisms regulating tumor dissemination and metastasis1. However it is accepted that 
metastasis proceeds via a series of interrelated steps, each of which can be rate-limiting. These 
steps include: tumor cell local invasion; entry into systemic circulation (‘intravasation’); 
movement from the circulatory system into a new host tissue (‘extravasation’); and proliferation 
and growth of the secondary tumor2. One of the major processes regulating tumor local invasion 
is termed epithelial to mesenchymal transition (EMT)3,4. EMT is a transcriptional regulated 
transdifferentiation process characterized by a decrease in epithelial markers such as E-cadherin 
loss cell-cell adhesion, cell apical-basal polarity and increased mesenchymal markers such as 
vimentin associated with an increase in cell motility and invasion capacity5-8. EMT has been 
positively correlated with increase breast and colon cancer metastasis and decreased patient 
surviva3,9,10. 
In the last decade there has been increasing evidence suggesting that tumor metastasisation is 
also regulated by non-malignant cells of the tumour microenvironment, namely by bone marrow 
(BM)-derived cell populations11. In fact distinct BM-derived populations have been implicated in 
distinct steps of metastization12. For instance tumor associated macrophages (TAMs), pre-
metastatic niche cells, metastasis recruited macrophages and endothelial progenitor cells (EPCs) 
have been shown to enhance metastization via multiple processes13,14, to promote the formation 
of a permissive metastatic niche15, to increase tumor cell extravasaion and micrometastasis 
growth16, and to promote micrometastasis vascularization17, respectively. Nevertheless a direct 
role of BM-derived cells in promoting EMT has not been described so far.  
In the present study we used mouse models of ectopic colon cancer in recipient mice containing 
actin-GFP+ bone marrows to exploit the concept that BM-derived cells co-localize with tumor 
regions undergoing EMT. We observed that later stage tumors contain myeloid (CD11b+ 
F4/80+) populations in tumor regions undergoing EMT. In vitro data suggests that this 
population might induce EMT by Jagged-2 mediated Notch pathway activation. This data further 
supports the need to develop Notch pathway blocking agents as a therapeutic approach for 
metastatic colon cancer treatment. 
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Materials and Methods  
 
Mouse strains, bone marrow transplants and ectopic colon carcinoma model 
In vivo experiments were performed on 4-8 weeks old female Nude mice (C57/BL6 background) 
that received bone marrow (BM) transplats from male Actin-GFP mice (C57/BL6 background). 
Briefly Nude (athymic) mice received a whole body lethal irradiation (950 rads) and 24 hours 
later received an intravenous injection of 2-3x106 BM mononuclear cells collected from Actin-
GFP mice (C57/BL6 background). Mice were allowed to recover for 2-4 weeks. After this period 
peripheral blood samples were collected and analysed by flow cytometry using FACScalibur 
(BD Biosciences) for GFP+ cells, mice were considered suitable for further experiments when 
the proportion of GFP+ cells in the peripheral blood was over 80% of total cells. Concerning the 
ectopic colon carcinoma model used briefly, 5x106 HCT15 (human carcinoma cell line, isolated 
from an human colon adenocarcinoma) were ressuspended in 200 ul of PBS and subcutaneously 
injected in Nude mice containing Actin-GFP BMs. Tumors were allowed to grow for 1 (early 
tumors) or 3 to 4 weeks (late tumors), time after which mice were sacrificed and tumors 
collected. 
 
Isolation and characterization of tumor associated BM-derived cells 
Tumor samples were collected from tumor bearing Nude mice that had previously received 
Actin-GFP BM transplant. Tumors were mechanically fragmented into 2mm per 2mm pieces and 
then digested enzimatically by collagenase (2mg/ml in serum free DMEM medium)(Sigma-
Aldrich) for 2 hours at 37ºC and 5% C02. After digestion tumor samples were passed trough a 
mesh and then washed in sterile PBS. Further isolation of tumor cell population was performed 
by cell sorting using FACSaria (BD Biosciences). Isolation of tumor GFP+ population was done 
without the use of any antibody staining, while isolation of Jagged-2+ and CD11b+ population 
required previous staining with fluorochrome conjugated antibodies (PE anti-mouse Jagged-2, 
131007, BioLegend and FITC anti-mouse CD11b, 101205 BioLegend). Characterization of 
tumor Jagged-2+ cells was performed using flow cytometry analysis against Jagged-2 and 
CD11b (FITC anti-mouse CD11b, 101205 BioLegend), Gr-1 (APC/Cy7 anti-mouse Ly-6G/Ly-
6C (Gr-1), 108423 BioLegend), F4/80 (FITC anti-mouse F4/80, 123107, BioLegend), Sca-1 
(FITC Rat Anti-Mouse Ly-6A/E, 557405, BD Pharmingen), c-Kit (APC/Cy7 anti-mouse CD117 
(c-kit), 105825, BioLegend), CD3 (FITC anti-mouse CD3, 100203, BioLegend) and CD19 
(Alexa Fluor® 488 anti-mouse CD19, 115524, BioLegend). Antibodies used were diluted 1:100 
in PBS+BSA 0,5% and incubated in the dark with rotation, at 4ºC for 45 minutes. 
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In vitro co-culture assays  
HCT15 cells were cultured at 1x104/cm2 cell density in DMEM supplemented medium (GIBCO) 
with 10% FBS (foetal bovine serum, Sigma-Aldrich). After 24h medium was changed to DMEM 
supplemented medium with 2% FBS and 1x105 tumor associated BM-derived cells (GFP+, 
GFP+ Jagged-2+, GFP+ Jagged-2 negative or Jagged-2+ CD11b+ cells). Co-culture was 
maintained for 48h. After this period tumor associated BM-derived cells were washed from the 
culture and HCT15 cells collected for mRNA extraction or fixed with 2% paraformaldehyde for 
15 minutes for further cytochemistry staining. γ-secreatase inhibitor or GSI (DAPT, Sigma 
Aldrich) was added to co-cultures at a final concentration of 10uM and respective controls  
received DMSO (Sigma-Aldrich). 
 
Quantitative Reverse-transcription Polymerase Chain Reaction (qRT-PCR) 
RNA extraction (Trizol, Invitrogen), cDNA synthesis (Reverse-transcription with Superscript II 
reverse transcriptase (Invitrogen)) and oligo (dT) primer (Roche) were performed following 
standard protocols. mRNA levels were measured by real time RQ-PCR on the ABI Prism® 
7900HT Sequence Detection System (Applied Biosystems) using the following primers human 
E-Cadherin (ccaccaaagtcacgctgaatac; ggagttgggaaatgtgagcaa), hVimentin 
(ggaagagaactttgccgttgaa; gtgacgagccatttcctcctt), hHey1 (gaagttgcgcgttatctgag; 
gttgagatgcgaaaccagt) hHey2 (tgaatccgcatgggcaaacg; tcgcctctccacaacttcag), mDll1 
(ttgaagccctccatacagactct; tggtcaggcggctgatg), mDll4 (tttgtgaccaagatctaactactactctac; 
ctttggcccactgttggaa), mJag1 (ccagccagtgaagaccaagt; tcagcagaggaaccaggaaa) and mJag2 
(gaggtcaaggtggaaacagt; tgtccaccatacgcagataa). The housekeeper gene used to normalize human 
samples was h18s (gccctatcaactttcgatggtagt; ccggaatcgaaccctgatt) and to normalize mouse 
samples was mβ-actin (agccatgtacgtagccatcc; ctctcagctgtggtggtgaa). 
 
Tumor histocytochemistry analysis 
Tumors samples were included in either gelatin or paraffin. Parafin tumor sections were further 
subjected to antigene retrievel protocols (PT high). Tumours cryosections were blocked with a 
5% FBS / 0,1% BSA solution in PBS for 30 minutes. Slides were then covered with primary 
antibodies: anti-mouse PECAM (553369, Pharmingen), anti-mouse CD11b (550282, 
Pharmingen), anti-human E-cadherin (M3612, Dako); anti-human Cytokeratin-19 (M0888, 
Dako), anti-human (M0851, Dako), anti-human C-Kit (A4502, Dako), anti-mouse B220 (553085, 
Pharmingen) and anti-human Jagged-2 (AbCam). After overnight incubation at 4ºC, tumor 
sections were washed 3 times in PBS and incubated with secondary antibodies from Invitrogen 
(anti-rat-FITC, anti-mouse-Alexa568, anti-rabbit-Alexa488, respectively) for 2 hours at room 
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temperature. For the quantification of GFP+ lineage+ cells in tumor samples the total number of 
GFP+ lineage+ cells was quantified in 5 high power fields (x400 magnification) and then divided 
by total GFP+ cells. Vimentin+ cells quantification was preformed by direct count of Vimentin 
expressing cells in 5 high power fields (x400 magnification). Quantification of E-cadherin 
expression on tumor samples was preformed by direct quantification of staining intensty using 
ImageJ software.  
 
Statistical Analysis 
Differences between the experimental groups were calculated using ANOVA or T student test 
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Results 
 
Colon carcinoma ectopic tumors recruit mixed populations of BM-derived cells consisting 
mostly of CD11b+ myeloid cells 
In order to characterize the contribution of BM-derived populations to colon cancer progression, 
ectopic tumors we inoculated HCT15 (human colon carcinoma cell line) sub-cutaneously in 
Nude mice containing actin-GFP+ BM. Tumors where allowed to growth for 1 (termed early 
tumors) or 3 to 4 (termed late tumors) weeks and then mice where sacrificed and tumors 
collected. Accordingly with the GFP staining we observed that BM-derived cells (GFP+ cells) 
where actively recruited to both early and later tumor, although at higher frequency in later 
tumors (Figure 1A). Characterization of the BM-derived GFP+ population present in the tumor 
revealed that in both early and late tumor most GFP+ cells express the myeloid marker CD11b 
(ranging form 70-90%), while a more restricted population express the mesenchymal marker 
SMA (average of 30-40%). Other BM-derived populations such as CD31+ (endothelial), B220+ 
(B-lymphocytes) or C-Kit+ (progenitor cells) cells represent a minor portion of GFP+ cells 
(Figure 2A). Altogether these data suggests that the main BM-derived population recruited 
during ectopic colon cancer growth is of myeloid origin (CD11b+). 
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Figure 1. Colon carcinoma ectopic tumors recruit mixed populations of BM-derived cells 
consisting mostly of CD11b+ myeloid cells. A. Representative image of early (1week) and late 
(3-4 weeks) sub-cutaneous colon carcinoma tumors implanted in Nude mice containing Actin-
GFP BMs. Scale bar: 100um. Quantification of GFP staining on both early and late tumors using 
ImageJ software. B. Quantification of GFP+ CD31/CD11b/SMA/C-Kit/B220+ in early and late 
sub-cutaneous colon carcinoma tumors implanted in Nude mice containing Actin-GFP BMs. 
Representative image of tumor GFP+ cells expressing CD31, SMA or CD11b. Scale bar: 10um. 
Each experiment was performed in triplicate and the mean represented n=3. Error bars indicate 
SD. 
 
BM-derived cells localize in tumor regions containing tumor cells undergoing EMT 
Having characterized the BM-derived population recruited during tumor growth we next looked 
into evidences of EMT in both early and late tumors. Considering that loss of the epithelial 
marker E-cadherin is considered the hallmark of EMT9, we looked preferentially into E-cadherin 
expression in the primary tumor. Interestingly we observed that in later tumors there is a 
significant decreased in E-cadherin expression (Figure 2A and C) and a significant increase in 
the expression of the mesenchymal marker Vimentin (Figure 2B and C) compared to early 
tumors. Interestingly both the decreased expression of E-cadherin and the increase in Vimentin 
expression occurred in tumor regions highly infiltrated by GFP+ cells (Figure 2A and 2B).  A 
detailed observation of tumor cells (expressing cytokeratin 19 – CK19) in proximity of GFP+ 
reveals that these cells acquire the expression of vimentin (not expressed in tumor cells further 
away from GFP+ cells) (Figure 2D). In fact CK19+ vimentin+ cells can be found between GFP+ 
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cells suggesting that tumor cells in these regions adquire a migratory phenotype. Consistent with 
the EMT phenotype tumor cells in proximity of GFP+ that express vimentin also show a 
decrease in E-cadherin expression (Figure 2D, lower panel). Altogether these data suggests that 
the presence of BM-derived cells in later tumor is positively correlated with the onset of EMT in 
the primary tumor. 
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Figure 2. BM-derived cells localize in tumor regions containing tumor cells undergoing 
EMT. A. Representative image of GFP (green) and E-cadherin (red) expression on early and late 
tumors. Dashed line delimitates tumor regions that show decreased expression of E-cadherin. 
Scale bar: 100um. B. Representative image of GFP (green) and Vimentin (red) expression on 
early and late tumors. Scale bar: 100um. C. Quantification of E-cadherin and Vimentin 
expression on early and late tumors. Quantifications where performed using ImageJ software. 
Each experiment was performed in triplicate and the mean represented, n=3. Error bars indicate 
SD. D. Representative image of sequential tumor sections of the same region stained for GFP 
and CK19, GFP and Vimentin, GFP and E-cadherin. Arrows point tumor cells (CK19+) in close 
contact with GFP cells that acquire Vimentin expression and lose E-cadherin expression. Scale 
bar: 10um. 
 
 
 
BM-derived cell mediated EMT on colon carcinoma cells depends on Notch signalling 
activation 
In order to further explore the concept that BM-derived cells induce EMT on tumor cells, we 
preformed in vitro co-culture experiments with HCT15 cells and BM-derived cells collected 
from late sub-cutaneous tumors. As depicted on Figure 3A in the presence of BM-derived tumor 
associated cells HCT15 show a decrease in the expression levles of E-cadherin and a significant 
increase in the vimentin expression, as measured by RQ-PCR. This can also be observed in the 
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quantification of E-cadherin expressing HCT15 cells by imunostainning after co-culture (Figure 
3B), suggesting that BM-derived tumor associated cells induce EMT by increasing vimentin 
expression and decreasing E-cadherin expression at both transcriptional and translational level. 
Next we decided to look into the molecular pathway regulating EMT in colon carcinoma cell line 
HCT15. Accordingly to the literature the Notch pathway activation has been shown to induce E-
cadherin repression via up-regulation of the transcriptional repressor Slug18. In accordance 
HCT15 cells express Notch receptors 1, 4 and ligands (data not shown). Therefore we preformed 
the co-culture assays and add a Notch pathway inhibitor termed gamma secretase inhibitor (GSI) 
and determined its effect on E-cahderin and vimentin expression. Interestingly as shown in 
figure 3A and B the addition of GSI inhibits the BM-derived tumor associated cells induced 
decrease in E-cadherin and increase in vimentin expression. Further confirmation of the 
involvement of the Notch-pathway on BM-derived tumor associated cells in tumor EMT is the 
fact that the Notch pathway downstream targets Hey 1 and 2 are upregulated in HCT15 cells 
undergoing EMT (Figure 3A lower graphs). Considering the data presented we conclude that 
BM-derived tumor associated cells induce tumor EMT via Notch pathway activation on tumor 
cells. 
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Figure 3. BM-derived cell mediated EMT on colon carcinoma cells depend on Notch 
signalling activation. A. Quantification of E-cadherin, Vimentin, Hey 1 and Hey 2 gene 
expression (normalized to 18s rRNA expression) by qRT-PCR on HCT15 alone (HCT15 C), in 
the presence of 10uM GSI (HCT15 + GSI), in the presence of tumor associated BM-derived cells 
(HCT15 + TGFP) or in the presence of 10uM GSI and tumor associated BM-derived cells 
(HCT15 + TGFP + GSI). B. Quantification of cytoplasmic membrane E-cadherin+ HCT15 cells 
on HCT15 C, HCT15 + GSI, HCT15 + TGFP and on HCT15 + TGFP + GSI groups. 
Representative images of E-cadherin (red) expression in HCT15 cells. Tumor associated BM-
derived cells are GFP+ (green). Each experiment was performed in triplicate and the mean 
represented n=3. Error bars indicate SD.  *: P<0.05. 
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BM-derived cell mediated EMT on colon carcinoma cells depends on Jagged-2 mediated 
Notch signalling activation 
Considering that the Notch pathway activation on HCT15 is responsible for BM-derived tumor 
associated cells induced EMT on primary tumor we next decided to determine which Notch 
pathway ligands expressed by BM-derivd where involved. In order to do this we compared the 
expression of the ligands Dll1, Dll4, Jagged-1 and Jagged-2 in BM-derived cells collected from 
the late tumors and from BMs. Interestingly we observed that only the ligand Jagged-2 was 
significantly upregulated in BM-derived tumor associated cells in comparison with BM-derived 
cells collected from the BM (Figure 4A). In fact flow cytometry (FCM) analysis of both tumor 
and BM samples reveals that there is a population of GFP+ Jagged-2+ cells on both tissues, 
thought it is significantly higher in tumor, representing an average of 5,5% of total tumor cells 
(Figure 4B). Taking into account the high frequency of GFP+ Jagged+ cells on tumors we next 
decided to investigate whether this population was able per se to reduce E-cadherin expression 
on HCT15 colon carcinoma cell line. GFP+ Jagged-2+ and also GFP+ Jagged-2 negative cells 
where isolated from late tumors and co-cultured with HCT15 in the presence or absence of GSI. 
As depicted on figure 4B GFP+ Jagged-2+ but not GFP+ Jagged-2 negative can reduce E-
cadherin transcription in a Notch pathway dependent way. In accordance the number of HCT15 
E-cadherin+ cells is significantly reduced when these cells are co-cultured with tumor 
GFP+Jagged-2+ (Figure 4C). This phenotype is reversed when GSI is added or when HCT15 
cells are cultured with GFP+ Jagged-2 negative cells, further suggesting that BM-derived tumor 
associated cells induce tumor EMT via Jagged-2 mediated Notch pathway activation on tumor 
cells. To confirm the effect of BM-derived Jagged-2+ cells on primary tumor E-cadherin 
downregulation we performed immunostainning in late tumors for both Jagged-2 and E-
cadherin. Our results clearly show that Jagged-2+ cells (GFP+ not shown) localize in tumors 
regions with reduced E-cadherin expression (areas marked by arrows), further confirming the in 
vitro data (Figure 4D). Altogether our data shows that BM-derived tumor associated cells induce 
primary tumor EMT via Jagged-2 mediated Notch pathway activation on tumor cells. 
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Figure 4. BM-derived cell mediated EMT on colon carcinoma cells depends on Jagged-2 
mediated Notch signaling activation. A. Quantification of o gene expression of Jagged-1, 
Jagged-2, Dll1 and Dll4 (normalized to 18s rRNA expression) by qRT-PCR in GFP+ cells 
collected from tumor and BM samples. Right graph shows the quantification of the percentage of 
GFP+ Jagged-2+ cells in BM and tumor samples. B. Quantification of E-cadherin and Hey 1 
gene expression (normalized to 18s rRNA expression) by qRT-PCR on HCT15 alone (HCT15 C), 
in the presence of 10uM GSI (HCT15 + GSI), in the presence of tumor associated BM-derived 
Jagged-2+ cells (HCT15 + TGFP+Jag2+), in the presence of 10uM GSI and tumor associated 
BM-derived Jagged-2+ cells (HCT15 + TGFP+Jag2+ + GSI) or in the presence of tumor 
associated BM-derived Jagged-2 negative cells (HCT15 + TGFP+Jag2-). C. Quantification of 
cytoplasmic membrane E-cadherin+ on HCT15 C, HCT15 + GSI, HCT15 + TGFP+Jag-2+, 
HCT15 + TGFP+Jag-2+ + GSI or HCT15 + TGFP+Jag-2 negative groups. Representative 
images of E-cadherin (red) expression in HCT15 cells.Tumor associated BM-derived Jagged-2+ 
cells are GFP+ (green). D. Representative images of sequential tumor sections stainned for 
Jagged-2+ (red) and E-cadherin (red). Arrows poit to tumor regions adjacent to Jagged-2+ cells 
that show reduced E-cadherin expression. Each experiment was performed in triplicate and the 
mean represented n=3. Error bars indicate SD.  *: P<0.05. 
 
 
BM-derived CD11b+ Jagged-2+ cells induce tumor cell EMT via Jagged-2 mediated Notch 
pathway activation  
Having shown that BM-derived Jagged-2+ cells are responsible for Notch signalling induced 
tumor cell EMT we next performed a series of experiments to define the exact nature of this 
population. Accordingly to our results Jagged-2+ also express CD11b (75%), CD11b/Gr-1 
(15%), F4/80 (60%), Sca-1 (10%), c-kit (2%) and CD3 (30%) (Figure 5A). This suggests that 
Jagged-2 is expressed in different lineages, but is preferentially expressed in myeloid cells, 
 173 
namely in CD11b+ F4/80+ cells. Interestingly co-culture of HCT15 tumor cells with BM-
derived tumor associated CD11b+ Jagged-2+ cells leads to a decrease in E-cadherin expression 
at both the mRNA and protein level (Figure 5B and C). This decrease in E-cadherin expression is 
Notch pathway dependent as observed in the Hey 1 expression levels (Figure 5B). 
Immunostainning of primary tumor sections confirms that CD11b+ co-localize partially with 
Jagged-2+ cells as observed in Figure 5D (upper panel). A more detailed observation of CD11b+ 
cells (white box) shows that tumor cells in close contact with CD11b+ cells show a decreased 
expression of E-cadherin (Figure 5D, lower panel, arrows), further confirming the in vitro data. 
These data suggests that HCT15 sub-cutaneous tumor recruit actively CD11b+ Jagged-2+ cells 
that once in the tumor tissue interact with tumor cells via Jagged-2:Notch receptor interactions 
leading to a decrease in E-cadherin expression and consequent initiation of EMT in tumor cells. 
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Figure 5. BM-derived CD11b+ Jagged-2+ cells induce tumor cell EMT via Jagged-2 
mediated Notch pathway activation. A. Quantification of Jagged-2+ CD11b/CD11b Gr-
1/F4/80/Sca-1/c-Kit/CD3/CD19 expressing cells on tumor and BM samples. Right graph 
represents the percentage of Jagged-2+ cells that express CD11b/CD11b Gr-1/F4/80/Sca-1/c-
Kit/CD3/CD19 markers. B. Quantification of E-cadherin and Hey 1 gene expression (normalized 
to 18s rRNA expression) by qRT-PCR on HCT15 alone (HCT15 C), in the presence of 10uM 
GSI (HCT15 + GSI), in the presence of tumor associated BM-derived CD11b+Jagged-2+ cells 
(HCT15 + CD11b+Jag2+) and in the presence of 10uM GSI and tumor associated BM-derived 
CD11b+Jagged-2+ cells (HCT15 + CD11b+Jag2+ + GSI). C. Quantification of cytoplasmic 
membrane E-cadherin+ on HCT15 C, HCT15 + GSI, HCT15 + CD11b+Jag-2+ and HCT15 + 
CD11b+Jag-2+ + GSI groups. Representative images of E-cadherin (red) expression in HCT15 
cells and CD11b (green) expression on tumor associated CD11b+ Jagged-2+ cells. D. 
Representative images of tumor sections stained for CD11b (green) and Jagged-2 (red). Scale 
bar: 100um. Lower panel shows an ampliation of the region contained within the white square of 
the upper panel. Lower panel showns stainning for CD11b (green) and E-cadherin (red). Arrows 
point to tumor regions adjacent to CD11b cells that show reduced   E-cadherin expression. Scale 
bar: 100um. Each experiment was performed in triplicate and the mean represented n=3. Error 
bars indicate SD. *: P<0.05. 
 
 
 
 
 
 
 
 
 
 
 175 
DISCUSSION  
Over the last decade there has been an increase in our understanding of the contribution of tumor 
stromal components in the regulation of tumor progression and metastases formation19. EMT has 
been shown to be essential for carcinoma progression, namely in breast, colon and prostate 
carcinoma3, preceding invasion and metastasis formation20. One of the major molecular 
regulators of EMT is E-cadherin. E-cadherin is a member of the cadherin family of homophilic 
cell adhesion molecules, and is essential for the maintenance of adherens junctions that confer 
physical integrity and polarization to epithelial cells. Notably, targeted disruption of this 
molecule during tumor progression resulting in decreased intercellular adhesiveness is one of the 
most common alterations in human cancers21,22. Further, abolishing E-cadherin function in vitro 
confers invasive properties to noninvasive cells and conversely, introduction of E-cadherin into 
invasive epithelial cell lines abrogates their invasive potential. Thus E-cadherin is considered a 
broadly acting suppressor of invasion and metastasis, and its functional inactivation represents a 
critical step in the acquisition of this capability. Not surprisingly, then, loss of E-cadherin 
expression is a defining feature of EMT9. 
Although many molecular regulators of EMT have been identified23 the cellular interactions 
between tumor cells and tumor stromal cells responsible for tumor EMT are still unclear. 
Interestingly cancer associated fibroblasts (CAFs) have been shown to induce changes 
characteristic of EMT in in vitro breast cancer models24. BM-derived cells, on the other hand, 
have been shown to directly impact tumor pathophysiology regulating multiple aspects of the 
metastasation process11, namely increased angiogenesis, promotion of tumor cell invasion, 
extravasation, intravasation and micrometastasis establishment, growth and vascularization11. 
However a direct role of BM-derived cells regulating the first steps of epithelial tumor 
transformation, termed epithelial to mesenchymal transition (EMT) has not been addressed. 
However the role of BM-derived tumor stromal cells in epithelial carcinoma EMT has not been 
addressed. 
In this study we addressed a putative role for BM-derived cells in regulating EMT in metastatic 
colon cancer. Our data shows that both early and late subcutaneous ectopic colon tumors show 
significant infiltration of BM-derived cells, which are mainly of myeloid origin as depicted by 
CD11b+ staining. There is also a significant portion of BM-derived cells that are SMA+, 
possibly representing pericyte progenitor cells which have been shown to be essential in neo-
vessel stabilization and formation25. Furthermore we observe that in late tumors there are regions 
highly infiltrated by BM-derived cells that show evidence for EMT, namely a robust decrease in 
E-cadherin expression but also a significant increase in vimentin expression in CK19+ tumor 
cells. Although the occurrence of EMT in primary tumors is still controversial since its difficult 
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to follow EMT in human tumors either temporally or spatially because of the great diversity of 
cellular organization displayed by neoplasms in vivo26, it is clear from our analysis of serial 
tumor slides that tumor cells (CK19+) in close proximity with BM-derived cells (GFP+) show 
the described molecular signatures of EMT. This major observation led us to speculate that the 
direct interaction of BM-derived and tumor cells could modulate EMT in the later. To further 
confirm this we used in vitro co-culture experiments, where HCT15 carcinoma cell line was 
cultured with BM-derived tumor associated cells for 48h hours. Interestingly in the presence of 
BM-derived tumor associated cells HCT15 cells show a significant decrease of E-cadherin 
expression at both RNA and protein levels, and a significant increase in vimentin expression at 
the RNA level. Altogether the in vivo and in vitro data suggests that BM-derived cells can induce 
EMT in colon carcinoma tumor cells. 
Concerning the molecular regulation of EMT induction by BM-derived tumor associated cells 
we tested both the TGF-β pathway and the Notch pathway. Although TGF-β pathway activation 
has been extensively described as an inducer of EMT23, inhibition of TGF-β with neutralizing 
antibodies in our co-culture experiments, failed to inhibit the EMT-inducing capacity of BM-
derived CD11b+ cells (data not shown). On the other hand, the Notch pathway has also been 
extensively described as being up regulated in breast cancer brain metastasis27. Another study 
showed that in breast cancer patients, increased expression of either Jagged1 or Notch1 is 
predictive of poor overall survival28. In colon cancer Notch 1 is overexpressed and correlates 
with pathologic grade, progression, and metastasis of colon cancer patiens29. Considering this we 
tested the effect of a Notch pathway inhibitor, γ-secretase inhibitor (GSI) on BM-derived tumor 
associated CD11b+ cells induced EMT on HCT15 cells. GSI addition inhibited EMT induction 
by BM-derived cells, accompanied by a significant reduction in the expression of Notch pathway 
downstream targets Hey 1 and 2. Recent studies suggest the mechanisms by which Notch may 
induce EMT might involve activation of E-cadherin transcriptional repressor Slug18,30. 
We showed the tumor associated BM-derived CD11b+ cells show increased expression of 
Jagged-2, but not of other Notch ligands. Further quantification of the GFP+ Jagged-2+ 
populations present in the BM and in the tumors revealed a 10-fold increase in the percentage of 
this population in tumors, suggesting the GFP+ CD11b+Jagged-2+ cells are actively recruited to 
the tumor tissue. One can also speculate a putative mitogenic stimulus (stimuli) present in the 
tumor tissue that would particularly favor the expansion of this particular BM-derived cell 
population; we have not attempted at identifying such putative stimulus in the tumor 
microenvironment.  
We tested whether tumor associated BM-derived Jagged2+ cells could induce EMT on HCT15 
cells, in the presence and absence of GSI. We found that only in the absence of GSI, tumor 
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associated BM-derived Jagged2+ induce EMT on HCT15 cell line, suggesting an essential role 
of the Notch pathway in the communication between tumor and BM-derived cells. The need of 
Jagged-2 in EMT induction is further supported by the fact that BM-derived Jagged2 negative 
cells fail to decrease the expression of E-cadherin at both RNA and protein level. In order to 
validate the in vitro data we preformed immunohistochemistry against Jagged-2 in primary 
tumors and confirmed that Jagged-2+ cells localize in close proximity with tumor cells showing 
reduced E-cadherin expression.  
Taken together, these data highlight the importance of looking at the initial steps of the 
metastasis cascade also in a systemic manner. Most studies performed to date have focused on 
the tumor cell and the tumor tissue, revealing an intricate array of molecular and cellular 
interactions that result in EMT induction, “selection” of adequate tumor clones with invasive 
potential and ultimate intravasation/invasion of such tumor cells into intratumor lymphatics 
and/or blood vessels. Our data strongly suggests that a BM-derived monocyte/macrophage 
CD11b+ Jagged2+ population can activate Notch signaling, resulting in EMT induction in colon 
carcinoma cancer cells in vitro and in vivo. Given the recent excitement from clinical trials using 
Notch pathway inhibitors for the treatment of tumors, and particularly aiming at blocking tumor 
angiogenesis31,32, the data presented in this chapter paves the way for possible use of Notch 
pathway inhibitors to impede metastases onset, by impeding EMT induction at a primary tumor 
site. 
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Chaper 7 - General Discussion 
 
The cardiovascular system has evolved in vertebrates to allow oxygen, nutrient, waste product 
removal and blood cell delivery into virtually all tissues in the organism thus being essential for 
homeostasis. New blood vessel formation is essential both during embryonic development, 
where it regulates organogenesis and organ growth, but also in adult individuals where it 
regulates numerous physiological processes (wound healing, revascularization of ischemic tissue, 
ovulation, menstruation, implantation and pregnancy). However any defects in new blood vessel 
formation that leads to excessive or insufficient tissue vascularization contributes to the 
pathogenesis of numerous disorders. In fact there are over 70 described diseases that are 
associated with defective new blood vessel formation, namely cancer, inflammatory or ocular 
disorders (among many others) which result from excessive blood vessel formation while 
delayed wound healing, ischemic diseases or neurodegeneration (among others) result from 
insufficient blood vessel formation. Altogether it is estimated that in the next decades over 500 
million people worldwide will benefit from pro- or anti-blood vessel formation treatments1,2.  
Considering the importance of new blood vessel formation in human health and disease it is 
essential to fully understand the molecular and cellular mechanisms regulating it. Although most 
new vessels are formed by activation, proliferation and migration of pre-existing endothelial 
cells (ECs), termed angiogenesis, evidence collected in the last decade has lead to the concept 
that new blood vessels can be formed via postnatal vasculogensis, recapitulating the 
vasculogenic process observed during embryonic vascular system formation. Postnatal 
vasculogenesis is defined as the process by which bone marrow-derived endothelial progenitor 
cells (EPCs) are recruited to vascular remodeling sites where they differentiate into vessel 
incorporated ECs, thus leading to neo vessel formation3,4. EPCs can also stimulate new vessel 
formation by paracrine interactions with mature ECs5,6. Considering this, the global aim of this 
PhD thesis is to elucidate the molecular mechanism regulating EPC differentiation and 
paracrine/justacrine interacions during postnatal vasculogenesis occuring during wound healing 
and tumor progression, focusing on pathways that are essential to embrionary vasculogenesis, 
namely: Notch-Delta pathway and Integrin:Extracellular matrix (ECM) interactions. 
Additionally, the role of the Notch-Delta pathway on the communication between BM-derived 
populations, other than EPCs, and tumor cells is also a major goal of the present thesis, 
contributing to the identification of the Notch-Delta pathway as a major regulator of tumor 
growth and progression. 
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Contribution of Integrin-ECM interactions to the initial steps of EPC endothelial 
differentiation 
 
EPC-Fibronectin interactions 
One of the major questions addressed in this PhD thesis, namely on Chapter 3, concerned the 
contribution of integrin-mediated adhesion to ECM components in EPC endothelial 
differentiation. In order to address this question we performed flow cytometry analysis on 
integrin sub-units expressed by freshly isolated EPCs that pointed out that these cells express 
mainly the fibronectin (FN) receptor integin α5β1 and also the vitronectin (VN) receptor integin 
αVβ3 at significantly lower levels. We also detected low levels of integrin α2 and α3 
expression. In accordance with the high expression levels of integrin α5β1 we observed that in 
vitro EPCs have a high affinity for the ECM component FN, while showing a reduced affinity 
for laminin (LN), Collagen type I (ColI) and gelatin (Gel). In fact the adhesion of EPCs to FN is 
inhibited significantly when integrin α5β1 is neutralized. Interestingly besides promoting 
increased adhesion, FN also induces increased EPC endothelial differentiation. The precise 
mechanism by which EPC adhesion to FN increases EPC endothelial differentiation was not 
addressed but previous studies suggest that interaction between FN and integin α5β1 potentiates 
VEGF interaction with VEGFR-2 thus increasing endothelial differentiation 7. The role of FN 
adhesion on VEGF-dependent EPC differentiation is also supported by the fact that FN can bind 
and present VEGF8.  Altogether this data suggests that EPC adhesion to FN is a necessary step 
for the success of endothelial differentiation. 
The essential role of integrin α5β1-FN interactions in EPC differentiation is supported by 
knockout mice for these components. In agreement, Integrin α5 knockout mice die at embryonic 
day 10-11 (E10-11)9 with severe vascular defects in both embryonic and extraembryonic 
vesculature while integrin β1 knockout mice die at E5.5 before embryonic vasculature 
formation10. However inhibition of integrin β1 with neutralizing antibodies during quail embryos 
vasculogenesis impairs cord-like assemblies of angioblasts and consequently aortic vessel 
formation11. Concerning FN, the respective knockout mice die at E8.5 with defective embryonic 
and extraembryonic vasculature. On the other hand, in adult individuals FN has been described 
has being upregulated during angiogenic remodelling namely in wound healing12, cardiovascular 
diseases and tumorigenesis13. Interestingly interaction between EPCs and FN has been described 
in vivo, using breast tumor mouse models where it was shown that FN expression on tumor 
periphery is a homing signalling for EPC14. In addition unpublished data from our lab indicates 
that EPCs recognize, via integrin α5β1, interstitial and basement membrane associated FN, 
particularly on tumor vessels where FN is highly and aberrantly expressed. Altogether our data 
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suggests that as observed in angioblasts during embryonic vasculogenesis, integrin α5β1-FN 
interactions are essential for the adhesion and differentiation of EPCs into ECs.  
 
EPC-Fibrin interactions 
Besides testing the effect of interstitial and basement membrane ECM components on EPC 
adhesion and differentiation, we also tested the effect of provisional plasma derived matrices 
which are assembled in response to tissue injury. One of the major components of plasma 
derived matrices is fibrinogen which upon activation of the coagulation cascade is cleaved by 
thrombin generating fibrin that in turn together with plasma derived FN, VN, thrombospondin 
and platelets forms a clot15. In regions of intense inflammatory response and angiogenic 
remodelling (wound healing, active atherosclerotic plaques, tumor formation, venous 
thrombosis) there is an increase turnover of fibrin, which is degradated by plasmin generating 
multiple fibrin fragments16,17. One of this fragments termed fibrin fragment E (FnE) has been 
described as a potent migration and proliferation inducer on ECs18 and on smooth muscle cells 
(SMCs)19. Considering the homeostatic role of fibrin matrices and specifically the angiogenic 
effect of FnE we tested their effect on EPC adhesion and differentiation in the context of wound 
healing. 
Accordingly to our in vitro data we observed that total fibrin has no effect on EPC adhesion 
however it improves endothelial differentiation relatively to gelatin or collagen. This result 
suggests that fibrin matrices potentiate EPC differentiation, thus accelerating the 
revascularization of damaged tissues. In agreement fibrin-containing thrombi have been shown 
to collaborate with platelets supporting EPC migration and differentiation on sites of vessel 
injury20. Concerning the interaction between EPC and FnE, we observed that FnE has a potent 
effect on EPC adhesion, showing a stronger effect that fibrin or FN. Interestingly the interaction 
between EPCs and FnE was inhibited in the presence integrin α5β1 neutralizing antibodies. In 
fact FnE contains an RGD binding site on residues 95 to 97 of the Aα chain21 to which integrin 
α5β1 can bind. However we observed that inhibition was not complete suggesting that the α5β1 
integrin neutralization was insufficient or that there was compensation by other integrin 
expressed on EPCs. Possibly integrin αVβ3 is also binding FnE, since this integrin also shows 
high affinity for RGD binding sites22. Additionally to the increased adhesion on FnE we also 
observed an increased endothelial differentiation of EPCs plated on FnE compared to cells plated 
on FN or fibrin. Supporting once again the notion that adhesion is an essential step that 
determines the efficiency of the endothelial differentiation.  
Despite the effect of FnE and other ECMs components on EPC adhesion and endothelial 
differentiation, we observed that depending on the ECM component that EPCs were cultured on 
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they produced different amounts of paracrine factors. Interestingly EPCs cultured on FnE show 
increase production of numerous growth factors, chemokines and cytokines. Namely we observe 
an increase in VEGF-A, TGF-β1, SDF-1, IL-8, MIP-1α and MCP-1 on EPCs cultured on FnE 
compared to EPCs grown on other ECMs (gelatin or FN). Although many studies have shown 
that EPCs can act by producing paracrine factors5,6, there has not been reported any influence of 
the ECM on the repertoire of paracrine factors produced by adherent EPCs. Interestingly FnE has 
been shown to promote IL-6 production in macrophages via direct interaction with CD11c, 
pointing out that direct binding of FnE to integrins can modulate paracrine factor production23. 
On the other hand FnE induced IL-1β production in monocytes does not require integrin 
aggregation induced by actin polymerization24. Whether FnE induced paracrine factor production 
in EPCs is integrin mediated is still unknown.  
Regardless of the mechanisms by which different ECM components induce differential 
expression of paracrine factors the implications of this observation are extremely important at 
many levels: 1) paracrine factors produced by EPCs can act autocrinaly influencing their 
properties in vitro and in vivo, namely their endothelial differentiation. In fact VEGF-A is a 
positive regulator of EPC endothelial differentiation3,25 therefore it is possible that the increase of 
VEGF-A produced by EPC cultured on FnE can act autocrinally increasing the efficiency of 
endothelial differentiation. This is one possible mechanism explaining why FnE is a more potent 
inducer of endothelial differentiation than FN; 2) The increase in the factors produced by EPCs 
cultured on FnE can have a direct influence on the properties of other cell types, namely during 
wound healing. In fact of the factors upregulated in FnE cultured EPCs VEGF-A, SDF-1 and IL-
8 are pro-angiogenic, inducing EC proliferation and migration26-29 while MIP-1α (CCL3), MCP-
1 (CCL2) and also SDF-1 and IL-8 are strong chemoattractants for monocytes/macrophages and 
other imuno cells30. Further confirming this we observed that conditioned media collected from 
FnE cultured EPCs induced higher EC tube formation and monocyte chemoattraction in in vitro 
assays compared to conditioned media collected from EPCs cultured on other ECM components. 
To investigate the effect of FnE on EPCs during wound healing in vivo we tested an FnE 
enriched scaffold, termed Smart-Matrix (SM) pre-incubated or not with EPCs on cutaneous 
wound healing mouse models. Direct observation and quantification of wound size revealed that 
mice receiving SM with EPCs have an increased wound closure compared to mice receiving SM 
alone, Integra (commercial dermal scaffold consisting of an outer layer of silicone and an inner 
layer containing a complex of 3-dimensional porous matrix cross-linked collagen and 
gylcosaminoglycan fibres) either alone or with EPCs or mice not receiving any scaffold (control 
mice). Interestingly wounds of mice receiving SM with EPCs show an increased number of 
blood vessels compared to other conditions. Analysis of blood vessels in the wound of mice 
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receiving SM with EPCs shows that only a small fraction of blood vessels contain EPCs further 
suggesting that the pro-angiogenic effect of EPCs in SM might be a result of the paracrine pro-
angiogenic factors produced by EPCs rather than differentiation into vessel incorporated ECs. 
Altogether we propose that EPC-FnE interactions potentiate the adhesion, differentiation and the 
production of paracrine factor production by EPCs thus providing a very promising approach to 
addressed pathologies that are associated with insufficient vascularization, namely wound 
healing associated with burn lesions, acute trauma or chronic ulcerations secondary to diabetes 
mellitus, pressure, and venous stasis31-33 (Figure 9).  
 
 
Figure 9 – Schematic diagram showing the effect of FnE on EPC vasculogenic properties. EPCs (CD34+ 
CD133+ KDR+ CXCR4+ cells) cultured on FnE show increased α5β1-mediated adeshion, enhanced paracrine 
factor production and endothelial differentiation. EPCs cultured on FnE show increase production of VEGF-A, 
TGF-β1, SDF-1, IL-8, MIP-1α and MCP-1. Factors produced by EPCs cultured on FnE act in a paracrine fashion on 
monocytes and endothelial cells (ECs) inducing migration and angiogenesis respectively. Possibly EPC paracrine 
factors act autocrinally on EPCs further enhancing their vasculogenic properties. 
 
According to the data presented in this PhD thesis (Chapter 3 and 4) we propose that the 
influences of integrin-ECM interactions in EPC biology are essential, regulating multiple but 
interrelated aspects of the endothelial differentiation process, namely: adhesion to ECM 
substrates, enhancement of endothelial differentiation and regulation of paracrine factor 
production (Figure 9). 
Concerning adhesion, of the ECM components tested (Laminin, Collagens, Gelatin, Fibronectin, 
Fibrin, Fibrin frangment E), EPCs show higher adhesion to FnE followed by FN. Interestingly 
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interaction with both FnE and FN depends on integrin α5β1 which is also the most expressed 
integrin on EPCs. This suggests that in the initial steps of the endothelial differentiation process 
integrin α5β1-FN/FnE interactions are essential to establish EPC adhesion and spreading onto 
the ECM, providing essentially structural cues for EPCs.  
Besides providing structural support for EPCs, we believe that integrin α5β1-FN/FnE 
interactions further potentiate the endothelial differentiation, namely by promoting survival, 
proliferation and maturation of EPCs into ECs. This notion is based on the observaton that EPCs 
cultured on FnE and FN show increased differentiation towards an endothelial phenotype. In 
fact, integrin α5β1 is expressed throughout endothelial differentiation34 and has been shown to 
induce, when bound to FN, survival and proliferation of ECs35,36. Furthermore integrin α5β1:FN 
interactions have been shown to potentiate VEGF-dependent EPC endothelial differentiation37. 
Finally we provide evidence that integrin-ECM regulates paracrine factor production by EPCs. 
In fact, EPCs cultured on different ECMs (Gel, FN, FnE) show differential paracrine factor 
production. Although the precise mechanism connecting adhesion and paracrine factor 
production is undisclosed it is known that ECM-mediated adhesion together with growth factor 
signaling cooperatively determine the final outcome of the signaling regulating downstream gene 
expression38. In accordance, α6β4 integrin has been shown to regulate VEGF expression at 
translational level39 while β1 integrin has been reported to up-regulate IL-8 transcription and 
protein secretion40. The precise mechanisms by which different ECMs induce differential 
paracrine factor production in EPCs remain undetermined.  
 
Contribution of the Notch-Delta signalling pathway during endothelial differentiation 
The involvement of the Notch-Delta pathway on angiogenesis has been extensively described 
during both embryonic development and in adult individuals, however the direct role of this 
pathway during EPC endothelial differentiation has not been addressed. Considering this on 
Chapter 4 we tested the effect of modulating the Notch pathway on the endothelial 
differentiation of bone marrow-derived progenitor cells (BM-PCs), consisting of BM-derived 
mononuclear lineage negative (cells negative for CD5, CD45R (B220), CD11b, Gr-1 (Ly-6G/C) 
and Ter-119) Sca-1 + cells. Although BM-PCs share markers with hematopoietic stem cells 
(HSCs) they behave in vitro and in vivo as EPCs differentiating into ECs, therefore for 
clarification of the present discussion will be addressed as EPCs.  
Accordingly to our data BM-derived EPCs show expression of Notch-1 receptor and the ligands 
Jagged-1, DLL1 and 4. Furthermore we observed that Notch pathway downstream targets (Hes-1, 
Hey-1 and -2) are expressed throughout EPC endothelial differentiation, showing an increase in 
the late stages of differentiation. Interestingly early inhibition of the Notch-pathway reduced 
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significantly the adhesion of EPCs to all tested ECM components (LN, Col, FN and gelatin), 
while its activation (using a constitutively active Notch receptor) increased adhesion. Also we 
observed that Notch pathway inhibition reduced the percentage of ECs obtained at the end of 
differentiation, further suggesting that Notch-mediated EPC adhesion is a necessary step for the 
success of endothelial differentiation. 
Consistently with the impaired adhesion of EPCs upon Notch pathway inhibiton we observed 
that there was a reduced expression at both the mRNA and the protein level of intergrin α3β1. In 
addition downregulation of α3β1 integrin expression by siRNA approach resulted in reduced 
EPC adhesion, further supporting the essential role of this integrin on Notch-mediated EPC 
adhesion. Integrin α3β1 has been described mainly as a LN-5 receptor, however some studies 
suggest that this integrin also binds weakly other ECM proteins, including FN, collagens, LN-1, 
entactin/nidogen, and thrombospondin41-46. Knockout mice for integrin subunit α3 die shortly 
after birth with major defects in kidney and lung defects47, while no endothelial alterations have 
been reported. Interestingly EC specific deletion of integrin α3 subunit leads to increased tumor 
angiogenesis, suggesting that integrin α3β1 acts as a angiogenic repressor, inducing EC VEGF 
production which in turn represses VEGFR-2 expression in ECs48. However the role of integrin 
α3 deletion on EPCs was not addressed. Concerning the regulation of integrin α3β1 expression, 
sequence and functional analysis of integrin α3β1 promoter reveals that the Ets-family of 
transcription factors is a major regulator of this integrin transcription49. Interestingly recent data 
suggests that Ets transcription factor Er71 is a downstream target of the Notch pathway, that 
together with BMP and Wnt signaling directly modulates FLK1+ mesoderm formation from 
embryonic stem cells (ESCs), from which blood and vessel progenitors are specified50.  
Although it has not been addressed it is possible that during EPCs differentiation integrin α3β1 
is regulated by Notch signalling induced Er71 transcription factor. 
Considering that Notch signaling inhibition on EPCs impaired adhesion and endothelial 
differentiation in vitro, we tested whether this inhibition could impair the ability of EPCs to 
stimulate angiogenesis. Interestingly while control EPCs increased EC branching and 
incorporated endothelial tubular structures during matrigel in vitro tube formation assays, Notch 
inhibited EPCs fail to induce EC branching and showed significantly reduced incorporation into 
endothelial tubular structures. Furthermore Notch inhibition also reduced the ability of EPCs to 
accelerate the restoring of the EC monolayer in an in vitro scratch assay. In fact Notch pathway 
inhibited EPCs fail to adhere at the exposed ECM and to the activated ECs at the scratch leading 
edge, further suggesting that EPC wound healing properties depend on Notch pathway 
activation.  This data suggests that Notch signaling activation on EPCs is essential (via integrin 
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α3β1 mediated adhesion) for the in vitro pro-angiogenic and wound healing properties of these 
cells.  
Next we tested the effect of Notch signalling inhibition on EPCs in an in vivo mouse model of 
wound healing. In fact EPCs have been shown to improve wound healing by increasing wound 
vascularization51. Accordingly we observed the while injection of control EPCs increased wound 
closure and wound vascularization, injection of EPCs with inhibited Notch pathway activation 
failed to increase wound closure and vascularization. Furthermore pre-activation of Notch 
signalling on EPCs further potentiates their pro-wound healing properties. Interestingly the 
ability to increase wound healing is directly correlated with the frequency at which EPCs were 
found in wound tissues. Considering this EPCs with inhibited Notch pathway were found at 
significantly reduced frequency compared to control and Notch activated EPCs. One of the 
possible mechanisms that explains this observation is that in the absence of Notch activation 
EPCs express lower levels of integrin α3β1 and consequently fail to interact with ECM proteins 
and activated ECs present in the wound.  Altogether these data suggests that Notch activation in 
EPCs potentiates the ability of these cells to induce wound vascularization and consequent 
increased wound closure. 
 
In conclusion the data present in Chapter 4 establishes a new role for Notch-Delta signalling 
pathway on the biology of EPCs. Accordingly we show that Notch activation on EPCs induces 
integrin α3β1 expression which in turn increases EPC adhesion and endothelial differentiation. 
Furthermore we demonstrate that Notch pathway activation is essential for the in vitro and in 
vivo pro-angiogenic and wound healing properties of EPCs. In order to contextualize the effect 
of Notch pathway activation on EPC during in vivo wound healing we propose a model. 
Accordingly, we suggest that upon wounding there is a mobilization of BM-derived EPCs, that 
home to the wounded site via circulation. Once at the wounded site EPCs interact with local 
cells, namely with activated ECs, that have been shown to express high levels of notch ligands, 
namely Jagged-1 and 252, that in turn activate Notch pathway on EPCs. Notch activation on 
EPCs induces expression of integrin α3β1 that allow EPC adhesion to ECM components in the 
wound tissue. Once adherent EPCs can differentiate into vessel incorporated ECs and also 
activate in a paracrinaly and justacrine manner ECs, inducing new vessel formation and 
consequently increasing wound closure (Figure 10). 
Interestingly recent data from other groups confirms our observations, in fact Sang-Mo Kwon 
and colleagues have shown that specific Jagged-1-derived signals from the BM environment 
activate Notch pathway on BM-EPCS increasing survival, proliferation, invasiveness, 
mobilization and endothelial differentiation. In vivo data further suggests that Jagged-1–mediated 
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Notch activation in BM-EPCs enhances their vasculogenic potential in ischemic diseases53. 
However these authors do not provide a molecular explanation for the observed phenotype. In 
another study RBPJ-/- EPCs show increased mobilization but reduced adhesion, migration and 
ability to form vessel-like structures in matrigel. Accordingly these authors show that the defects 
observed are due to a reduction on CXCR4 expression on RBPJ-/- EPCs54. Altogether this data 
suggests that Notch activation on BM-derived EPCs is essential for their vasculogenic functions 
thus representing a very interesting therapeutic target in vascular deficiency related diseases such 
as delayed wound healing or ischemia. 
 
Role of EPC Dll4 mediated Notch-Delta pathway activation on tumor angiogenesis 
In Chapter 5 we addressed the role of the Notch pathway ligand Dll4, expressed by EPCs, on 
tumor angiogenesis. The involvement of Dll4 in angiogenesis has been addressed during 
embryonic development where it was shown essential for arterial specification and vascular 
remodelling, with both homo and heterozygous mice showing embryonic lethality55,56. 
Furthermore the involvement of Dll4 on tumor angiogenesis has been intensively studied. 
Accordingly Dll4 mediated Notch activation on ECs has been shown to be essential for vessel 
normalization and consequent tumor oxygenation and growth57-59. However the effect of Dll4 
expressed by BM-derived EPCs in a context of tumor angiogenesis has not been addressed. 
In this study EPCs were defined has BM-derived lineage negative Flk-1+ cells. Accordingly to 
our data Dll4 expression on EPCs is increased by VEGF and also SDF-1, which have been 
shown to be tumor produced factors that induce EPC mobilization and retention at perivascular 
sites60,61. Interestingly the effect of SDF-1 on Dll4 expression is more pronounced than VEGF, 
being directly mediated by SDF-1 interaction with its receptor CXCR4. Although SDF-1 has 
been shown to promote EPC adhesion to ECs62 an increase in Dll4 expression was not described. 
Altogether it is possible that SDF-1 increases EPC adhesion to ECs and also increases Dll4 
expression on EPCs further promoting Dll4 mediated Notch signaling activation on ECs. 
To test the direct effects of Dll4 expressed on EPCs on ECs we used co-culture experiments with 
ECs and EPCs overexpressing Dll4 or heterozygous for Dll4 or in the presence of a neutralizing 
antibody specific for mouse Dll4. Analysis of EC gene expression after co-cultures revealed that 
in fact EPC Dll4 mediated Notch signaling activation on ECs induces expression of ICAM2 and 
FN. We also observed an increase in VE-Cadherin although it was not consistent suggesting that 
Dll4 mediated induction of VE-Cadherin might involve other unidentified molecular pathways. 
Interestingly in mice overexpresing Dll4 there is a decrease in vessel branching, an enlargement 
of artery caliber associated with an increase in FN deposition, suggesting that FN production by 
ECs is downstream of Notch signaling and that FN accumulation in the vessel basement 
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membrane induces vessel stability63. ICAM-2 is a type I transmembrane glycoproteins expressed 
by ECs that is necessary for leukocyte transendothelial migration during inflammation64. ICAM2 
has also been implicated in angiogenesis, where it was shown to promote tube formation. 
Furthermore ICAM-2 has been shown to be expressed at the endothelial junctions together with 
VE-Cadherin and PE-CAM where it regulates migration and protects ECs from apoptosis65. VE-
Cadherin is an endothelial cell-cell junction protein that is essential for vessels formation and 
embryonic development66. VE-Cadherin is also required to prevent the disassembly of the blood 
vessel walls67 and to coordinate the passage of macromolecules through the endothelium68, thus 
being considered essential for blood vessel stabilization69. Altogether these data shows that EPC 
can in fact interact with ECs via Dll4 induced activation of the Notch pathway modulating EC 
stability, namely by upregulating basement membrane components (FN) and increasing 
endothelial junction formation (ICAM-2 and VE-cadherin). 
After determining the effect of EPCs Dll4 on ECs we decided to test the effect of reducing EPC 
Dll4 expression on tumor angiogenesis and growth in vivo. Interestingly tumors implanted in 
mice transplanted with Dll4+/- EPCs show increased vessel density but reduced growth, reduced 
proliferation index and increased apoptosis compared to tumors implanted in mice transplanted 
with wild-type EPCs. In fact tumor vessels in mice transplanted with Dll4+/- EPCs are unstable 
and leaky with reduced expression of FN and pericyte coverage, resulting in increased hypoxic 
areas in the tumor tissue. Although it was not addressed it is possible that EPC interact directly 
with pericytes via Dll4-mediated Notch activation. In fact, Dll4 has been shown to be essential 
for BM-derived pericyte/smooth formation and consequent vessel stabilization70. In order to 
further demonstrate the role of EPC Dll4 on tumor angiogenesis we analysis the effect of 
injecting EPC overexpressing Dll4 in tumor vascularization. Accordingly we observed that 
although the overall tumor size and tumor vessel number was unaffected the vessel of tumors 
receiving EPC overexpressing Dll4 showed increased vessel diameter and increased FN 
deposition on vessel basement membrane, corroborating the effects of Dll4 overexpression in 
embryonic development63. Altogether the data presented suggestes that Dll4 EPC mediated 
Notch activation on ECs during tumor angiogensis is essential for keeping vessel stability and 
functionality and consequent tumor perfusion and growth (Figure 10).  
 
The results presented on Chapter 5 support a new role for EPCs during tumor vessel formation, 
suggesting that these cells can in fact contribute to the stabilization and functionality of new 
blood vessels via Dll4 mediated activation of the Notch signaling on ECs. Moleculary we 
observe that EPC Dll4 mediated activation of the Notch signaling regulates vessel stability by 
increasing the expression of ECM components of the basement membrane, namely FN, but also 
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by increasing the expression of major components of endothelial cell-cell junctions like ICAM2 
and VE-Cadherin, which are necessary for keeping structural integrity of blood vessels. Further 
more, vessel stabilization is also achieved in vivo via pericyte recruitment although the precise 
mechanism was not addressed it is possible that Dll4 has a direct effect on these cells70 or maybe 
Dll4 Notch activation on ECs leads to production factors that induce pericyte recruitment. 
Therefore we suggest that EPCs are a major determinant of vessel stabilization via Dll4 
activation of Notch pathway on ECs, further confirming the studies relating Dll4 inhibition with 
a more unstable tumor vasculature and decreased tumor growth57-59. These results suggest that 
EPCs expressing reduced Dll4 can in fact contribute to destabilization of tumor vessels 
formation, further suggesting that these cells can have a therapeutical potential as tumor vessel 
destabilization agents. On the other hand, although destabilization of tumor vasculature can 
indeed lead to tumor regression there is some evidence that unstable vessels can in fact be 
prejudicial to anticancer therapies mostly because of the infective delivery of therapeutical 
agents to the tumor71. Also the high hypoxic state of these tumors may induce genetic instability 
and select more malignant cells with increased metastatic potential72. Therefore another possible 
therapeutical approach regarding EPC-mediated Notch pathway regulation might be the 
conjugation of Notch activation mediated tumor stabilization with an efficient delivery of 
chemotherapeutic agents into the tumor tissue.  
Regardless of the direct therapeutical application of the data here presented, our results suggests 
that tumor vessel stability modulation can be achieved trough dosage of Dll4 expression on 
EPCs, pointing out that EPCs are in fact essential for new vessel formation not only by direct 
differentiation into ECs, or by paracrine activation of ECs but also by justacrine interactions with 
ECs via Dll4-mediated Notch pathway activation. These conclusions points out the need to 
develop EPC centered approached to act therapeutically on angiogenesis related diseases. 
Interestingly data presented on Chapter 4 and 5 demonstrate that the Notch-Delta signaling 
pathway can in fact act bidirectionally on EPCs depending on the environmental conditions that 
surround them. This suggests that Notch pathway is essential in the communication between 
EPCs and resident cells they encounter at vascular remodeling sites (mainly ECs), namely in 
wounds and tumors (Figure 10). 
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Figure 10 – Bidirectional Notch-Delta pathway activation between EPCs and ECs during wound healing and 
tumor progression. Schematic representation of the role of the Notch signaling pathway on EPCs function during 
wound healing and tumor progression. In a wound healing setting ECs expressing Jagged-1 and 2 activate the Notch 
pathway on EPCs increasing integrin α3β1 expression, thus increasing EPC vasculogenic properties. In a tumor 
setting CXCR4:SDF-1 increases Dll4 expression  on EPCs which in turn activate Notch signalling (via direct 
binding to Notch receptor 1 and/or 4) on tumor ECs, increasing FN, ICAM2 and VE-cadherin expression and 
consequently vessel stability. 
 
Contribution of BM-derived cells towards tumor epithelial to mesenchymal transition ans 
metastasis formation 
In Chapter 6 we addressed whether BM-derived populations could modulate other tumor 
properties besides angiogenesis, namely tumor properties associated with metastasis formation. 
In fact metastisation is the major cause of cancer-associated mortality due to the fact that most 
metastatic lesions show resistence to conventional chemo- and radiotherapy approaches. In fact 
metastisation is a complex process that involves multiple steps: tumor cells local invasion, 
intravasation into blood vessels, migration via blood flow into distant organs, extravasation and 
colonization of distant organs generating micro/macrometastasis73. However one of the major 
processes regulating tumor local invasion is termed epithelial to mesenchymal transition (EMT), 
which is a transcriptional regulated transdifferentiation program that occurs in epithelial tumor 
cells causing them to lose epithelial markers (E-Cadherin among others) and properties (basal 
apical polarity and cell-cell contacts) and to acquire mesenchymal markers (Vimentin among 
others) and properties (highly invasive and migratory behavior). Interestingly while different 
BM-derived populations have been associated with all of the metastisation steps74 none has been 
associated with EMT. In fact EMT has been described as a tumor cells intrinsic propertie and not 
a microenvirnment-regulated process. Considering this we decided to test the role of BM-derived 
populations on tumor EMT. 
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To test the contribution of BM-derived cells to tumor progression we used BM-transplants to 
generate mice containing GFP+ BMs, and then inoculated these mice subcutaneously with a 
colon carcinoma cell line. Interestingly we observed that as tumors progressed the number of 
BM-derived cells (GFP+) present in the tumor tissue increased significantly. Furthermore 
characterization of BM-derived cells revealed that this population is composed mainly by 
myeloid (CD11b+) and mesenchymal (SMA+). However a detailed observation of late tumor 
sections suggested that tumor cells in close contact with BM-derived cells show a significant 
decrease in the expression of E-Cadherin, while displaying an increase on Vimentin expression 
compared to early tumors. These data suggested that in later stage colon carcinoma tumors the 
close interaction between BM-derived cells and tumor cells induced EMT in the later. 
Considering this in vivo observations we decided to performed in vitro co-culture assays to 
further understand whether BM-derived cells could be directly mediating EMT induction on 
tumor cells. Thus BM-derived cells that were in tumor tissues were isolated and co-cultured with 
carcinoma cells. Interestingly carcinoma cells cultured with tumor associated BM-derived cells 
show an EMT phenotype, with a significant loss of E-Cadherin expression and increased 
Vimentin expression. Moreover BM-derived cell induction of tumor EMT was shown to be 
dependent on Notch pathway activation on tumor cells.  In fact the Notch pathways activation by 
Jagged-1 has been shown to induce EMT through Slug-induced repression of E-Cadherin75. In 
another sudy it was reported that Notch signalling activation induces EMT in chemotherapy-
resistant pancreatic cancer cells76. However these studies only addressed tumor cell derived 
Notch activation, and did not investigate the contribution tumor stromal components to tumor 
cell Notch activation. 
Having shown that tumor associated BM-derived cells can induce EMT on tumor cells via Notch 
activation we looked into the Notch-ligands upregulated on tumor associated BM-derived cells 
cell. We observed that tumor associated BM-derived cells show an increase in Jagged-2 
expression compared to other ligands and compared to ligands expressed on total  BM cells. 
Furthermore we observe that Jagged-2+GFP+ cells are indeed enriched in tumor samples and 
that these cells could per se induce downregulation of E-Cadherin at both mRNA and protein 
levels in a Jagged-2-mediated Notch pathway activation dependent manner. Also we obvserved 
co-localization of Jagged-2+ cells with tumor cells undergoing E-Cadherin downregulation, on 
tumor samples further confirming the role of tumor associated BM-derived expressing Jagged-2 
in induction tumor EMT.  
Next we decided to characterize moleculary the Jagged-2+ tumor associated BM-derived 
population. Flow citometry analysis revealed that this population is composed mainly by 
CD11b+ F4/80+ myeloid cells, altought there are other residual populations expressing Jagged
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2, namely Sca-1+ cells or CD3+ T-cells. Interestingly co-culture experiments revealed that 
CD11b+ Jagged-2+ cells could induce the same phenotype as total tumor associated BM-derived 
GFP+ or Jagged-2+ GFP+, reducing significantly E-Cadherin expression on carcinoma cells in a 
Notch-dependent manner. Furthermore immunohistological analysis of tumor samples showed 
that CD11b+Jagged-2+ cells co-localize with tumor regions undergoing EMT. Altogether these 
data suggests that BM-derived CD11b+, and possibly F4/80+, Jagged-2+ cells are recruited to 
primary colon carcinoma tumors where they activate Notch signalling on tumor cells causing in 
turn the activation of EMT.  
Interestingly the contribution of myeloid cells in tumor progression and metastization has been 
extensively documented. Namely tumor associated macrophages (TAMs: CD11b+ CD45+ 
VEGFR1+ F4/80+ CD14+ CD68+ CD133- CD31-) have been shown to constitute a large 
portion of the tumor mass77 correlating with poor cancer prognosis in 80% of published studies 
78. Concerning their role in tumor progression TAMs have been shown to induce 6 properties 
that enhance tumor incidence, progression and metastasis: inflammation, matrix remodelling, 
tumor cell invasion, intravasation, angiogenesis and extravasation/seeding at distant sites79. 
Interestingly accordingly with our results tumor associated BM-derived Jagged-2+ cells share 
some markers with TAMs, namely CD11b and F4/80, therefore it is possible that these cells are 
in fact TAMs. If this is true than our results suggest that TAMs can in fact induce 7 properties, 
with the 7th property being induction of tumor EMT. 
Still in agreement with our results, both expression of Notch receptors and ligands as well as 
overall Notch pathway activation have been shown to be associated with cancer metastasis. In 
fact Notch signalling activation has been described in breast cancer brain metastasis80 and in 
patients with breast cancer expression of either Jagged1 or Notch1 is predictive of poor overall 
survival81. In colon cancer it was shown that Notch 1 is overexpressed and correlates with 
pathologic grade, progression, and metastasis of colon cancer patients82. Despite all this data 
relating the involvement of the Notch pathway with cancer metastasis none of the above 
mentioned studies addressed specifically the role of the BM-derived component of the tumor 
stroma. Therefore we believe that our results report for the first time a direct role of tumor 
stromal components, namely BM-derived CD11b+ F4/80+ myelod cells (possibly TAMs), on the 
induction of EMT in epithelial cancer via Jagged-2 mediated Notch activation. This data further 
confirms the essential role of the tumor stromal components, namely the BM-derived cell, on 
tumor progression pointing out the need for the development of new therapeutic targets that can 
target specifically these compartments and the pathways they regulate. 
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Figure 10 – Schematic representation of BM-derived cell mediated EMT induction in epithelial tumors. 
During tumor progression tumor cells interact with the BM compartment recruiting numerous cell types. CD11b+ 
F4/80+ Jagged-2 cells interact with epithelial tumor celIs activating the Notch pathway, which in turn downregulates 
E-cadherin expression on tumor cells. Furthermore Jagged-2 mediated activation increases Vimentin expression on 
tumor cells thus promoting epithelial-to-mesenchymal transition (EMT). Mesenchymal tumor cells become more 
invasive contributing to tumor metastisation. 
 
In conclusion data presented on the Chapter 6 of this PhD thesis identifies a BM-derived 
population of CD11b+ F4/80+ myeloid cells (possibly TAMs) that is actively recruited into 
tumor tissue during tumor growth where it induces EMT via Jagged-2 mediated Notch activation 
on tumor cells. These data together with the one presented on Chapter 5 suggest that different 
BM-derived populations can in fact use the same molecular pathway (Notch signalling pathway) 
to communicate and induce cellular responses on different tumor components, thus regulating 
overall tumor progression, further suggesting that targeting the Notch pathway during tumor 
growth can act at multiple levels, enhancing the therapy efficiency.  
Our data together with preclinical and cinical evidence collected in the last decade support a pro-
oncogenic function for Notch signalling in several solid tumors83. Considering this several drugs 
targeting different steps of the Notch pathway signalling cascade have been developed. However 
the most promising drugs to block Notch activity are γ-secretase inhibitors (GSI), that are 
currently in early clinical trails in various institutions, monoclonal antibodies (mAbs) that ‘lock’ 
Notch receptors in an inactive conformation by binding to the ‘negative regulatory region’ 
(NRR), that are in preclinical development84 and also mAbs that target Dll4 are also being tested 
as antiangiogenic or antineoplastic agents85-87. Despite some secondary effects, most of the 
therapies targeting Notch pathways show promising results especially in lymphoma and 
advanced breast cancer patients88,89. Hopefully, more intensive basic research on the role of 
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Notch signaling in multiple cancers and a more specific generation of Notch inhibitors that target 
specific cancer cell components (either tumor cells or stromal cells) will provide more efficient 
therapies that will ultimately lead to increase survival and life quality of cancer patients 
worldwide. 
 
Final conclusions 
Altogether the data obtained in this PhD thesis has shed some light into the molecular 
mechanisms that regulate the function of BM-derived populations (EPCs and TAMs) during 
wound healing and tumor progression focusing specifically on the role of integrin:ECM 
interactions and on the Notch-Delta signalling pathway. In accordance we have shown that: 
 
1. Interaction between EPC integrins and ECM protein is essential not only for the initial 
adhesion steps but also for later steps of the differentiation process, where it regulates paracrine 
factor production of EPCs; 
A. Fibrin fragment E (FnE) potentiates the vasculogenic properties of EPCs, increasing 
their adhesion (via integrin α5β1), endothelial differentiation and paracrine factor production 
(namely VEGF-A, TGF-β1, SDF-1, IL-8, MIP-1α and MCP-1). 
B. Usage of a FnE based scaffold (smart matrix scaffold) enriched with EPCs in a mouse 
wound healing models increases wound vascularization and closure thus representing a 
promissing approach to treat patients suffering from severe skin loss. 
 
2. Notch-Delta signalling pathway mediates bidirectional interactions between BM-derived 
cells and tissue resident cells, thus being essential in the communication between the BM-
compartment and tissue cells during wound healing and tumor progression; 
 A. Activation of the Notch pathway on EPCs increases integrin α3β1 expression 
improving EPC adhesion and endothelial differentiation as well as their por-angiogenic and 
wound healing potential in vitro and in vivo. 
 B. EPC Dll4 mediated activation of the Notch signaling on ECs regulates vessel stability 
by increasing the expression of basement membrane components (fibronectin) as well as 
endothelial cell-cell junction proteins (ICAM2 and VE-cadherin), thus being essential for neo-
vessel normalization during tumor growth. 
C. TAMs (CD11b+ F4/80+) Jagged-2 mediated activation of the Notch signalling on 
colon carcinoma cells induces tumor EMT, contributing to tumor progression and metastisation. 
 
 
 
 196
References 
 
1. Carmeliet, P. Angiogenesis in health and disease. Nat Med 9, 653-660 (2003). 
2. Carmeliet, P. Angiogenesis in life, disease and medicine. Nature 438, 932-936 (2005). 
3. Asahara, T., et al. Isolation of Putative Progenitor Endothelial Cells for Angiogenesis. 
Science 275, 964-966 (1997). 
4. Asahara, T., et al. Bone Marrow Origin of Endothelial Progenitor Cells Responsible for 
Postnatal Vasculogenesis in Physiological and Pathological Neovascularization. Circ Res 
85, 221-228 (1999). 
5. Barcelos, L.S., et al. Human CD133+ Progenitor Cells Promote the Healing of Diabetic 
Ischemic Ulcers by Paracrine Stimulation of Angiogenesis and Activation of Wnt 
Signaling. Circ Res 104, 1095-1102 (2009). 
6. Ji Yeon Kim, S.-H.S., Koung Li Kim, Yong-Sun Maeng, Ji-Eun Im, Se Won Yie, Young 
Keun Ahn, Duk-Kyung Kim, Wonhee Suh. Human Cord Blood-derived Endothelial 
Progenitor Cells and their Conditioned Media Exhibit Therapeutic Equivalence for 
Diabetic Wound Healing Cell Transplant. (2010). 
7. Errol, S.W., et al. Fibronectin promotes VEGF-induced CD34+ cell differentiation into 
endothelial cells. Journal of vascular surgery : official publication, the Society for 
Vascular Surgery [and] International Society for Cardiovascular Surgery, North 
American Chapter 39, 655-660 (2004). 
8. Wijelath, E.S., et al. Heparin-II Domain of Fibronectin Is a Vascular Endothelial Growth 
Factor-Binding Domain: Enhancement of VEGF Biological Activity by a Singular 
Growth Factor/Matrix Protein Synergism. Circ Res 99, 853-860 (2006). 
9. Yang, J.T., Rayburn, H. & Hynes, R.O. Embryonic mesodermal defects in alpha 5 
integrin-deficient mice. Development 119, 1093-1105 (1993). 
10. Fassler, R. & Meyer, M. Consequences of lack of beta 1 integrin gene expression in mice. 
Genes & Development 9, 1896-1908 (1995). 
11. Drake, C. Antibodies to beta 1-integrins cause alterations of aortic vasculogenesis, in 
vivo. Dev Dyn. 193, 83-91 (1992). 
12. Repesh, L.A., Fitzgerald, T.J. & Furcht, L.T. Fibronectin involvement in granulation 
tissue and wound healing in rabbits. Journal of Histochemistry & Cytochemistry 30, 351-
358 (1982). 
13. Astrof, S. & Hynes, R. Fibronectins in vascular morphogenesis. Angiogenesis 12, 165-
175 (2009). 
14. Jin, H., et al. A homing mechanism for bone marrow-derived progenitor cell recruitment 
to the neovasculature. The Journal of Clinical Investigation 116, 652-662 (2006). 
15. Laurens, N., Koolwijk, P. & De Maat, M.P.M. Fibrin structure and wound healing. 
Journal of Thrombosis and Haemostasis 4, 932-939 (2006). 
16. Slade, C.L., Pizzo, S.V., Taylor, L.M., Steinman, H.M. & McKee, P.A. Characterization 
of fragment E from fibrinogen and cross-linked fibrin. Journal of Biological Chemistry 
251, 1591-1596 (1976). 
17. Thompson WD, H.J., Kazmi MA, Stout AJ. Fibrinolysis and angiogenesis in wound 
healing. J Pathol. 165, 311-318 (1991). 
18. Thompson WD, S.E., Stirk CM, Marshall FI, Stout AJ, Kocchar A. Angiogenic activity 
of fibrin degradation products is located in fibrin fragment E. J Pathol. 168, 47-53 (1992). 
19. Kodama, M., et al. Role of D and E domains in the migration of vascular smooth muscle 
cells into fibrin gels. Life Sciences 71, 1139-1148 (2002). 
20. de Boer, H.C., et al. Fibrin and Activated Platelets Cooperatively Guide Stem Cells to a 
Vascular Injury and Promote Differentiation Towards an Endothelial Cell Phenotype. 
Arterioscler Thromb Vasc Biol 26, 1653-1659 (2006). 
21. Guo, Y.-H., et al. Caveolin-1-dependent apoptosis induced by fibrin degradation products. 
Blood 113, 4431-4439 (2009). 
 197 
22. Smith, J.W. & Cheresh, D.A. Integrin (alpha v beta 3)-ligand interaction. Identification of 
a heterodimeric RGD binding site on the vitronectin receptor. Journal of Biological 
Chemistry 265, 2168-2172 (1990). 
23. Lee ME, R.K., Nham SU. Fragment E derived from both fibrin and fibrinogen stimulates 
interleukin-6 production in rat peritoneal macrophages.. Mol Cells. 9, 7-13 (1999). 
24. Lee ME, K.S., Ha KS, Nham SU. Fibrin stimulates microfilament reorganization and IL-
1beta production in human monocytic THP-1 cells. Mol Cells. 11, 13-20 ( 2001). 
25. Young, P.P., Hofling, A.A. & Sands, M.S. VEGF increases engraftment of bone marrow-
derived endothelial progenitor cells (EPCs) into vasculature of newborn murine 
recipients. Proceedings of the National Academy of Sciences of the United States of 
America 99, 11951-11956 (2002). 
26. Yoshifumi Watanabe, S.W.L., Michael Detmar, Itsuki Ajioka and Harold F Dvorak. 
Vascular permeability factor/vascular endothelial growth factor (VPF/VEGF) delays and 
induces escape from senescence in human dermal microvascular endothelial cells. 
Oncogene 14, 2025-2032 (1997). 
27. He, T., Peterson, T.E. & Katusic, Z.S. Paracrine mitogenic effect of human endothelial 
progenitor cells: role of interleukin-8. American Journal of Physiology - Heart and 
Circulatory Physiology 289, H968-H972 (2005). 
28. Li, A., et al. Autocrine Role of Interleukin-8 in Induction of Endothelial Cell 
Proliferation, Survival, Migration and MMP-2 Production and Angiogenesis. 
Angiogenesis 8, 63-71 (2005). 
29. Salcedo R, W.K., Young HA, Grimm MC, Howard OM, Anver MR, Kleinman HK, 
Murphy WJ, Oppenheim JJ. Vascular endothelial growth factor and basic fibroblast 
growth factor induce expression of CXCR4 on human endothelial cells: In vivo 
neovascularization induced by stromal-derived factor-1alpha. Am J Pathol. 154, 1125-
1135 (1999). 
30. Low QE, D.I., Duffner LA, Quinn DG, Cook DN, Rollins BJ, Kovacs EJ, DiPietro LA. 
Wound healing in MIP-1alpha(-/-) and MCP-1(-/-) mice. Am J Pathol 159, 457-463 
(2001). 
31. Epstein, F.H., Singer, A.J. & Clark, R.A.F. Cutaneous Wound Healing. New England 
Journal of Medicine 341, 738-746 (1999). 
32. Mustoe, T. Understanding chronic wounds: a unifying hypothesis on their pathogenesis 
and implications for therapy. American journal of surgery 187, S65-S70 (2004). 
33. Clark, R.A.F., Ghosh, K. & Tonnesen, M.G. Tissue Engineering for Cutaneous Wounds. 
J Invest Dermatol 127, 1018-1029 (2007). 
34. Igreja, C. et al. Detailed molecular characterization of cord blood-derived endothelial 
progenitors. Experimental hematology 36, 193.e191-193.e115 (2008). 
35. Kim, S., Bell, K., Mousa, S.A. & Varner, J.A. Regulation of Angiogenesis in Vivo by 
Ligation of Integrin {alpha}5{beta}1 with the Central Cell-Binding Domain of 
Fibronectin. Am J Pathol 156, 1345-1362 (2000). 
36. Kim, S., Bakre, M., Yin, H. & Varner, J.A. Inhibition of endothelial cell survival and 
angiogenesis by protein kinase A. The Journal of Clinical Investigation 110, 933-941 
(2002). 
37. Wijelath, E.S., et al. Fibronectin promotes VEGF-induced CD34+ cell differentiation into 
endothelial cells. Journal of vascular surgery : official publication, the Society for 
Vascular Surgery [and] International Society for Cardiovascular Surgery, North 
American Chapter 39, 655-660 (2004). 
38. Miyamoto, S., Teramoto, H., Gutkind, J.S. & Yamada, K.M. Integrins can collaborate 
with growth factors for phosphorylation of receptor tyrosine kinases and MAP kinase 
activation: roles of integrin aggregation and occupancy of receptors. The Journal of Cell 
Biology 135, 1633-1642 (1996). 
 198
39. Chung, J., Bachelder, R.E., Lipscomb, E.A., Shaw, L.M. & Mercurio, A.M. Integrin 
alpha6 beta4 regulation of eIF-4E activity and VEGF translation. The Journal of Cell 
Biology 158, 165-174 (2002). 
40. Garcia-Velasco, J.A. & Arici, A. Interleukin-8 expression in endometrial stromal cells is 
regulated by integrin-dependent cell adhesion. Molecular Human Reproduction 5, 1135-
1140 (1999). 
41. Wayner, E.A. & Carter, W.G. Identification of multiple cell adhesion receptors for 
collagen and fibronectin in human fibrosarcoma cells possessing unique alpha and 
common beta subunits. The Journal of Cell Biology 105, 1873-1884 (1987). 
42. Gehlsen KR, D.L., Engvall E, Ruoslahti E. The human laminin receptor is a member of 
the integrin family of cell adhesion receptors. Science 241, 1228-1229 (1988). 
43. Elices, M.J., Urry, L.A. & Hemler, M.E. Receptor functions for the integrin VLA-3: 
fibronectin, collagen, and laminin binding are differentially influenced by Arg-Gly-Asp 
peptide and by divalent cations. The Journal of Cell Biology 112, 169-181 (1991). 
44. Dedhar, S., Jewell, K., Rojiani, M. & Gray, V. The receptor for the basement membrane 
glycoprotein entactin is the integrin alpha 3/beta 1. Journal of Biological Chemistry 267, 
18908-18914 (1992). 
45. DeFreitas, M.F., et al. Identification of integrin alpha3beta1 as a neuronal 
thrombospondin receptor mediating neurite outgrowth. Neuron 15, 333-343 (1995). 
46. DiPersio, C.M., Shah, S. & Hynes, R.O. alpha 3A beta 1 integrin localizes to focal 
contacts in response to diverse extracellular matrix proteins. J Cell Sci 108, 2321-2336 
(1995). 
47. Kreidberg, J.A., et al. Alpha 3 beta 1 integrin has a crucial role in kidney and lung 
organogenesis. Development 122, 3537-3547 (1996). 
48. da Silva RG, T.B., Robinson SD, Reynolds LE, Szekeres C, Lamar J, Batista S, 
Kostourou V, Germain MA, Reynolds AR, Jones DT, Watson AR, Jones JL, Harris A, 
Hart IR, Iruela-Arispe ML, Dipersio CM, Kreidberg JA, Hodivala-Dilke KM. Endothelial 
alpha3beta1-integrin represses pathological angiogenesis and sustains endothelial-VEGF. 
Am J Pathol. 177, 1534-1548 (2010). 
49. Kato, T., et al. Characterization of the promoter for the mouse α3 integrin gene. 
European Journal of Biochemistry 269, 4524-4532 (2002). 
50. Lee, D., et al. ER71 Acts Downstream of BMP, Notch, and Wnt Signaling in Blood and 
Vessel Progenitor Specification. Cell stem cell 2, 497-507 (2008). 
51. Real C, C.F., Dias S. Endothelial progenitors in vascular repair and angiogenesis: how 
many are needed and what to do? Cardiovasc Hematol Disord Drug Targets. 8, 185-193 
(2008). 
52. Lindner, V., et al. Members of the Jagged/Notch Gene Families Are Expressed in Injured 
Arteries and Regulate Cell Phenotype via Alterations in Cell Matrix and Cell-Cell 
Interaction. The American journal of pathology 159, 875-883 (2001). 
53. Kwon, S.-M., et al. Specific Jagged-1 Signal From Bone Marrow Microenvironment Is 
Required for Endothelial Progenitor Cell Development for Neovascularization. 
Circulation 118, 157-165 (2008). 
54. Wang, L., et al. Notch-RBP-J Signaling Regulates the Mobilization and Function of 
Endothelial Progenitor Cells by Dynamic Modulation of CXCR4 Expression in Mice. 
PLoS ONE 4, e7572 (2009). 
55. Nicholas W. Gale, M.G.D., Irene Noguera, Li Pan, Virginia Hughes, David M. 
Valenzuela, Andrew J. Murphy, Niels C. Adams, Hsin Chieh Lin, Jocelyn Holash, Gavin 
Thurston, and George D. Yancopoulos. Haploinsufficiency of delta-like 4 ligand results 
in embryonic lethality due to major defects in arterial and vascular development. Proc 
Natl Acad Sci U S A 45, 15949–15954 (2004 ). 
56. Duarte, A.n., et al. Dosage-sensitive requirement for mouse Dll4 in artery development. 
Genes & Development 18, 2474-2478 (2004). 
 199 
57. Noguera-Troise, I., et al. Blockade of Dll4 inhibits tumour growth by promoting non-
productive angiogenesis. Nature 444, 1032-1037 (2006). 
58. Ridgway, J., et al. Inhibition of Dll4 signalling inhibits tumour growth by deregulating 
angiogenesis. Nature 444, 1083 - 1087 (2006). 
59. Scehnet, J.S., et al. Inhibition of Dll4-mediated signaling induces proliferation of 
immature vessels and results in poor tissue perfusion. Blood 109, 4753-4760 (2007). 
60. Aghi, M., Cohen, K.S., Klein, R.J., Scadden, D.T. & Chiocca, E.A. Tumor Stromal-
Derived Factor-1 Recruits Vascular Progenitors to Mitotic Neovasculature, where 
Microenvironment Influences Their Differentiated Phenotypes. Cancer Research 66, 
9054-9064 (2006). 
61. Li, B., et al. VEGF and PlGF promote adult vasculogenesis by enhancing EPC 
recruitment and vessel formation at the site of tumor neovascularization. The FASEB 
Journal 20, 1495-1497 (2006). 
62. Yamaguchi, J.-i., et al. Stromal Cell-Derived Factor-1 Effects on Ex Vivo Expanded 
Endothelial Progenitor Cell Recruitment for Ischemic Neovascularization. Circulation 
107, 1322-1328 (2003). 
63. Trindade A, K.S., Scehnet JS, Lopes-da-Costa L, Becker J, Jiang W, Liu R, Gill PS, 
Duarte A. Overexpression of delta-like 4 induces arterialization and attenuates vessel 
formation in developing mouse embryos. Blood 5, 1720-1729 (2008). 
64. Woodfin, A., et al. Endothelial cell activation leads to neutrophil transmigration as 
supported by the sequential roles of ICAM-2, JAM-A, and PECAM-1. Blood 113, 6246-
6257 (2009). 
65. Huang, M.-T., et al. Endothelial intercellular adhesion molecule (ICAM)-2 regulates 
angiogenesis. Blood 106, 1636-1643 (2005). 
66. Carmeliet, P., et al. Targeted Deficiency or Cytosolic Truncation of the VE-cadherin 
Gene in Mice Impairs VEGF-Mediated Endothelial Survival and Angiogenesis. Cell 98, 
147-157 (1999). 
67. Crosby, C.V., et al. VE-cadherin is not required for the formation of nascent blood 
vessels but acts to prevent their disassembly. Blood 105, 2771-2776 (2005). 
68. Gavard, J. & Gutkind, J.S. VEGF controls endothelial-cell permeability by promoting the 
[beta]-arrestin-dependent endocytosis of VE-cadherin. Nat Cell Biol 8, 1223-1234 (2006). 
69. Gavard, J. Breaking the VE-cadherin bonds. FEBS letters 583, 1-6 (2009). 
70. Stewart, K.S., Zhou, Z., Zweidler-McKay, P. & Kleinerman, E.S. Delta-like ligand 4-
Notch signaling regulates bone marrow-derived pericyte/vascular smooth muscle cell 
formation. Blood 117, 719-726. 
71. Jain, R.K. Normalization of Tumor Vasculature: An Emerging Concept in 
Antiangiogenic Therapy. Science 307, 58-62 (2005). 
72. Bottaro, D.P. & Liotta, L.A. Cancer: Out of air is not out of action. Nature 423, 593-595 
(2003). 
73. Chambers, A.F., Groom, A.C. & MacDonald, I.C. Metastasis: Dissemination and growth 
of cancer cells in metastatic sites. Nat Rev Cancer 2, 563-572 (2002). 
74. Qian, B.-Z. & Pollard, J.W. Macrophage Diversity Enhances Tumor Progression and 
Metastasis. Cell 141, 39-51. 
75. Kevin G. Leong, K.N., Iva Kulic, Afshin Raouf, Connie Eaves, Ingrid Pollet and Aly 
Karsan. Jagged1-mediated Notch activation induces epithelial-to-mesenchymal transition 
through Slug-induced repression of E-cadherin. J Exp Med. 204, 2935–2948 (2007). 
76. Wang, Z., et al. Acquisition of Epithelial-Mesenchymal Transition Phenotype of 
Gemcitabine-Resistant Pancreatic Cancer Cells Is Linked with Activation of the Notch 
Signaling Pathway. Cancer Research 69, 2400-2407 (2009). 
77. Pollard, J.W. Tumour-educated macrophages promote tumour progression and metastasis. 
Nat Rev Cancer 4, 71-78 (2004). 
 200
78. Bingle, L., Brown, N.J. & Lewis, C.E. The role of tumour-associated macrophages in 
tumour progression: implications for new anticancer therapies. The Journal of Pathology 
196, 254-265 (2002). 
79. Condeelis, J. & Pollard, J.W. Macrophages: obligate partners for tumor cell migration, 
invasion, and metastasis. Cell 124, 263-266 (2006). 
80. Nam, D.-H., et al. Activation of Notch Signaling in a Xenograft Model of Brain 
Metastasis. Clinical Cancer Research 14, 4059-4066 (2008). 
81. Reedijk, M., et al. High-level Coexpression of JAG1 and NOTCH1 Is Observed in 
Human Breast Cancer and Is Associated with Poor Overall Survival. Cancer Research 65, 
8530-8537 (2005). 
82. Zhang, Y., Li, B., Ji, Z.-Z. & Zheng, P.-S. Notch1 regulates the growth of human colon 
cancers. Cancer 116, 5207-5218. 
83. Koch, U., Radtke, F. & Raphael, K. Notch Signaling in Solid Tumors. in Current Topics 
in Developmental Biology, Vol. Volume 92 411-455 (Academic Press). 
84. Li, K., et al. Modulation of Notch Signaling by Antibodies Specific for the Extracellular 
Negative Regulatory Region of NOTCH3. Journal of Biological Chemistry 283, 8046-
8054 (2008). 
85. Noguera-Troise, I., et al. Blockade of Dll4 inhibits tumour growth by promoting non-
productive angiogenesis. Nature 444, 1032 - 1037 (2006). 
86. Thurston, G., Noguera-Troise, I. & Yancopoulos, G.D. The Delta paradox: DLL4 
blockade leads to more tumour vessels but less tumour growth. Nat Rev Cancer 7, 327-
331 (2007). 
87. Yan, M. & Plowman, G.D. Delta-like 4/Notch Signaling and Its Therapeutic Implications. 
Clinical Cancer Research 13, 7243-7246 (2007). 
88. Rizzo, P., et al. Cross-talk between Notch and the Estrogen Receptor in Breast Cancer 
Suggests Novel Therapeutic Approaches. Cancer Research 68, 5226-5235 (2008). 
89. Qiao, L. & Wong, B.C.Y. Role of Notch signaling in colorectal cancer. Carcinogenesis 
30, 1979-1986 (2009). 
 
 
